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Chapter 1
INTRODUCTION
1.1 Chronic Kidney Disease
1.1.1 Introduction 
There is a growing awareness that chronic kidney disease (CKD) poses a major health problem 
worldwide. Large screening programs indicate that 5-10% of the adult population show mild to moderate 
kidney damage, with or without concomitant renal function loss. It is clear that CKD is a risk factor for the 
development of end-stage renal failure (ESRF), but more importantly for the development of cardiovascular 
disease (CVD) and overall mortality. Interestingly, the majority of CKD cases are not associated with primary 
renal disease, but with systemic conditions like diabetes and hypertension. Only a minority of patients with 
diabetes and/or hypertension develops CKD, indicating that other aspects also determine susceptibility to 
develop CKD. Familial clustering and ethnic differences in the prevalence of CKD point to the importance of 
genetic and/or socio-economic factors infl uencing the development of CKD. 
Completion of sequencing of the human, mouse and rat genomes enables the rapid expansion 
of comparative genomic studies that may be advantageous to identify genes involved in human complex 
diseases. Rodent models of CKD will eventually lead to positional cloning of genes that infl uence the 
susceptibility to renal damage in various conditions, such as hypertension, diabetes, or reduced renal 
mass. The genes identifi ed can then be examined in humans. Furthermore, they may help to resolve 
pathophysiological mechanisms, and possibly lead to new targets for treatment or prevention of CKD.  
1.1.2 Defi nition and staging of chronic kidney disease.
Kidneys are regulatory organs important in helping to preserve the constancy of the internal environment 
necessary for cells and organ systems to function normally. This is achieved by excretion of toxic waste 
products produced during several metabolic pathways, and by selectively conserving and excreting water 
and electrolytes. Furthermore, kidneys secrete hormones that participate in the regulation of systemic and 
renal haemodynamics, red cell production, and mineral metabolism. The glomerular fi ltration rate (GFR) is 
considered to be a good indicator of renal function.211,264
In 2002 the National Kidney Foundation in the USA published guidelines for the defi nition and 
staging of CKD.142,177 In the NKF report CKD was divided into fi ve severity stages (Table 1). The staging 
system is based on the GFR calculated from serum creatinine levels42,141, and kidney damage ascertained 
by either biopsy or markers of kidney damage, such as proteinuria or albuminuria.
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Table 1. Stages and prevalence of chronic kidney disease
Stage Description GFR Related Terms US prevalence
.1. Kidney damage with normal or  GFR ≥90
Albuminuria, proteinuria, 
hematuria 3.3%
.2. Kidney damage with mild ↓ GFR 60-89
Albuminuria, proteinuria, 
hematuria 3.0%
.3. Moderate ↓ GFR 30-59 Chronic renal insuffi ciency, early renal insuffi ciency 4.3%
.4. Severe ↓ GFR 15-29 Chronic renal insuffi ciency, renal failure, pre-ESRD 0.2%
.5. Kidney failure < 15 (or dialysis)
Renal failure, uremia, ESRD: 
Renal replacement therapy 0.1%
1.1.3 Epidemiology of CKD, and CKD as risk factor for kidney failure, cardiovascular disease and 
mortality
 The prevalence of all stages of CKD was about 11-12% of the US population, surveyed in the 
early and late 1990s CKD (Table 1).43,44 Screening programs in Australia, Japan, the Netherlands, and 
Thailand identifi ed between 6-11% of the adult population having some degree of CKD.34,58,104,112 In the US 
study, a total of up to 6.6% have signs of kidney damage, but the calculated GFR is still ≥60 ml/min per 1.73 
m2, i.e. ≥50% of normal GFR. Another 4.3% has a GFR between 25 and 50% of normal. Despite a high 
prevalence, CKD awareness is low.44 
Prevalence rates of CKD increase with age and are strongly associated with the presence or 
absence of two major risk factors – diabetes and hypertension.263 Depending on age prevalence rates of 
CKD in patients with diabetes and hypertension are 10-18 times higher compared to those without diabetes 
and/or hypertension. Prevalence CKD rates in patients with either diabetes or hypertension are 4-7 times 
higher than those without both risk factors. The prevalence of CKD further increases to 50-60% when high-
risk individuals are screened.26 
 It is not clear how this high prevalence of CKD relates to number of patients affected by ESRF 
or treated by dialysis or kidney transplantation. As indicated in Table 1 the prevalence of kidney failure in 
the USA is about 0.1%. This equals only 1% of those defi ned as having CKD.  Apparently only a fraction of 
those with CKD eventually progress to kidney failure and renal replacement therapy. A study of the natural 
history of stage 2-4 CKD patients indicated that during a 5-year observation period 3.1% progressed to 
kidney failure (dialysis or transplantation), whereas 24.9% died. The rate of renal replacement therapy was 
1.1%, 1.3%, and 19.9%, respectively for the stages 2, 3, and 4, while mortality rates were 19.5%, 24.3%, 
and 45.7%, respectively. Therefore, death, mainly from CVD, was far more common than dialysis at these 
stages of CKD.123 Consequently, patients at all stages CKD should be considered in the “highest risk group” 
for the development of CVD.161,217 
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GFR in ml/min per 1.73 m2. Related terms for CKD stages 1 and 2 depend on the marker of kidney damage. Albuminuria, 
proteinuria, and hematuria have been studied most. Related terms for CKD stages 3 to 5 do hot have specifi c defi nitions, except 
for ESRD.
1.1.4 Epidemiology of End-Stage Renal Disease (ESRD)
 The terms ESRD and kidney failure are not synonymous.143 ESRD is an administrative term based 
on conditions for payment for health care by the Medicare ESRD Program for patients treated by dialysis 
and transplantation. Every year the US Renal Data System documents the incidence, prevalence, age, and 
primary cause of renal failure in ESRD patients. The most recent one reports data from 2002, the 20th year 
of coverage.263 More than 1.5 million people have now been treated through this program, and in 2002 over 
100.000 entered for therapy (an adjusted incident rate of 333 new cases per million population), while the 
total program expenditures reached over $25 billion in 2002. Of the reported ESRD patients 50% was aged 
65 or older, while over 70% had diabetes and hypertension as primary diagnosis. Primary renal diseases 
like glomerulonephritis, interstitial nephritis, polycystic kidneys and renal neoplasms, etc. accounted for less 
than one third of the ESRD patients. 
 The distribution of primary diagnosis in the pediatric ESRD population differs signifi cantly from 
that in adults. Diabetes and hypertension are virtually absent.  Hypoplasia, dysplasia and hereditary disease 
have been the main causes of ESRD in the 0-4 year-old, while glomerulonephritis and pyelonephritis 
predominate in the older child.265 The incidence rates in the pediatric age group are low. In the USA, 
the incidence rate between 0-19 years amounts to only 1% of that age 65 or older, 15 vs. 1500 patients 
per-million-population.263 Because of the uniqueness of the pediatric ESRD population, a special CKD 
classifi cation system for CKD in children and adolescents has been established.106 
1.1.5 Risk factors for CKD and concept of CKD susceptibility
 A risk factor is defi ned as “an attribute that is associated with increased risk of an outcome”. 
Four types of risk factors for adverse outcome in CKD have been distinguished (Table 2).177 In principle, 
risk factors for the early development of CKD would include susceptibility factors and initiation factors. The 
diffi culty of detecting the onset of CKD makes it hard to determine whether identifi ed risk factors relate more 
to susceptibility, initiation, or progression. 
Table 2. Types and examples of risk factors for adverse outcomes of chronic kidney disease
Type Defi nition Examples
Susceptibility factors Increased susceptibility to 
kidney damage
Old age, ethnicity, family history
Initiation factors Directly initiate kidney 
damage
Diabetes, High blood pressure
Progression factors Cause worsening of kidney 
damage and faster decline in 
kidney function after initiation
Poor glycemic control, Higher blood 
pressure level Higher proteinuria, 
Smoking
End-stage factors Cause complications in 
patients with kidney failure
Inadequate dialysis, Anemia
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A partial list of clinical and sociodemographic factors that have been implicated as susceptibility or 
initiation factors is presented in Table 3. Hypertension, diabetes, and reduced renal mass are established risk 
factors in the initiation and progression of CKD. However, whether these factors are susceptibility, initiation, 
or progression risk factors for CKD is less clear.14,67,71,127 For instance, three possibilities exist regarding the 
role of hypertension in CKD: (1) hypertension is necessary and suffi cient to produce CKD; (2) hypertension 
is necessary but not suffi cient to produce CKD, other risk factors are also needed; (3) hypertension is 
neither necessary nor suffi cient to produce CKD, but increases the risk in individuals who are otherwise 
predisposed or increases the rate of progression of CKD. In the fi rst situation, CKD is hypertension-induced, 
while in the latter two situations CKD will be hypertension-associated.25 
Table 3. Potential risk factors for susceptibility to and initiation of chronic kidney disease
Clinical factors Socio-demographic factors
Diabetes Family history of CKDHypertension
Reduction in kidney mass Ethnic status: African American,
Native American, Australian Aboriginal,
Maori, Pacifi c Islander
Autoimmune disease
Systemic infections
Urinary tract infections Older-ageUrinary stones 
Urinary tract obstruction Low income/educationLow birth weight
In the absence of primary renal disease, the development of CKD associated with hypertension 
and/or diabetes appears to be limited to susceptible individuals. Essential hypertension causes renal injury, 
but renal susceptibility genes may determine whether hypertension-induced renal damage occurs and how 
severe it is.262 Multiple lines of evidence suggest that susceptibility to develop CKD or ESRF has a signifi cant 
genetic component.19 A genetic or familial predisposition to develop CKD is implicated from the observation 
that CKD commonly clusters within families.11,79,121,139,220,227 A genetic predisposition is also implicated by the 
large ethnic differences in CKD prevalence rate. African and Native Americans in the USA, Afro-Caribbeans 
in the UK, and indigenous peoples in Australia and New Zealand all show a high prevalence of CKD related 
to diabetes, hypertension, or both.27,201,229,247,263 Although it is attractive to imply genetic factors to explain the 
familial clustering and ethnic differences of CKD, other socio-economic explanations are also possible as 
extensively discussed by Cass et al.33  
 Genetic studies in humans have not yet been very successful in defi ning candidate genes 
infl uencing susceptibility to develop renal damage. Studies in congenital and familial forms of nephrotic 
syndrome has led to the identifi cation of genes and podocyte-specifi c proteins that are essential to the 
maintenance of the normal structure of glomerular fi ltration barrier.122,125,149,179,194,295 Mutations in these genes 
result in proteinuria and glomerulosclerosis, but none of these mutations has yet been defi nitively linked to 
the occurrence of CKD in the general population. 
Linking CKD and various polymorphisms of candidate genes encoding putative mediators of kidney 
damage has provided various results.151,164  Most studies aimed at delineating a possible role of genetic 
variability in the renin-angiotensin-aldosterone system in nephropathy. An association between angiotensin-
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converting enzyme genotype and diabetic nephropathy was fi rst described in 1994.60,155 Numerous studies 
in diabetic and other forms of nephropathy followed this fi nding with inconsistent results, as did studies 
investigating a possible role of polymorphisms of the angiotensinogen gene, the angiotensin-type1 receptor 
gene, and the aldosterone synthase gene.163 A new approach is to look simultaneously at genetic variants 
and whether they act synergistically to increase the risk or confer protection to develop renal failure.70 
Another approach to identify genes that predispose for kidney failure is to carry out a whole 
genome scan in multiple families. A number of studies have resulted in the detection of linkage between 
several chromosomal regions .18,37,39,74,76,77,78,80,86,111,114,166,184,202,203,259,277,294 These regions, summarized in Table 
4, may be considered as “priority regions for further study” (Freedman et al 2004).77 
Table 4. Linkage obtained in genome scans in human nephropathy
Chr. region LOD-score ESRD-type Race/Ethnicity Reference
7q
3q, 9, 20p
2.7
1.1 – 1.9 T2DM Pima Indian 111
3q 3.1 T1DM Caucasian 166
11q21-q22 9.9 FSGS Caucasian 295
6q22-q23 5.6 IgAN Caucasian 86
1q25-31 4.0 FSGS Brazilian 259
10q 3.4 DN and non-DN ESRD African American 78
2q34-q35
10q22.3
11p15.6
3.2
3.3
SLE nephritis European American and African American 202,203
18q22.3-q23 6.1 T2DM Turkish 277
9q31-q32 5.4 Htn-assoc ESRD African American 39
10p n.a. T2DM Caucasian and African American 114
1q31-q41 n.a. IgAN Japanese 184
3q, 7p, 18q 4.6, 3.6, 3.7 T2DM African American 18
3q23-q24 n.a. T1DM Russian 37
1q25.1, 2q32
9p21.3, 13q33
1.6, 3.9
2.0, 1.0 Htn-assoc ESRD African American 77
1q25.1, 
4p15.32
9q34.3, 
13q33.3
1.0, 1.1
1.2, 1.7 All cause ESRD African American 76
LOD is logarithm of odds; ESRD is end-stage renal disease; T2DM and T1DM are type 2 and type 1 diabetes mellitus, respectively; 
FSGS is focal segmental glomerulosclerosis; IgAN is IgA Nephropathy; DN and non-DN are diabetic- and non-diabetic nephropathy; 
SLE is systemic lupus erythematosus; Htn-assoc is hypertension associated.
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1.2 How to investigate the genetics of susceptibility to CKD
1.2.1 Comparative genomics (human, mouse, rat)
 Apparently CKD in humans has all characteristics of a complex trait. There is genetic heterogeneity, 
complicated by gene-gene and gene-environment interactions affecting the susceptibility of the kidney to be 
damaged. This complexity will markedly hinder the direct discovery of susceptibility genes in humans. Studies 
in animal models may help to reveal genes infl uencing genetic susceptibility to develop renal damage. With 
the completion of the sequencing of the human, mouse and rat genome, genomic comparisons between 
these three species are greatly facilitated.87,135,278,287 Comparative genomics combined with physiological 
information will facilitate the discovery of mammalian genes that underlie physiological pathways that are 
involved in disease.261 In addition, it should lead to the development of better pre-clinical models of human 
disease, which will aid in the discovery of new therapeutic targets.23,116,250
1.2.2 Mouse and rat model systems 
The mouse and rat model systems have several advantages over humans for the investigation 
of mammalian biology. In both species there are genetically well-defi ned lines that differ in phenotypic 
characteristics. Coupled with their modest costs maintenance and short generation times has resulted in 
an explosion of studies in genetic mapping and development of genetic modifi cation tools. Consequently, 
both mice and rats are used in experimental studies aiming to detect genes involved in complex multi-
factorial diseases such as diabetes, obesity, hypertension, cardiovascular disease, asthma and chronic 
kidney damage.48 
1.2.3 How to assess renal susceptibility in rodent models?
Assessment of renal damage in rodent models is usually done by determining the urinary excretion 
of albumin and/or total protein or by determining the incidence and/or severity of structural renal damage. 
Structural renal damage can then be separated in glomerular or tubulo-interstitial damage.  Inbred rodent 
models are ideally suited to detect genetic components of renal susceptibility. Not only are they genetically 
identical, all genes are homozygous present. When renal susceptibility is compared between inbred strains 
under identical circumstances, ideally differences will only be due to genetic divergence. 
Differences in renal susceptibility are present between strains of aging animals with two intact 
kidneys10, and between strains with different forms of genetic hypertension.20,66,95,99,215,238,245,283 However, 
differences in renal susceptibility between strains of rats and mice are mostly tested following surgical 
or pharmacological intervention, or by the induction of various forms of nephritic renal disease. Surgical 
intervention consists of unilateral nephrectomy (UNX)239,291 or more extensive forms of renal ablation.16,97,130 
Pharmacological intervention upon the kidney may be indirect by the induction of a systemic disease, such 
as hypertension274,275 or diabetes119, or directly by injection of glomerular toxins, such as puromycin98,138 
or adriamycin.183  Combinations of surgical and pharmacological interventions have also been applied. In 
addition, it has been well established that dietary protein intake (total amount as well origin – animal or 
vegetable) infl uences the development of renal damage.
Employing various models has revealed marked differences in renal susceptibility between inbred 
rodent strains.25,84,175,195,224,225,234,235 This opens the opportunity to carry out genetic linkage studies aiming to 
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detect genes (chromosomal loci) infl uencing renal susceptibility. As the pathophysiological mechanisms 
may differ between strains and the various test models, it is highly likely that renal susceptibility genes may 
also differ. Thus, it is to be expected that eventually a substantial number of renal susceptibility genes will 
emerge from rodent studies investigating multiple model systems. Once identifi ed, the rodent susceptibility 
genes can then be examined in humans to ascertain a possible role in explaining differences in renal 
susceptibility in humans.
1.2.4 Mouse studies
Mouse strains have been shown to differ in susceptibility with respect to spontaneous renal 
lesions109,126,185, to renal damage induced by hyperglycemia307, after renal mass reduction69,130,152, and 
following DOCA-salt-treatment.100 The ICGN mouse strain has spontaneous glomerular lesions and 
albuminuria.185,186 A single gene (named nep) was thought to be responsible, which was localized by 
linkage mapping on the distal part of mouse chromosome 15.188 The FGS/Nga mouse strain is a model 
for spontaneous glomerulosclerosis, and is considered to have two pairs of autosomal recessive genes 
associated with FGS.109,302 Linkage analysis in a HIV-1 transgenic mouse strain identifi ed a locus on mouse 
chromosome 3 linked with nephropathy.85 A genome-wide scan in a murine IgA-nephropathy model identifi ed 
a susceptibility locus on mouse chromosome 10, in a region syntenic to human IGAN1 on chromosome 
6q22-23.253 The importance of the genetic background has been shown in a mouse model (ROP-OS/+ 
strain) of glomerulosclerosis due to a 50% reduction in nephron number.102 Glomerulosclerosis in ROP-
OS/+ mice appears inherited to be in a recessive fashion involving 8-10 loci.140 Recently, a study in KK/Ta 
mice has detected a region on chromosome 2 of the mouse that is linked to albuminuria.233 This region is 
homologous to the Rf-3 region of the FHH rat.
Studies in congenic mice have been crucial to unravel the complex genetics of lupus nephritis.171,49,297 
Several mouse models of diabetic nephropathy have been characterized and are potentially useful for 
genetic studies.4,119,230 Molecular profi ling of diabetic mouse kidneys has revealed several novel genes that 
might be involved in glomerular damage.252 Furthermore, a role of leptin has been suggested to play a role 
in diabetic nephropathy in a mouse model of lipoatrophic diabetes.251 
The technology for disrupting gene expression (knockout) or produce over-expression (transgenic) 
is well established in the mouse. Various mouse models have been successfully employed to investigate 
the function of genes and their possible connection or disconnection with kidney disease.254 As new 
models constantly emerge, only a few examples will be presented. Transgenic Alb/TGF-β mice that are 
over-expressing transforming growth factor-β1 develop progressive renal disease.128 Glomerulosclerosis 
was found in mice transgenic for human insulin-like growth factor-binding protein-161, while Wt1+/R394W 
transgenic mice display glomerulo-sclerosis and early-onset renal failure characteristic of human Denys-
Drash syndrome.82 Mice transgenic for the macrophage migration inhibitory factor (MIF) develop podocyte 
injury and progressive mesangial sclerosis.218 
No aggravation of renal injury was seen in apolipoprotein E knockout mice after subtotal 
nephrectomy.29 Knockout mice have also been employed to delineate the role of angiotensin-converting 
enzyme in renal function and blood pressure control13, and the function of several podocyte-specifi c 
molecules like Neph-1 and nephrin59,147,212,296, CD2-adaptor protein296, and podocin.212 
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Recently, Rathkolb et al. reported on a large-scale albuminuria screen for nephropathy models in 
N-ethyl-N-nitrosourea (ENU) induced mouse mutants. Proteinuria was used as a parameter for identifying 
nephropathy phenotypes in ENU-mutagenized mice. This is the fi rst study describing ENU-mutagenesis 
especially used for detecting nephropathy models in mice.209
Taken together, studies in mice concentrate on transgenic and knockout model, rather than linkage 
studies in established models of spontaneous renal damage. Overexpression or loss of different single 
genes does infl uence the development of renal damage. The few linkage studies indicate that spontaneous 
renal damage appears to be inherited from one, two or multiple genes.
1.2.5 Rat studies
 Like mice, inbred rat strains vary widely in their susceptibility to develop renal damage. In contrast 
to mice, some of the strains are well characterized and have already been used in linkage analyses to detect 
chromosomal regions, i.e. quantitative trait loci (QTLs) infl uencing the development of renal damage. 
The FHH (Fawn-Hooded Hypertensive) rat is one of the best-characterized models of hypertension-
associated renal damage. The FHH rat is prone to develop mild hypertension and marked proteinuria (UPV), 
albuminuria (UAV), and focal and segmental glomerulosclerosis (FGS) at relatively young age. Numerous 
studies have been performed in the FHH rat to characterize the (patho)physiology51,52,53,54,189,198,210,238,239,272,273,
279,288, and histopathology.131,132,133 Furthermore, several studies have established the effi cacy of inhibiting the 
renin-angiotensin system to prevent or slow down the progression of renal damage in the FHH rat.279,282,308 
Altogether, these studies indicated that in FHH the moderately elevated systemic blood pressure 
is transmitted into the glomerulus due to an impaired myogenic renal autoregulation. The resulting increased 
intraglomerular pressure initiates the development of vascular-pole-associated glomerulosclerosis, 
eventually progressing to total nephron degeneration and interstitial fi brosis through misdirected fi ltration 
and peritubular spreading of the fi ltrate. There appears to be a general up-regulation of systems important 
in the control of intra-renal haemodynamics, like preglomerular renin activity, and NO-synthase and cyclo-
oxygenase-2 activities in the macula densa. However, no primary defect initiating these abnormalities has 
yet been identifi ed. It is surmised that genetic studies will eventually lead to the detection of the responsible 
gene(s), the molecular events, and physiological pathways.
Other susceptible inbred strains have also been studied to detect the genetics of renal damage 
susceptibility. They include BUF (Buffalo), MWF (Munich Wistar Fromter), SHRSP (Spontaneously 
Hypertensive Rat-Stroke Prone), and SS (Dahl Salt Sensitive).  However, in contrast to FHH, they are all 
defi cient in pathophysiological characterization. The availability of large sets of genetic markers has opened 
the possibility of detailed linkage analyses employing the renal susceptible strains and crossing them with 
contrasting renal resistant strains, such as ACI (August Copenhagen Irish), WKY (Wistar Kyoto), LEW 
(Lewis), SHR (Spontaneously Hypertensive Rat), and BN (Brown Norway).25,84,175,195,224,225,234,235 
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1.3 Finding genes infl uencing renal susceptibility
1.3.1 Linkage analysis to detect ‘renal susceptibility QTLs’
Linkage analysis offers the possibility to detect quantitative trait loci (QTLs) infl uencing parameters 
of functional renal damage, like proteinuria and albuminuria, or structural renal damage, like the incidence 
or severity of glomerular or tubular damage. About 90 QTLs have been identifi ed linking chromosomal 
markers to renal damage traits, summarized in Table 5 and Figure 1.
The fi rst linkage analyses involving crosses between FHH and the renal resistant ACI rat revealed 
the presence of fi ve QTLs linked to UPV and other parameters of renal damage. These QTLs were named 
Renal-failure-1 (Rf-1) to Rf-5.25,234 It is surmised that each of these QTLs contains gene(s) that play a role 
in the initiation and/or progression of renal damage in the FHH rat. The Rf-1-QTL has by far the highest 
LOD-score and is considered to play a major role. In addition, the linkage analysis suggested complex 
interactions between the fi ve QTLs. The Rf-2, Rf-3, Rf-4, and Rf-5 QTL, being homozygous for FHH, by 
itself showed little effect on UPV. However, a marked increase in UPV level was noted when one of these 
QTLs was combined with Rf-1.234
As indicated in Table 5 and Figure 1, QTLs linked to parameters of renal damage are spread all 
over the rat genome. With the exception of chromosomes 20, all chromosomes carry one or more QTLs. 
Some of the renal QTLs appear to cluster, i.e. on chromosomes 1, 2, 3, 6, 8, 9, 10, 11, and 17. Taken 
together about 15-20 QTL clusters can be distinguished.  Such a sizeable number of QTLs indicates that the 
renal susceptibility is indeed a complex trait. Although some strains may have QTLs in common, it seems 
that different, strain specifi c, sets of genes underlie renal susceptibility in the various rat models.  
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1.3.2 From linkage to susceptibility genes
 Localizing a QTL is only the beginning of a long road to gene identifi cation via a positional cloning 
strategy.90,117 Once a set of QTLs is identifi ed, the next step is to generate a series of congenic strains 
in which each chromosomal region carrying a QTL is introgressed from the renal susceptible strain to 
the genome of the renal resistant strain or vice versa. These congenic rat strains may then be tested 
for changes in renal susceptibility. This approach is currently widely tested in other complex traits like 
hypertension, diabetes, arthritis, and obesity. For instance, over 25 congenic rat strains and substrains, 
carrying various blood pressure QTLs, have been generated and studied.56,159,207
 The generation and testing of a panel of congenic strains carrying the various Rf-QTLs from the 
FHH strain onto the genomic background of the ACI strain will be described in this thesis.  The fi rst congenic 
strain being tested carried a 20cM (24.2 Mb) region including the Rf-1 QTL from FHH upon the ACI genomic 
background. These ACI.FHH-Rf1 rats showed an increased susceptibility to renal damage when compared 
with the ACI parental strain. However, an increased renal susceptibility in ACI.FHH-Rf1 was only noted in 
the presence of an increased haemodynamic stress upon the kidney, i.e. following unilateral nephrectomy 
(UNX) or UNX combined with L-NAME-induced hypertension.199
The degree of renal damage observed in strains congenic for only a single Rf-QTL remains far 
below that of the FHH parental strain. This is in accordance with the assumption that renal damage in FHH 
is a polygenic trait. Consequently, signifi cant gene-gene interactions can be expected. Such interactions 
can be investigated in double or multiple congenic rats.  
Apart from our experimental work in ACI.FHH congenics no other studies have yet been reported 
employing congenic rat strains that have been generated based on previous linkage studies. However, an 
effect on renal susceptibility has been reported in a congenic strain generated for hypertension research. An 
increased renal susceptibility was reported after transgressing a chromosomal region (D1Mit3-Igf) from BN 
into the SHR genome.243 This region coincides with the Rf-2 region found in the FHH.25,234 
1.3.3 Consomic rats 
 A consomic rat strain is one in which an entire chromosome is introgressed into the isogenic 
background of another inbred strain. Consomic rats are yet another tool to help identifying genes infl uencing 
complex traits. Whereas congenic rats are developed based on QTL regions linked to a specifi c trait (blood 
pressure, proteinuria, etc), a panel of consomic rats is generated by replacing the chromosome from a 
disease model one by one by the chromosome from a healthy control strain.45,46 In the PhysGen project (http://
pga.mcw.edu; part of the NIH Program for Genomic Applications (PGA) initiative) two panels of consomic 
rats will be generated that are of major interest to study susceptibility to renal damage.  By replacing the 
individual chromosomes from the Dahl Salt-sensitive (SS) or the FHH (two models of progressive renal 
damage) by those from the Brown Norway (BN) rat, a total of 44 consomic strains will be generated and 
phenotyped for various renal and blood pressure related traits. When a chromosome is thought to harbor 
a QTL, consomic rats enable the rapid development of congenic strains over a narrow region in just two 
generations. Furthermore, they enable one to perform F2 linkage studies to positionally locate QTLs on a 
single chromosome with a fi xed genetic background.
Chapter 1
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The situation as of June 24, 2005 (Release 17) regarding UPV, UAV and mean arterial blood 
pressure (MAP) is summarized in Table 6. In the SS strain several chromosomes appear to infl uence the 
development of UPV and/or UAV (i.e. chromosomes 5, 6, 7, 8, 11, 13, and 18) and blood pressure (i.e. 
chromosomes 5, 7, 8, 13, and 18). Five consomic strains (i.e. chromosome 5, 7, 8, 13, and 18) show a 
simultaneous reduction of UPV, UAV and MAP when compared with SS rats, suggesting that attenuation of 
renal damage is achieved through a reduction in blood pressure. Studies with congenic rats derived from 
these consomics should further elucidate these suppositions. 
In the FHH, the replacement of chromosome 1, 14, 16 and 20 signifi cantly attenuates the 
development of UPV, while only the replacement of chromosome 1 signifi cantly attenuated the development 
of UAV. The MAP was attenuated only by replacement of chromosome 20. These fi ndings are in line with 
the presence of the Rf-1 and Rf-2 QTLs on chromosome 1, and Rf-4 on chromosome 14 infl uencing UPV 
and UAV. In contrast, a role of the Rf-5 QTL on chromosome 17 is not confi rmed in the FHH-17BN consomic 
rats. The FHH chromosomes 16 and 20 could contain QTLs affecting UPV that were not found in the linkage 
analysis using FHH and ACI rats.25,234 An effect on MAP was only noted by replacing chromosome 20. No 
QTL had been found on this chromosome, while the previously reported QTLs for SBP on chromosomes 1 
and 17 were not confi rmed in the consomic strains.
Further studies dealing with the FHH-1BN consomic rats, confi rmed the signifi cance of FHH 
chromosome 1 in renal susceptibility158, emphasizing the important role of the Rf-1 and Rf-2 QTLs both 
located on FHH chromosome 1. Studies in FHH-1BN subcongenics resulted in the positional cloning of a 
strong candidate gene for Rf-2 and the bleeding disorder present in FHH rats.204 Additional publications 
involving consomic rat strains keep emerging47,63,65,72,157, indicating the potential strength of using the 
consomic rats in functional genomics.
Consomic strains were also used to investigate the genetic basis of the difference in renal 
susceptibility between two strains of Sabra rats. The Sabra SBH/y rat strain is more susceptible to develop 
proteinuria than the Sabra SBN/y strain. Consomic rats were constructed by introgressing chromosome 1 
(which harbors Rf-1 and Rf-2) or chromosome 17 (which harbors Rf-5) from SBH/y onto the SBN/y genomic 
background. Following UNX, the consomic strains developed more proteinuria than SBN/y, suggesting a 
functional role of gene systems located on chromosomes 1 and 17 in inducing proteinuria in the SBH/y 
strain.299
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1.3.4 Gene expression studies
 After identifying a QTL and the subsequent confi rmation of an effect on the trait under investigation 
in a congenic strain, a next step on the path from QTL to gene may be the application of gene expression 
studies.196 To narrow the number of candidate genes in a QTL region, one may focus on genes that show 
differential expression between the parental strains as well as the congenic and the recipient strain. This 
approach has been used to identify Cd36 as a gene underlying cellular defects in glucose and fat metabolism 
in the spontaneously hypertensive rat (SHR).1,2  However, successful studies using microarray expression 
profi ling to identify genes in complex traits are scarce. 
 A new concept called ‘genetical genomics’ or ‘expression genetics’ applies gene expression 
assays from an experimental cross, treating the transcript abundance as a quantitative trait, to identify QTLs 
that infl uence the expression of genes.24  Regulation of gene expression was studied in tissues in a panel 
of rat recombinant inbred strains derived from the SHR and BN strains. By combining the gene expression 
QTLs with previously mapped blood pressure QTLs a data set of 73 candidate genes for hypertension was 
generated that merit further testing.108 A similar approach for identifying candidate genes infl uencing renal 
susceptibility has not yet been reported.
1.3.5 Bioinformatics to integrate human, mouse and rat 
In the current era, several websites are providing data for researchers on various species, 
for instance Rat Genome Database (RGD, rgd.mcw.edu), Human Phenome Database (HPD, hpd.mcw.
edu), and comparative maps of human, rat and mouse (http://www.ncbi.nlm.nih.gov/projects/Homology). 
Integrating rat physiology with mouse genetics and clinical results from human by using the respective 
genomes provides a novel route to capitalize on comparative genomics and the strengths of model organism 
biology (Figure 2).116,260,261 In the end, it will hopefully lead to a better understanding of the pathogenesis and 
pathophysiology of a disease and ultimately prevention of a disease.145,150
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Figure 2: Using data from rat and mouse studies for studies of human complex diseases 
(adapted from Jacob, Kwitek, 2002)116
1.4 Outline of this thesis
 Linkage analyses of involving crosses between FHH and ACI rats revealed the presence of fi ve 
QTLs linked to parameters of renal damage (Rf-1 through Rf-5), and two QTLs linked to SBP. The fi rst aim 
of this thesis is to directly assess the role of each of these QTLs in determining the susceptibility to renal 
damage. These studies are performed in single congenic rats, carrying one of the Rf-QTLs from the FHH 
strain on the genomic background of the ACI strain. The linkage analyses also suggested interactions 
between Rf-1 and other Rf-QTLs. Therefore the second aim is to directly assess the possible interaction 
between Rf-1 and the other four Rf-QTLs in enhancing renal damage susceptibility. These studies are 
performed in double congenic rats, carrying both Rf-1 and another Rf-QTL from FHH on the genomic 
background of the ACI strain. The third aim is to establish whether the supposed interactions between the 
QTLs are affected by the treatments employed to induce chronic renal damage. It has been shown that an 
impaired renal autoregulation is involved in the high susceptibility to renal damage in the FHH rat. Thus, the 
fourth aim is to establish the role of the Rf-QTLs in the autoregulation of the renal blood fl ow.
 The outline of this thesis is as follows. Chapter 2 describes the generation and genetic lay-out 
of the ACI.FHH-Rf single and double congenic rats. The congenic strains were generated using a speed 
congenic strategy with marker-assisted breeder selection. Each of the congenic rats has been characterized 
by dense genotyping. 
Functional studies
Drug studies
Linkage analysis
Consomic rats
Congenic rats
ENU-induces mutagenesis
Knockouts, knockins
Linkage analysis
Association analysis
Clinical studies
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Chapter 3 describes the renal damage susceptibility and renal autoregulation in single 
congenics rats carrying either the Rf-1B or Rf-5 region of the FHH rat onto an ACI genomic background. 
The susceptibility to renal damage was assessed using four models. First the control situation where no 
interventions were made, and the rats remained with two kidneys and were normotensive. In the second 
model, an UNX is performed to reduce the functional renal mass. The third model consisted of rats receiving 
L-NAME to induce a level of hypertension, which is normally present in the FHH rat. The fourth model was 
a combination of UNX and L-NAME induced hypertension.
 Chapter 4 describes the renal damage susceptibility and renal autoregulation in congenic rats 
carrying either the Rf-1A or Rf-4 regions alone as well as the combination of Rf-1A and Rf-4. Renal damage 
susceptibility is again tested using the four treatment models.
Chapter 5 describes the role of the Rf-3 region alone and combined with the Rf-1A region in the 
development of renal damage. 
Chapter 6 describes the susceptibility to renal damage of the combination of the Rf-5 region with 
Rf-1B and the comparison with a similar double congenic carrying the Rf-1B and Rf-4 region.
 Chapter 7 describes the renal damage susceptibility and renal autoregulation in double congenic 
rats carrying the Rf-1A and Rf-2 regions in comparison with FHH and FHL rats. Due to an increased 
susceptibility to L-NAME, renal damage susceptibility in these strains is only tested in the 2K and UNX-
situation.
 Chapter 8 describes the results of employing the remnant kidney model (RKM) to assess 
differences in renal susceptibility. In the RKM about 75% of the renal mass is removed inducing hypertension 
and chronic renal failure.
Chapter 9 contains the general discussion and presents the conclusions drawn from the various 
studies described in this thesis. It also presents perspectives for future studies. 
Chapter 10 ends the thesis with an English and a Dutch summary.
Chapter 1
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A panel of congenic rat strains derived from ACI and FHH rats to study 
the genetics of progressive renal damage
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Introduction
Chronic kidney disease (CKD) is a major health problem all over the world.160,244,263,285 The 
presence of CKD is not only a risk factor for the development of end-stage renal failure (ESRF), but also for 
cardiovascular disease (CVD).217 Hypertension and diabetes are the underlying causes in most patients.181 
However, hypertension and diabetes do not always result in ESRF, but are rather risk factors infl uencing the 
susceptibility to renal damage.71,75,127 Familial clustering and ethnic differences in the prevalence of ESRF 
are well documented.11,201,220,222,226,247,248,263 Therefore, genetic factors are thought to play an important role 
in the initiation and rate of progression of ESRF. Genetic linkage studies in patients with various forms of 
nephropathy indicate that multiple chromosomal loci appear to be involved.18,37,39,74,77,78,86,111,114,166,184,202,203,259,277,294 
In addition, there may be predisposing environmental risk factors, and gene-gene and gene-environment 
interactions.38,169,219 Animal studies may be helpful to unravel the complex genetics of ESRF.
Renal damage susceptibility in rats
Inbred rat strains also vary widely in their susceptibility to develop renal damage. Strains such 
as the Fawn-Hooded Hypertensive (FHH), the Buffalo (BUF), the Munich Wistar Fromter (MWF), and the 
Dahl Salt Sensitive (SS) develop some degree of spontaneous proteinuria (UPV) and albuminuria (UAV). 
Linkage analyses have identifi ed about 70 quantitative trait loci (QTL) linking chromosomal markers to 
renal damage traits, such as UPV, UAV, structural renal damage, etc.25,84,88,113,172,175,224,225,234,235 Our studies 
involve the FHH rat, prone to develop mild hypertension and marked renal damage at a young age, and are 
well characterized by numerous physiological and histological studies.133,198,238,239,272,273,279 Crosses between 
FHH and the renal damage resistant ACI rat revealed the presence of fi ve QTLs linked to UPV and other 
parameters of renal damage. These QTLs were named Rf-1 to Rf-5.25,234 The LOD-scores and the position 
of these QTLs are presented in Table 1. The Rf-1, Rf-2, and Rf-3 QTLs were signifi cantly linked to UPV, 
whereas the Rf-4 and Rf-5 QTLs were suggestive for linkage. It is surmised that each of these QTLs contain 
one or more genes that play a role in the development of progressive renal damage in the FHH rat. The high 
LOD-score peak for UPV indicates that Rf-1 must contain one or more genes that play an important role in 
defi ning the high susceptibility to renal failure in the FHH rat. However, the presence of four additional QTLs 
that infl uence UPV underscores the complexity of the genetics of renal failure.234
Localization of the chromosomal regions that contain susceptibility genes is only the beginning 
of a long road that should lead to the identifi cation of the individual genes. Gene identifi cation is essential 
for further understanding of the function of genes and the pathway by which the mutated genes may result 
in an increased susceptibility to renal damage. The fi rst step to reach these goals is to generate a panel of 
congenic rat strains.89,300 
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Table 1: Location of the rat renal failure QTLs and their human and mouse homologs.
QTL LOD-score
Rat
95% C.I. 
Human
Homolog
Mouse
Homolog 
Chr. Mb Chr. Mb Chr. Mb
Rf-1 16.7 (1) 1 243-257 10 95-109 19 37-50
Rf-2 5.4 (1) 1 138-173
15
11
11
81-78
88-71
3-15
7 68-102
Rf-3 6.1 (1) 3 117-146
20
20
20
1-25
0-1
29-33
2 126-155
Rf-4 4.1 (2) 14 5-20 14
90-89
89-73 5 103-88
Rf-5 3.0 (2) 17 55-68
7
1
10
1
39-42
0.2-0.2
32-29
0.2-0.2
13
18
13
17-13
7-3
13-12
Congenic strains in general 
Congenic strains are animal strains in which the native genomic background of the recipient is 
maintained unchanged except for a specifi c genomic region of interest, which incorporates the QTL that is 
transferred from a donor strain.207,236 Congenic strains are useful for studying the effects of specifi c genes 
or genomic regions against a common inbred background. The use of congenic strains has evolved during 
the past decade as the major working algorithm used by researchers in their attempts to narrow down the 
span of QTLs.136,300 
Single congenics provide direct evidence for an effect of the QTL, i.e. on the disease trait or a 
physiological parameter of a disease trait. Interactions between a gene and the environment can also be 
revealed. Double congenics are used because they provide direct evidence for gene-gene interactions that 
can either be additive or epistatic and for gene-environment interactions. When more QTLs are involved, 
triple or multiple congenics can also be generated and studied. 
Breeding of congenic rats
Several crossing methods have been developed for generating congenic rat strains207,154,236, 
depending on whether the characteristic that has to be dealt with is either recessive, co-dominant or 
dominant. The method shown in Figure 1 is a widely used method to generate congenic rat strains. After eight 
to twelve backcrosses, according to Mendelian laws, more than 99% of the genetic background is that of the 
recipient strain. On completion of the backcrossing, the fi nal step of brother x sister mating fi xes the strain 
so that the desired chromosomal region is homologous for the donor’s alleles in one quarter of the offspring. 
The generation of congenic rat strains can be accelerated by using marker-assisted breeding selection or 
“speed” congenic method. This allows for the selection of a ‘best male’ at each stage of backcrossing which 
has the least amount of donor alleles in the genetic background whilst still maintaining heterozygosity at 
QTL = quantitative trait locus; LOD = logarithm of the odds; Rf = congenic rat strain; Chr. = chromosome; C.I. = confi dence 
interval; Mb = Megabase;  (1): signifi cant linkage for UPV; (2): suggestive linkage for UPV.
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the chromosomal region of interest. By selecting for the ‘best male’ the number of backcross generations 
needed to establish congenic strains in the rat is reduced to approximately fi ve instead of the traditional 
eight to twelve. This speed congenic strategy can save nearly two years of backcrossing at the price of 
genotyping hundreds of markers.120,154,159,207 
Figure 1:  Scheme of producing an Rf-congenic 
rat 
*1 selected on development of renal damage; *2 genotyped 
for heterozygosity of Rf and with the most ACI alleles; *3 
selected for homozygosity of Rf; *4 can be used to set up a 
congenic line; N = generation; F = offspring
   
     FHH x ACI
             ¾
           F1 x F1
       ¾
                           (3x) ♀ ACI x ♂ F2*1
    ¾
                          ♂ ACI x ♀ N1
      ¾
                  ♀ ACI x ♂ N2*2
     ¾
          ♀ ACI x ♂ N3*2
   ¾
 ♀ ACI x ♂ N4*2
  ¾
      ♀ N5*2 x ♂ N5*2
   ¾
            ♀ N5F1*3 x ♂ N5F1*3
     ¾
                         N5F2*4
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Two types of congenic strains can be generated. In the fi rst type, a QTL region that is linked to a 
trait in the disease in the recipient strain can be substituted by the region of a non-diseased donor. These 
congenics are then tested to determine if the trait is absent, or less severe. In other words, research is 
focused on (partly) rescuing the phenotype by the congenic substitution. In the second type, congenic rats 
are generated by introgressing a QTL region of a diseased donor strain into the genomic background of the 
non-diseased recipient. This type of congenics is then tested to determine if the disease trait does (partly) 
occur in the congenic strain because of the introgressed QTL region. For our studies the second type of 
congenic strains were generated.
The advantage of congenic rats is that it is possible to establish alleles of a small and well-defi ned 
set of loci on a common genetic background. The major disadvantages are the loss of genetic variability and 
the extreme effort that is necessary to develop and maintain congenic rats.89
So far, several congenic strains have been generated to discover genes infl uencing the 
development of hypertension.56,64,159,207 Congenic strains for diseases such as diabetes, arthritis and obesity 
are also widely used.3,22,107,170,241 However, the use of congenic strains for assessing susceptibility to renal 
damage is still marginal and mainly linked to hypertension research. Congenic rats carrying Rf-regions will 
expand the amount of congenic strains available for assessing susceptibility to the development of renal 
damage.
Congenic rat strains to study renal susceptibility
Over the last decade we have been generating congenic rat strains carrying Rf-QTLs of the FHH 
rat on the background of the ACI rat strain. Here we present an overview of our progress in generating 
congenic strains carrying one or more Rf-regions. 
Congenic lines were generated by using the speed congenic method.154,199,267,270 Since the Rf-1 
QTL gave a LOD-score of around 16, our main interest is the single Rf-1 congenics and congenics carrying 
Rf-1 in combination with other Rf-QTLs. At this moment we have two Rf-1 single congenic rat strains, a 
single Rf-2, a single Rf-3, a single Rf-4 and a single Rf-5 congenic. The Rf single congenic rats carry 25-
117Mb of the FHH rat onto an ACI genomic background, which means that the rats are 96-99% ACI with 
the exception of the 1-4% Rf-region of the FHH rat. Figure 2 visualizes the Rf single congenics by depicting 
which Rf-regions of the FHH are introgressed into the ACI genomic background. Table 2 shows the total size 
of the introgressed regions of the FHH, where the regions are located and on which chromosome. 
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Table 2: Rf-regions introgressed in the Rf single congenics
Congenic RNO region Total (Mb)
Rf-1A 1 225-267 42
Rf-1B 1 229-254 25
Rf-2 1 112-188 76
Rf-3 3 46-163 117
Rf-4 14 5-30 25
Rf-5 17 21-69 / 82-97 48 / 15
Rf = renal failure; RNO = rat chromosome; Mb = Megabase
Double congenics are available in the combinations of Rf-1 and Rf-2, Rf-1 and Rf-3, Rf-1 and 
Rf-4, and Rf-1 and Rf-5. The Rf double congenic rats carry 74-154Mb of the FHH rat onto an ACI genomic 
background, which means that the rats are 95-98% ACI with the exception of the 2-5% Rf-region of the FHH 
rat. Figure 3 visualizes the Rf double congenics by depicting which Rf-regions of the FHH are introgressed 
into the ACI genomic background. Table 3 shows the total size of the introgressed regions of the FHH, 
where the regions are located and on which chromosome.
Complex gene-gene interactions should be revealed in double or multiple congenics, as well as 
the interaction of genes with environmental factors known to infl uence the progression of renal failure, such 
as hypertension, renal mass reduction, protein intake, and so forth. The ultimate goal will be to generate a 
congenic rat carrying all fi ve Rf-QTLs of the FHH rat onto an ACI genomic background.
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Table 3: Rf-regions introgressed in the Rf double congenics
Congenic RNO region Total (Mb)
Rf-1A+2A
1
1
230-267
112-212
37
100
Rf-1A+2B
1
1
230-267
97-188
37
91
Rf-1A+3B
1
3
230-267
46-163
37
117
Rf-1A+3C
1
3
238-267
53-163
29
110
Rf-1A+4
1
14
224-267
5-29 / 36-74
43
24 / 38
Rf-1B+4
1
14
224-258
5-26 / 36-74
34
21 / 38
Rf-1B+5
1
17
229-253
20-69 / 96-97
24
49 / 1
Rf = renal failure; RNO = rat chromosome; Mb = Megabase
Combining physiology with genetics
 Physiology must be combined with genetics in order to fi nd out which genes in the Rf-regions 
are responsible for susceptibility, initiation or progression of renal damage. The Rf-congenic rat strains that 
carry either a single Rf-QTL or the combination of Rf-1 and another Rf-QTL can be helpful to unravel the 
mechanisms of the development of severe renal damage.
Unravelling the mechanisms behind the development of renal damage can be done using various 
studies. First, renal susceptibility should be assessed. When renal susceptibility is present, studies looking 
into renal physiology should be performed. Gene expression studies can be done to fi nd out if there 
are differences in gene activity between two rat strains. When fi nding renal susceptibility genes in one 
species, comparative genomics can help to fi nd where these renal susceptibility genes are present in other 
species.
Various methods are available to assess susceptibility to develop renal damage. Several studies 
have shown that reduced renal mass, either congenital or acquired, increases the risk of developing 
renal damage.169,256,289 Renal mass can be reduced by performing unilateral nephrectomy (UNX) or 5/6 
subtotal nephrectomy.97,274 Another risk factor for the development of renal damage is hypertension. 
Hypertension can be spontaneously present117 or induced in several ways: deoxycorticosterone acetate-
salt-induced hypertension100,144, cadmium-induced hypertension8, angiotensin II-induced hypertension221, 
ouabain-induced hypertension213, or L-NAME-induced hypertension.274,275,276 For our studies we tested four 
experimental situations to compare the susceptibility to develop chronic kidney damage. First, we have a 
control situation, where no interventions are made. This model looks at a situation where renal mass and 
systolic blood pressure (SBP) are normal. The second model looks at the effect of reduced renal mass 
following UNX. The third model is a two-kidney model with L-NAME induced hypertension. The fourth model 
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combines UNX and L-NAME induced hypertension. With these models, differences in development of renal 
damage, dependent on the presence of renal susceptibility genes, can be detected.199,267,274,275,276
In addition, studying the renal physiology of the congenic strains can unravel potential pathways 
that may explain an enhanced susceptibility and may thus be helpful in the gene identifi cation studies. A 
possible pathway could be an impaired renal autoregulation. Previous studies indicated that FHH rats have 
an impaired myogenic response of the autoregulation system, however, the tubular glomerular feedback 
(TGF) is intact.272,273 Renal autoregulation system in general can be determined by assessing renal blood 
fl ow when increasing renal perfusion pressure. Whether myogenic response or TGF is impaired can be 
assessed by performing micropuncture studies.273 Another possible pathway is an increased glomerular 
permeability. Normally, the glomerular membrane is impermeable for proteins. When this glomerular 
membrane is damaged, leakage of proteins into the urine can occur. The permeability of the glomerular 
membrane can be assessed by the albumin permeability assay.232 
Gene expression studies create an opportunity to reveal differences in gene activity between 
different kinds of rats. There are many techniques that help us identify and isolate transcripts that are 
differentially expressed, e.g. microarray or suppressive subtraction hybridisation (SSH).57,83,223 Microarrays 
are commercially available (Affymetrix) but can also be custom made. Microarrays are used to assess 
which genes are upregulated or downregulated. The SSH can be performed with the help of commercially 
available kit. It is a powerful technique that makes it possible to compare two populations of mRNA and 
obtain clones of genes that are expressed in one rat strain but has a reduced expression or is not expressed 
at all in the other rat strain. The main difference between microarrays and SSH is that the SSH method 
leaves out the genes that are expressed equally in both subjects. The SSH method is particularly well suited 
for the identifi cation of target cDNAs that correspond to rare transcripts, which are typically the most diffi cult 
to obtain in microarrays.57,83,223 
Gene expression studies can reveal differences between FHH and ACI. More detailed differences 
can be obtained comparing ACI and congenic strains, especially when differences are present between 
genes located within the congenic regions of the FHH. These studies will hopefully lead to identifi cation of 
genes involved in the development of renal damage.
Rat, mouse and human homology
 With the completion of the sequencing of the human, mouse and rat genome, genomic 
comparisons between these three species are greatly facilitated.87,135,278,287 Comparative genomics combined 
with physiological information will facilitate the discovery of mammalian genes that underlie physiological 
pathways that are involved in disease.261 In addition, it should lead to the development of better pre-clinical 
models of human disease, which will aid in the discovery of new therapeutic targets.23,116,250 Chromosomal 
regions of human and mouse homologous to the Rf-regions in the rat are depicted in Table 1 (http://www.
ncbi.nlm.nih.gov/projects/Homology).
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Conclusion
The mapping of many physiological traits to the genome should help to accelerate our understanding 
of the biology of disease by guiding and facilitating the identifi cation and functional understanding of disease 
genes.116 Etiology and pathology of the susceptibility to the development of chronic renal insuffi ciency can 
be unravelled in congenic animal models. Characterization of genes and gene-gene interactions in rats 
can lead to identifi cation of homologous genes in humans. Finally, this can lead to a change in prediction, 
diagnosing, treatment and prevention of progressive renal damage in humans.
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Abstract
Background: Linkage analyses of crosses of the susceptible to renal damage FHH (fawn-hooded 
hypertensive) and the resistant to kidney damage ACI (August x Copenhagen Irish) rats indicated that 
fi ve quantitative trait loci (QTLs), Rf-1 to Rf-5, infl uence proteinuria (UPV), albuminuria (UAV) and focal 
glomerulosclerosis (FGS). Here we present data obtained in congenic rats to directly assess the role of the 
Rf-1 and Rf-5 QTLs. 
Methods: Renal damage (UPV, UAV, and FGS) was assessed in ACI, ACI.FHH-(D1Rat324-D1Rat156) (Rf-
1B), and ACI.FHH-(D17Rat112-D17Arb5)(D17Rat180-D17Rat51) (Rf-5) congenic rats in the two-kidney 
(2K) control situation, and following L-NAME-induced hypertension, unilateral nephrectomy (UNX), and 
UNX combined with L-NAME. In addition we investigated renal blood fl ow (RBF) autoregulation in 2K 
congenic and parental ACI and FHH rats.
Results: Compared to ACI, Rf-1B congenic rats after all three treatments showed a signifi cant increase in 
susceptibility to renal damage. The increase was most pronounced after UNX with L-NAME. In contrast, 
the degree of renal damage in Rf-5 congenic rats was not different from the ACI. Like FHH, Rf-1B rats 
had an impaired renal autoregulation. In contrast, RBF autoregulation of Rf-5 rats does not differ from 
ACI. Conclusion: The Rf-5 QTL does not show any direct effect. The Rf-1 QTL carries one or more genes 
impairing renal autoregulation and infl uencing renal damage susceptibility. Whether these are the same 
genes remains to be established. 
41
Renal damage susceptibility and autoregulation in Rf-1 and Rf-5 congenic rats
Introduction
The incidence and progression of kidney damage, eventually resulting in end-stage renal failure 
(ESRF) is an increasing international health care problem.263 Systemic hypertension is often seen in chronic 
kidney disease, but not every patient with hypertension develops ESRF. This indicates that systemic 
hypertension may be a risk factor, but is in itself not suffi cient to cause ESRF.14,71,127 Over the last 8 years, 
several studies in human and animal models have demonstrated that genetic components play a critical role 
in hypertension-associated ESRF.12,198,290 
The FHH (Fawn-Hooded hypertensive) rat is known to develop hypertension that is followed by 
renal damage at a young age.238 Our previous studies with crosses of the FHH and the ACI (August x 
Copenhagen Irish), which is resistant to renal failure, revealed the presence of 5 quantitative trait loci 
(QTLs) linked to the development of renal damage. These QTLs were named Renal failure-1 (Rf-1) to Rf-
5.25,234 It is surmised that each of these QTLs contains one or more genes that play a role in the development 
of progressive renal damage in the FHH rat. Although the nature of the genes has yet to be identifi ed, 
the separate role of each QTL in the initiation and progression of renal damage can be studied in single 
congenic rat strains carrying one Rf-region of the FHH rat transgressed into the genomic background of 
the resistant ACI rat. The ability to use these congenic rats, carrying about 30-60 Mb (i.e. 1-2%) of the FHH 
genome offers unparalleled power to investigate the mechanisms underlying the development of chronic 
renal damage. In a later stage, interaction between the QTLs can be studied in double, multiple congenic 
strains, or consomic strains.116
As the ACI is normotensive, and the renal failure requires an interaction with blood pressure, 
there is a need to increase blood pressure in the congenic animals. Previously, we reported about the 
development of renal damage after unilateral nephrectomy (UNX), and UNX combined with L-NAME 
induced hypertension in the congenic ACI.FHH-(D1Rat324-D1Rat156) rat, Rf-1B for short.199 The Rf-1B rats 
developed signifi cantly more proteinuria (UPV) and albuminuria (UAV) than the ACI control strain during a 
24-week study. As expected this difference was most pronounced when UNX was combined with L-NAME-
induced hypertension. These fi ndings indicated that the Rf-1B region of the FHH rat contains one or more 
genes affecting the susceptibility to progressive renal damage.
 Studies in the parental FHH strain have indicated an impaired autoregulation of the renal blood 
fl ow (RBF) and intraglomerular pressure (PGC) as an important mechanism in the early development of renal 
damage.272 Due to an impaired myogenic response, FHH rats are unable to maintain a constant PGC when 
faced with a change in systemic blood pressure.273 We hypothesized that autoregulation would be impaired 
in one or more of the congenic animals carrying a single renal failure locus.
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Methods
Animals (general)
Male Rf-1B, and ACI.FHH-(D17Rat112-D17Arb5)(D17Rat180-D17Rat51) (Rf-5 for short) congenic 
rats and control ACI/EUR and FHH/EUR rats were used. All breeding was performed at the Animal Research 
Centre at Erasmus MC, Rotterdam, the Netherlands. Animals were housed in individually-ventilated cages 
under SPF-conditions.180 Lights were on from 7:00 a.m. to 7:00 p.m. Standard commercial rat chow 
containing 44% carbohydrates, 29% digestible protein, 7% fat, 4% fi bre, and 8% minerals (SRM-A; Hope 
Farms, Woerden, the Netherlands) and drinking fl uid (tap water, acidifi ed to pH 2.4-2.8) were provided ad 
libitum. The protocols were approved by the animal ethical committee (DEC) at Erasmus MC, Rotterdam.
The Rf-5 congenic strain was generated using a speed congenic strategy as described for the Rf-
1B strain by Provoost et al.119 The congenic (homozygous FHH) region of the Rf-1B strain is on chromosome 
1 between markers D1Rat384 (229.4 Mb) and D1Rat156 (253.7 Mb), spanning 24.3 Mb, about 9% of the 
chromosome. The Rf-5 congenic region on chromosome 17 is split in two parts. One between markers 
D17Rat112 (21.0 Mb) and D17Arb5 (69.3 Mb), spanning 48.3 Mb, the other between markers D17Rat180 
(82.8 Mb) and D17Rat51 (96.6 Mb), spanning 13.8 Mb. The two regions cover about 64% of chromosome 
17. A whole genome scan with about 150 genetic markers distributed across the genome in each of these two 
congenic rats showed that they did not contain genetic contamination of FHH on other chromosomes.119
Renal damage susceptibility
Animals
Experiments for assessment of renal damage susceptibility were performed on 101 animals (35 
ACI, 31 Rf-1B, and 35 Rf-5) divided across the control and three treatment groups starting from the age 
of 6-7 weeks, with a body weight (BW) of 100-120g. The control group had both kidneys and received no 
treatment (2K). Group two had both kidneys and was chronically treated with Nω-nitro-L-arginine methyl 
ester (L-NAME, Sigma-Aldrich Chemicals, Zwijndrecht, the Netherlands) (2K+L-NAME) to induce systemic 
hypertension. The third group was unilaterally nephrectomized (UNX). The fourth group had both an UNX 
and received L-NAME (UNX+L-NAME). The number of rats per strain for each treatment is presented in 
Table 1.
Unilateral nephrectomy and induction of hypertension
UNX was performed as previously described.274 L-NAME was dissolved in the acidifi ed drinking 
water at a concentration of 150 mg/L.274 Treatment with L-NAME was started 5 days after surgery. Control 
animals were provided with acidifi ed drinking water. Actual L-NAME intake was in the order of 8-13 mg/day/
kg BW in the 2K+L-NAME situation, and 11-15 mg/day/kg BW in the UNX+L-NAME situation. No signifi cant 
differences in L-NAME intake were present between the four strains at all time points following 2K+L-
NAME treatment, nor at the fi rst and second evaluation with UNX+L-NAME treatment. However, at the 
fi nal evaluation, the Rf-1B rats showed a signifi cantly higher intake of L-NAME compared to ACI (data not 
shown).
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Urine collection and blood pressure monitory
Urine of individual rats was collected after 6, 12, and 18 weeks of treatment. The animals were 
housed in metabolic cages (Tecniplast, Buggugiate, Italy). Urine was collected during two consecutive days 
after a three-day adaptation period. 
Following the urine collection, SBP was measured by the tail-cuff method, using a photoelectric 
oscillatory detection device (IITC Life Science, Woodland Hills, CA) in awake, restrained rats, as described 
previously.199 
Autopsy
An autopsy was carried out shortly after the last series of urine collections and SBP measurements. 
The rats were anaesthetized and a 20-gauge needle (Braun, Melsungen, Germany) was introduced into the 
aorta at the bifurcation of the left and right iliac artery and a blood sample was taken. Kidneys were collected 
and weighed and the left kidney was used to determine extent of glomerular damage, i.e. the incidence of 
focal glomerulosclerosis (%FGS). Briefl y, kidneys were longitudinally dissected, and were then fi xed by 
immersion in 3% Formalin (Fresenius Kabi, ‘s-Hertogenbosch, the Netherlands). After fi xation, the kidneys 
were embedded in paraffi n, sectioned and prepared for light microscopy. The %FGS was determined in 1-
μm sections stained with periodic acid-Schiff (PAS) reagent, by examining 50 glomeruli.275
Renal blood fl ow autoregulation
Experiments to assess RBF autoregulation were performed on 63 animals (15 ACI, 15 FHH, 18 
Rf-1B, and 15 Rf-5 rats) with an average age of 14 weeks. Animals were anaesthetized with a mixture of 
3% Isofl urane®, 30% N2O, and 60% O2 and surgically prepared for autoregulation studies.272 After surgery 
and a 10-min equilibration period, the relationship between the left renal artery blood fl ow and the renal 
perfusion pressure (RPP) was determined. In each animal RPP was increased by ligating the celiac and 
mesenteric arteries together. RBF was recorded using a 1.5 mm fl ow probe and a fl ow meter (Transonic 
Systems Inc, Ithaca, USA) as the RPP measured at the femoral artery, using a Datex-Ohmeda S/5 Light 
Monitor (Datex-Ohmeda, Hoevelaken, the Netherlands) was lowered from 150 to 80 mm Hg in 10 mm Hg 
steps by tightening the clamp around the aorta above the renal arteries, followed by a 3-min equilibration 
period. When the RPP did not reach 150 mm Hg, we put a clamp around the aorta beneath the renal arteries 
and measured the RPP at the carotid artery. 
The degree of renal damage was also determined. Before the autoregulation experiment rats 
were put in the metabolic cages for one day, and a 24-hr urine sample was collected to measure UPV and 
UAV. After the evaluation, the left kidney was used to determine %FGS.
Calculations
 To normalize the outcome of the individual rats, the RBF at a RPP of 100 mm Hg (RBF100) was 
considered to be 100%. At each level of RPP (x) the percentage RBF (%RBF) was calculated using the 
following formula:
% RBFx = (RBFx/RBF100) * 100   
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Renal autoregulatory indexes  (RAIs) over the range of pressures from 80 to 150 mm Hg were calculated by 
the method of Semple and de Wardener228 using the following formula:
RAI = [(RBF2 - RBF1)/(RBF1)]/[(RPP2 – RPP1)/RPP1)]
The RAIs were calculated assuming that RPP was reduced in a single step from a high pressure (RPP2) to 
a lower pressure (RPP1). A RAI of 0 indicates perfect autoregulation of RBF, and a RAI of 1 indicates that 
there is no autoregulation present due to a fi xed renal vascular resistance.
Analytical procedures and statistics
 Plasma and urinary samples were analysed with an ELAN system (Eppendorf-Merck, Hamburg, 
Germany) using colorimetric assays. Total urinary protein was determined colorimetrically with pyrogallol 
red-molybdate complex.286 Urine and plasma albumin (Palb) was determined with bromocresol green.62 
Plasma creatinine (Pcreat) was determined with the Jaffe method without de-proteinisation.240
Data are presented as mean ± SEM. Statistical differences in mean values between groups were 
compared using one way analysis of variance (ANOVA). The ANOVA test was followed by the Bonferroni 
t-test to determine which of the congenic strains were signifi cantly different from each other. In all tests, a p-
value <0.05 was considered statistically signifi cant. All tests were performed using the Primer of Biostatistics 
for Windows program (Version 4.0, McGraw Hill, 1996).
Results
Assessment of renal damage susceptibility
Proteinuria, albuminuria, and systolic blood pressure
The UPV and UAV levels during the various treatments in the ACI and congenic rat strains are 
presented in Figure 1A-1D. To correct for small differences in BW between the strains and treatments, UPV 
and UAV values are presented per 100g BW. 
In the 2K-situation no signifi cant differences in UPV and UAV were observed between the three 
strains (Figure 1A). A signifi cant increase in UPV and UAV was present in Rf-1B rats following 12 and 18 
weeks of 2K+L-NAME treatment (Figure 1B). In Rf-1B congenics an elevation of UPV and UAV was present 
at 18 weeks after UNX (Figure 1C). Following UNX+L-NAME treatment, UPV and UAV were signifi cantly 
increased in the Rf-1B rats at all three time-points (Figure 1D). No statistically signifi cant differences in 
UPV or UAV were found in the Rf-5 rats when compared to ACI, regardless of treatment and time (Figure 
1A-1D).
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Figure 1: Proteinuria (total bar) and albuminuria (black part of the bar) in ACI, Rf-1B, and Rf-5 rats after 
6, 12 and 18 weeks of follow-up. A: 2K, 2-kidneys; B: 2K+L-NAME; C: UNX, unilateral nephrectomy; D: 
UNX+L-NAME. Values are given as mean ± SEM; Note the differences in scaling of the Y-axis. *: p < 0,05 
versus ACI for UPV; **: p < 0.05 versus ACI and Rf-5 for UPV; ***: p < 0.05 versus Rf-5 for UPV; +: p < 0.05 
versus ACI for UAV; ++: p < 0.05 versus ACI and Rf-5 for UAV; +++: p < 0.05 versus Rf-5 for UAV.
The SBP levels during the 18 week follow-up are presented in Figure 2A-2D. In the 2K- and 
UNX-situation, SBP in all strains remained normotensive, with no signifi cant differences present (Figure 
2A and 2C). As anticipated, chronic L-NAME treatment raised SBP in all strains. Signifi cant differences 
were occasionally noted. At 12 weeks, SBP after 2K+L-NAME treatment in Rf-1B and Rf-5 was signifi cantly 
increased compared to ACI, while after UNX+L-NAME treatment, Rf-5 had a signifi cantly higher SBP 
compared to ACI rats. At 18 weeks, SBP after 2K+L-NAME in Rf-1B was signifi cantly increased compared 
to ACI. No signifi cant differences were present between 2K+L-NAME or UNX+L-NAME treated Rf-1B and 
Rf-5 congenic rats, indicating that blood pressure alone cannot account for the differences in proteinuria 
between the two congenic strains.
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Figure 2. Systolic blood pressure in ACI ({), Rf-1B (S), and Rf-5 ( ) rats after 6, 12 and 18 weeks of 
follow-up. A: 2K, 2-kidneys; B: 2K+L-NAME; C: UNX, unilateral nephrectomy; D: UNX+L-NAME. Values are 
given as mean ± SEM (error bars); *: p < 0.05 versus ACI.
Autopsy fi ndings are summarized in Table 1. The % FGS was signifi cantly higher in Rf-1B rats 
compared to ACI following UNX+L-NAME treatment. In comparison to ACI, the Pcreat level was signifi cantly 
higher in Rf-1B rats following UNX+L-NAME treatment, while the Palb level was signifi cantly decreased. 
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Table 1: Autopsy fi ndings in the chronic experiment.
n BW (gram) FGS(% glom.)
Pcreat 
(μmol/l)
Palb
(g/l)
2K
ACI 8 315 ± 6 8 ± 2 49 ± 3 29.2 ± 0.2
Rf-5 7 283 ± 8* 2 ± 1 49 ± 3 29.7 ± 0.5
Rf-1B 8 309 ± 3 15 ± 3° 48 ± 2 28.5 ± 0.5
ANOVA P = 0.022 P = 0.006 P = 0.945 P = 0.167
2K+L-NAME
ACI 8 312 ± 2 6 ± 2 51 ± 2 29.0 ± 0.4
Rf-5 9 296 ± 8 5 ± 6 48 ± 1 29.9 ± 0.4
Rf-1B 7 293 ± 6 16 ± 5° 59 ± 5 27.4 ± 1.3
ANOVA P = 0.159 P =0.035 P = 0.090 P = 0.090
UNX
ACI 8 308 ± 5 5 ± 1 54 ± 2 29.4 ± 0.5
Rf-5 10 301 ± 4 2 ± 1 51 ± 2 28.3 ± 0.6
Rf-1B 8 284 ± 5* 9 ± 3° 52 ± 1 27.3 ± 0.9
ANOVA P = 0.008 P = 0.037 P = 0.568 P = 0.176
UNX+L-NAME
ACI 11 292 ± 9 13 ± 2 68 ± 4 27.9 ± 0.3
Rf-5 9 284 ± 6 8 ± 2 65 ± 2 28.7 ± 0.6
Rf-1B 8 235 ± 9*° 41 ± 9*° 118 ± 21*° 24.0 ± 1.0*°
ANOVA P < 0.001 P < 0.001 P = 0.010 P < 0.001
Assessment of renal blood fl ow autoregulation 
Autoregulation curves for the relative RBF (%RBF) are presented in Figure 3. There are signifi cant 
differences in %RBF between different strains as RPP is increased between 110 to 150 mm Hg. The relative 
increase in RBF at RPP at 150 mm Hg, compared to RBF at 100 mm Hg, was signifi cantly higher in FHH 
(35±3%) and Rf-1B (35±2%) as compared to ACI (12±1%) and Rf-5 (9±1%). The nearly 1 to 1 correlation 
in %RBF with each change in RPP in the FHH was as expected.272 Interestingly, only the Rf-1B congenic 
had an alteration in autoregulation, and appeared to completely recapitulate the FHH phenotype, while only 
carrying at most 1% of the FHH genome. These data suggests the gene(s) responsible for autoregulation 
is within the Rf-1 interval.
Values are given as means ± SEM. 2K, 2-kidneys; UNX, unilateral nephrectomy; BW, body weight; FGS, incidence 
of glomerulosclerosis; Pcreat, plasma creatinine level; Palb, plasma albumin level.  *: p <0.05 versus ACI; °: p< 0.05 
versus Rf-5.
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Figure 4 shows the renal autoregulation index (RAI), another way to express the effi cacy of the 
autoregulation. Over the pressure ranges from 90-110, 110-130, and 130-150 mm Hg, the RAIs were in the 
order of 0.2-0.3 in ACI as well as Rf-5 rats, indicating normal renal autoregulation. In contrast, RAI values 
were signifi cantly increased to levels of about 0.7-0.9 in FHH and Rf-1B rats. At no pressure interval was 
there any signifi cant difference in RAI between ACI and Rf-5 rats, nor between FHH and Rf-1B rats. 
Assessment of the degree of renal damage in the rats used this acute experiment indicated that 
UPV and UAV were signifi cantly higher in FHH rats compared to all other strains. No signifi cant differences 
were seen between ACI, and Rf-1B, and Rf-5 congenic rats (Table 2). Relatively small but statistically 
signifi cant increases in %FGS were noted in FHH and Rf-1B when compared to ACI. 
Figure 4: Renal blood fl ow autoregulatory index 
(RAI) for several renal perfusion pressures (RPP) 
ranges in ACI, FHH, Rf-1B, and Rf-5 rats. Values 
are given as mean ± SEM. ACI (white bar, n=15); 
Rf-5 (light grey bar, n=15); FHH (black bar, n=15); 
Rf-1B (dark gray bar, n=18). *:  p < 0.05 versus ACI 
and Rf-5.
Figure 3: Relationship between percentage of renal 
blood fl ow (%RBF) and renal perfusion pressure 
(RPP) in ACI ({, n=15), FHH ( , n=15), Rf-1B 
(S, n=18), and Rf-5 ( , n=15) rats. Values (as % 
RBF at RPP of 100 mm Hg) are given as means ± 
SEM. *: p < 0.05 FHH and Rf-1B versus ACI and 
Rf-5. 
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Table 2: Indices of renal damage in the animals used for the autoregulation study.
n BW(gram)
UPV
(mg/d/100 gBW)
UAV
(mg/d/100 gBW)
FGS
(% glomeruli)
ACI 15 269  ±  4 6.3  ±  0.3 1.8  ±  0.2 6  ±  1
Rf-5 15 248 ± 6 3.7 ± 0.2 1.3 ± 0.2 5  ±  1
FHH 15 308 ± 4* 39.0  ±  2.9* 28.7  ±  2.6* 13  ±  1*
Rf-1B 18 254 ± 4 7.5  ±  0.4 3.0  ±  0.2 10  ±  1*
Discussion
 The chronic in vivo studies reconfi rmed that the Rf-1B congenic rat is more susceptible to the 
development of renal damage than the ACI rat. In contrast, Rf-5 congenic rats do not show an increased 
susceptibility to renal damage, despite equivalent increases in blood pressure. As our hypothesis was that 
the inability to autoregulate renal blood fl ow is a contributing mechanism to renal failure in the FHH, we 
tested autoregulation in the two different congenic strains. If autoregulation was linked to both congenics, 
then it was the result of more then one gene and may even have been secondary to the renal disease.
This study showed that all the congenics in the control group were normotensive. Moreover, these 
data validate that Rf-1 and Rf-5 loci did not carry genes responsible for hypertension in this cross.25,234 As 
there is a clear interaction between blood pressure and renal disease there was a need to increase blood 
pressure, as the congenics we used are on the normotensive genome background of the ACI. We increased 
blood pressure by inhibiting nitric oxide using L-NAME. Hypertension is considered to be a key feature in 
the development of renal damage, and is one leading causes of ESRF all over the world.14,71,127 Loss of 
functional renal mass is another characteristic of progressive renal damage.21 Therefore, we also tested if 
the renal disease was simply the result of a decrease in renal mass, mimicked by UNX. It should be noted 
that the ACI was almost completely protected from signifi cant changes in UPV, UAV, Pcreat, and Palb, 
despite changes in renal mass and the presence of hypertension. Therefore, any change in renal indices 
found in the congenics must be the result of FHH genomic regions introgressed into the ACI genome.
In none of the four conditions was there signifi cant difference in the degree of renal damage 
between Rf-5 congenics and ACI rats. Neither hypertension nor renal mass reduction led to more severe 
kidney damage in Rf-5 congenic rats. In clear contrast, a signifi cant increase in renal susceptibility of Rf-
1B rats, compared to ACI, was present in all three conditions. Importantly, even in the 2K-situation, slight 
increase in UPV and UAV, albeit not statistically signifi cant, were present in the fi nal evaluation at 25 weeks 
of age. It is likely that with a longer follow-up the difference in UPV between Rf-1B and ACI would have 
become signifi cant. Elevating the SBP in the 2K-situation to levels similar to that of FHH rats134 enhances 
the differences in renal damage in the Rf-1B congenics, but not in the ACI rats or  Rf-5 congenics. A similar 
outcome was found by reducing renal mass. As expected, the most profound differences in renal damage 
between Rf-1B and ACI rats were present following UNX+L-NAME treatment.199
In concordance with an increased UPV and UAV in Rf-1B rats following UNX+L-NAME treatment, 
the incidence of FGS is also higher compared to other rat strains subjected to the same treatment. Similarly, 
Pcreat levels in the Rf-1B rats following UNX+L-NAME treatment were almost twice as high as obtained in 
Values are given as mean ± SEM. BW, body weight; UPV, proteinuria; UAV, albuminuria; FGS, incidence of focal 
glomerulosclerosis. *: P < 0.05 versus ACI.
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the other strains. Thus, there appears to be a good association between the degrees of structural glomerular 
damage, i.e. FGS, and functional damage, i.e. UPV, UAV, and Pcreat. A fi nal indication for an impaired renal 
function was the fi nding that in Rf-1B rats after UNX+L-NAME, the increase in UAV was paralleled by a 
decrease in Palb.
Next to 2K-control rats, three experimental situations were studied to detect differences in renal 
susceptibility. Reproducibility is by far the best in the UNX-model. Following UNX alone, Rf-1B rats already 
show increased levels of UAV and UPV compared to ACI and Rf-5 congenics, albeit statistically signifi cant 
compared to Rf-5 congenics only. However, in contrast to the parental FHH strain the congenic rats remain 
normotensive. Consequently, we have to raise blood pressure to detect changes in renal susceptibility 
resulting from the introgression of the Rf-QTLs on the ACI background. Based on our earlier experience we 
used chronic L-NAME treatment to raise systemic blood pressure.274,275 As indicated in our previous studies, 
using chronic L-NAME treatment has some disadvantages. It is diffi cult, if not impossible, to match SBP 
between the various strains at a level normally present in the FHH rat. Chronic L-NAME treatment may 
directly affect the vascular structure in the kidney, independent of its blood pressure effects.305 Furthermore, 
reducing endothelial NO-synthase activity by L-NAME may have a negative effect on the protective action 
of NO in organs that are targets of hypertensive injury.101  Thus, differences in renal damage between Rf-1B 
congenics and ACI may be partly due to an increased susceptibility to L-NAME. 
Normally, adequate renal autoregulation is able to protect the glomerular capillary structures from 
injury due to systemic hypertension. Impaired autoregulation increases susceptibility for renal damage in 
various rat models including FHH.15,94,272 Previous studies were not able to localize impaired autoregulation 
to particular chromosomal region. Here we clearly demonstrate that the Rf-1 region of rat chromosome 1 
contains one or more gene(s) responsible for impairing autoregulation before the development of severe 
renal damage. Whether it is the same gene responsible for both a lack of autoregulation and renal disease 
remains to be determined. In contrast to the fi ndings in Rf-1B, the Rf-5 congenics were shown to have a 
normal autoregulation, comparable to that of ACI rats. Consequently, the Rf-5 region contains no genes that 
infl uence renal autoregulation. 
The results from this study also shows that the severity of the renal damage in the Rf-1B congenic 
is signifi cantly less than the FHH, as would be anticipated if more than one region of the FHH were required to 
recapitulate the disease in the ACI background. Our previous linkage analyses indicated that renal damage 
in FHH is polygenic, and that the presence of Rf-1 would only have a small effect.25,234 The low LOD score 
(2.99 for UPV) of the Rf-5 QTL compared to Rf-1 (16.74 for UPV) would predict an even smaller effect on 
renal damage than Rf-1, a prediction confi rmed in our present study. It is expected that combinations of two 
or three QTLs, one of them being Rf-1 are needed to markedly increase renal susceptibility, although this 
may still not be suffi cient to induce the same severity of renal damage seen in the FHH rat. Consequently, 
although Rf-5 single congenics do not develop renal damage and do have a normal renal autoregulation, 
it is still possible that the Rf-5 QTL does infl uence development of renal damage, but only when interacting 
with other loci. It will require additional studies using double or multiple congenics carrying Rf-1 plus other 
loci. Given that impaired renal autoregulation alone does not account for the full spectrum of renal damages 
seen in FHH, it will also require physiological studies to explore other mechanisms that contribute to renal 
failure.
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Finally, it is worth noting that comparative genomics can be used to infer gene function between 
species most notably human, once a biological trait is assigned to a genomic location. Here we conclusively 
show that a gene or gene(s) infl uencing renal autoregulation reside within a 24.2Mb (229.5-253.7Mb) stretch 
of rat chromosome 1. The human homologous region is located on chromosome 10q24. In recent years, 
several studies have looked into a role of this region in human ESRF and found that it may contribute to 
renal disease in humans.78,114,303 This linkage in humans and our present data, suggests that lack of RBF 
autoregulation may contribute to renal disease in humans. Obviously, this question will require additional 
study.
In summary, the present studies indicate that transferring the Rf-1 region from the FHH to the 
ACI rat impairs renal autoregulation and increases susceptibility to renal damage, suggesting either a 
direct relationship or that the gene(s) responsible for autoregulation and the gene(s) responsible for renal 
disease are closely linked. In contrast, similar transfer of Rf-5 has no effect on autoregulation or any other 
indices of renal disease. The data suggest that the Rf-1 QTL harbors one or more genes infl uencing renal 
autoregulation. Further studies in double or multiple congenic strains are needed to provide direct evidence 
for a role of Rf-5 in the development of renal damage. Finally, renal autoregulation may need to be examined 
in patients showing linkage to the human homologous genomic region. 
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Abstract
Background. Five quantitative trait loci (QTLs), Rf-1 to Rf-5 were found in FHH (Fawn Hooded Hypertensive) 
rats infl uencing susceptibility to renal damage. Previously we found that single transfer of the Rf-1 QTL from 
FHH rats onto the renal resistant ACI (August x Copenhagen Irish) strain caused a small increase in renal 
susceptibility. To investigate the separate role of the Rf-4 QTL and its interaction with Rf-1, we generated a 
single congenic strain carrying Rf-4 and a double congenic carrying both Rf-1 and Rf-4.
Methods. Differences in renal susceptibility between ACI, Rf-1A, and Rf-4 single congenics and Rf-1A+4 
double congenics were assessed using four different treatments: control (2K), 2K with L-NAME induced 
hypertension, unilateral nephrectomy (UNX), and UNX+L-NAME. In separate experiments, renal blood fl ow 
(RBF) autoregulation was compared between two-kidney ACI and congenic rats. 
Results. Compared to ACI, Rf-1A rats developed more renal damage, while Rf-4 rats did not. The most 
severe renal damage was found in the Rf-1A+4 double congenic rats. Analysis of variance demonstrated 
a signifi cant interaction between the Rf-1A and Rf-4 QTLs. The magnitude of the interaction varied with 
the type and duration of the treatment. The RBF autoregulation was impaired in Rf-1A single and Rf-1A+4 
double congenics, while in Rf-4 single congenics it was similar to that of ACI controls.
Conclusion. These fi ndings indicate that the Rf-1 QTL directly infl uences renal susceptibility and 
autoregulation. In contrast, the Rf-4 QTL shows no direct effects, but signifi cantly increases susceptibility to 
renal damage via an interaction with Rf-1. 
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Introduction
Chronic kidney disease is assumed to be a complex polygenic disease.33,129,201,219,220 Chromosomal 
loci, as well as specifi c genes have been identifi ed in various inherited forms of renal disease.194,295 However, 
fi nding the genes involved in the more complex forms of human ESRF has been more arduous. Linkage 
analysis has identifi ed some chromosomal regions possibly involved in diabetic and non-diabetic forms of 
nephropathy, while candidate gene analyses have tested several genes with limited success.38,81,201 Studies 
in inbred rat strains might help to decrease the number of candidate gene, which could facilitate fi nding 
genes in human studies.
Inbred rat strains also vary widely in their susceptibility to develop renal damage. Our studies 
involve the Fawn Hooded Hypertensive (FHH) rat, prone to develop mild systolic hypertension and marked 
proteinuria (UPV), albuminuria (UAV), and focal and segmental glomerulosclerosis (FGS) at relatively 
young age. Male FHH rats die of ESRF within a year and a half if not treated.280,281,282 The FHH strain is well 
characterized by numerous physiological and histological studies.132,133,198,238,239,272,273,279 Crosses between 
FHH and the proteinuria resistant ACI rat revealed the presence of fi ve QTLs linked to UPV and other 
parameters of renal damage. These QTLs were named Renal failure-1 (Rf-1) to Rf-5.25,234 It is surmised that 
each of these QTLs contains gene(s) that play a role in the development of progressive renal damage in 
the FHH rat.
Even though the nature of the genes have not yet been identifi ed, the separate role of each QTL in 
the initiation and progression of renal damage can be studied in congenic rat strains that have a Rf-region of 
the FHH rat introgressed into the genomic background of the proteinuria resistant ACI rat. Next, interactions 
between the QTLs can be studied in double and multiple congenic strains. Previously, we reported about the 
susceptibility to renal damage in ACI.FHH-Rf-1B (Rf-1B for short) and ACI.FHH-Rf-5  (Rf-5 for short) single 
congenic rats.199,267 Since the ACI rat is resistant to renal damage even when made hypertensive we need 
to stress the kidney to initiate the renal failure phenotype and be able to study the effect of a single QTL 
in the ACI background. The Rf-1B congenic rats developed signifi cantly more UPV and UAV than the ACI 
progenitor strain. This difference was most pronounced following unilateral nephrectomy (UNX) combined 
with L-NAME induced hypertension. 
In Rf-1B congenic rats, renal autoregulation was impaired to the same extent as the parental FHH 
rat.272 In the FHH the impaired renal autoregulation, resulting in an elevated intra-glomerular pressure (PGC) 
is thought to be an important mechanism in the early development of renal damage.133,238,273 In contrast to 
the Rf-1B congenic rats, the Rf-5 single congenic strain showed no increase in renal susceptibility and a 
normal RBF autoregulation.267 In the Rf-1B congenic, the levels of UPV and UAV following UNX and L-
NAME treatment were much less than those found in FHH.239 This indicates that the Rf-1 QTL only accounts 
for part of the renal damage in FHH rats. Our previous linkage analysis suggested complex interactions 
between the QTLs. With the exception of Rf-1, the other Rf-QTLs by themselves showed little effect on UPV. 
However, a marked increase in UPV level was noted when these QTLs were combined with Rf-1.234 Direct 
evidence for such an interaction can be obtained by studying double congenic rats. Interactions between 
blood pressure QTLs in rats have been described previously.167,206 
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In the present experiments we wanted to test the presence of an interaction between the Rf-1 
and Rf-4 QTLs, as predicted from the linkage analysis.234 Therefore, we compared the renal susceptibility 
between the ACI progenitor strain and three congenic strains, i.e. ACI.FHH-Rf1A, ACI.FHH-Rf-4 single 
congenics, and ACI.FHH-Rf1+4 double congenics. We tested the hypothesis that a gene-gene interaction 
occurs between the Rf-1 and Rf-4 QTLs increasing the susceptibility to renal damage.
Methods
Congenic and control rat strains
For the experiments, single congenics ACI.FHH-(D1Rat298-D1Rat90) (Rf-1A for short), ACI.
FHH-(D14Mit11-D14Rat82) (Rf-4 for short), double congenic ACI.FHH-(D1Mit18-D1Rat90)/(D14Mit11-
D14Rat33/D14Rat65-D14Rat90) (Rf-1A+4 for short)  rats and ACI control rats were used. All breeding was 
performed at the Animal Research Centre at Erasmus MC, Rotterdam, Netherlands. Animals were housed 
in individually-ventilated cages under SPF-conditions as previously described.180,267 The protocol received 
approval from the animal ethical committee of Erasmus MC.
Congenic rat strains were generated using a speed congenic strategy as previously described for 
the Rf-1B strain by Provoost et al.199 A schematic view of the introgressed Rf-regions of the various congenic 
strains is presented in Figure 1. The congenics generated here contain the earlier reported 95% C.I. for Rf-1 
and Rf-4. In the Rf-1A single congenic strain, the congenic region is on chromosome 1 between markers 
D1Rat298 (227.2 Mb) and D1Rat90 (267.3 Mb), spanning 41.5 Mb, about 15% of the chromosome. The 
Rf-1A region is about 17 Mb larger than the region in the Rf-1B strain.199
In the Rf-4 single congenic strain, the region is on chromosome 14 between markers D14Mit11 
(5.0 Mb) and D14Rat82 (30.3 Mb), spanning 25.3 Mb, about 23% of the chromosome. In the Rf-1A+4 
double congenic rat the Rf-1 congenic region is between D1Mit18 (224.6 Mb) and D1Rat90 (267.3 Mb), 
spanning 42.7 Mb. In the Rf-1A+4 double congenic rat the Rf-4 region is between the markers D14Mit11 
(5.0 Mb) and D14Rat33 (29.3 Mb), spanning 24.3 Mb, i.e. 1.0 Mb smaller than in the Rf-4 single congenic. In 
addition, a second region of chromosome 14 from FHH has been introgressed between markers D14Rat65 
(36.4 Mb) and D14Rat90 (74.0 Mb), spanning 37.6 Mb. This region, however, is way outside the 95% C.I. for 
the Rf-4 QTL (between 5-20 Mb) on chromosome 14. A whole genome scan with 140-150 genetic markers 
on these three congenic strains showed that there was no detected FHH genomic contamination on other 
chromosomes.
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Fig 1. Genetic maps of rat chromosomes 1 and 14 depicting the homozygous FHH regions introgressed on 
the ACI background in the Rf-1A, Rf-4, and Rf-1A+4 congenic strains. The areas homozygous FHH in the 
congenic strains are indicated by the solid and striped lines. The arrows indicate the locations of the Rf-1 
and Rf-4 QTL peaks found in previous studies, i.e. D1Mgh12 for Rf-1, and D14Mgh7 for Rf-4.25,234 Distances 
are given in mega-base pairs (Mb). 95% C.I. represents the 95% confi dence interval of the QTLs. 
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Renal damage susceptibility
Experiments for assessment of renal damage susceptibility were performed on 164 animals 
starting from the age of 6-7 weeks. Per strain, the animals were randomly divided over four treatment 
groups (Table 1). The fi rst received no treatment, remaining with two kidneys (2K), i.e. control situation. 
The second remained with 2K and was chronically treated with Nω-nitro-L-arginine methyl ester (L-NAME, 
Sigma-Aldrich Chemicals, Zwijndrecht, the Netherlands) (2K+L-NAME) to induce systemic hypertension. 
The third treatment consisted of renal mass reduction by unilateral nephrectomy (UNX), the fourth of 
UNX+L-NAME-induced hypertension. 
Table 1: Number of rats studied in the renal susceptibility experiments.
2K 2K+L-NAME UNX UNX+L-NAME
ACI 6 6 10 9
Rf-1A 11 12 12 12
Rf-4 9 9 10 10
Rf-1A+4 12 10 12 14, 14, 10*
* Number of rats at fi rst, second and third follow-up, respectively. 2K, 2-kidneys; 
2K+L-NAME, 2K+L-NAME-induced hypertension; UNX, unilateral nephrectomy; 
UNX+L-NAME, UNX+L-NAME-induced hypertension.
Surgery for UNX and L-NAME treatment were performed as previously described.274 There was 
some variation in the amount of L-NAME intake. However, Figure 3 shows that blood pressure levels were 
equivalent among the different strains of rats within the different treatment groups. Urine of individual rats was 
collected after 6, 12, and 18 weeks of treatment. The animals were housed in metabolic cages (Tecniplast, 
Buggugiate, Italy). Urine was collected during two consecutive days after a three-day adaptation period. 
Following the urine collection, SBP was measured by the tail-cuff method, using a photoelectric oscillatory 
detection device (IITC Life Science, Woodland Hills, CA) in awake, restrained, but trained rats, as described 
previously.199 
Shortly after the last series of urine collections and SBP measurements the animals were sacrifi ced 
as previously described.267 Kidneys were collected and weighed. The left kidney was used for histological 
examination. The extent of glomerular damage was determined in 1-μm sections stained with periodic 
acid-Schiff (PAS) reagent. In each animal, 50 glomeruli of the left kidney were examined for the presence of 
sclerotic lesions, i.e., segmental glomerular scarring, obliteration of glomerular capillaries, mesangial matrix 
expansion, and adhesion formation between tuft and Bowman’s capsule. The extent of glomerular damage 
was expressed as the percentage of the glomeruli (%FGS) showed one or more of these features.267 
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Renal blood fl ow autoregulation
Experiments for assessment of renal blood fl ow autoregulation were performed on 54 animals 
(15 ACI, 12 Rf-1A, 15 Rf-4, and 12 Rf-1A+4 rats) with an age of 13-15 weeks. To get an indication of 
the presence of renal damage, UPV and UAV were assessed using a 24-hr sample obtained before the 
autoregulation experiments, while at the end of the evaluation both kidneys were collected and weighed and 
the left kidney was used to determine the %FGS, as previously described.267
Animals were anaesthetized with a mixture of 3% Isofl urane®, 30% N2O, and 60% O2 and 
surgically prepared for autoregulation studies.267,272 After surgery and a 10-min equilibration period, the 
relationship between the left kidney RBF and the renal perfusion pressure (RPP) was determined. The 
RBF was recorded as the RPP was lowered from 150 to 80 mm Hg in 10 mm Hg steps by tightening a 
clamp around the aorta, followed by a 3-min equilibration period. To normalize the outcome of the individual 
rats, the RBF at a RPP of 100 mm Hg (RBF100) was considered to be 100%. Renal autoregulatory indexes 
(RAIs) over the range of pressures from 80 to 150 mm Hg were calculated by the method of Semple and 
de Wardener.228 A RAI of 0 indicates perfect autoregulation of RBF, and a RAI of 1 indicates that there is no 
autoregulation present due to a fi xed renal vascular resistance.
Analytical procedures 
Plasma and urinary samples were analysed with an ELAN system (Eppendorf-Merck, Hamburg, 
Germany) using colorimetric assays. Total urinary protein was determined colorimetrically with pyrogallol 
red-molybdate complex.286 Plasma and urinary albumin levels were determined with bromocresol green.62 
Plasma and urinary creatinine levels were determined with the Jaffé method without deproteinisation.240
Statistics
Data are presented as mean ± SEM, unless stated otherwise. Statistical differences in mean 
values between groups were compared using one-way analysis of variance (ANOVA), followed by the 
Bonferroni-test to determine which pairs were signifi cantly different. These tests were performed using the 
Primer of Biostatistics for Windows program (Version 4.0, McGraw Hill, 1996). 
For different parameters (X) the magnitude of the effects of the presence of the Rf-1 or Rf-4 QTL 
on the ACI background and their interaction was calculated as follows: 
Effect of Rf-1 equals (XRf-1A – XACI), effect of Rf-4 QTL equals (XRf-4 - XACI), and the interaction between 
the Rf-1 and Rf-4 QTLs equals (XACI + XRf1+4 – XRf-1 – XRf-4). In these formulas Xstrain is the mean value of 
the parameter under investigation at the different time-points for the various strains and treatments. The 
standard deviation (SD) was calculated as the weighed SD of the variables in the formulae.
Statistical signifi cance of the main effect of the Rf-1 and Rf-4 QTLs and their interaction was 
calculated using a 2x2 factorial ANOVA procedure provided by VassarStats (http://faculty.vassar.edu/lowry/
anova2x2.html). In all tests, a p-value <0.05 was considered to be statistically signifi cant.
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Results
Animal survival and albuminuria
All 2K, 2K+L-NAME, and UNX rats survived the 18-week follow-up period. Following UNX+L-NAME 
treatment, four of the fourteen Rf-1A+4 double congenic rats did not survive up to the third measurement. 
Data obtained from these four rats are included in the results for the fi rst and second measurements.
Both UPV and UAV values were assessed, and no remarkable differences were found between 
the two values. Mean values for UAV during follow-up from the various treatments are presented in Figure 
2A-2D. In the 2K-situation, UAV was signifi cantly higher in Rf-1A+4 double congenic rats compared to 
Rf-4 single congenics at all time points, to ACI at the 2nd and 3rd time point, and to Rf-1A single congenic 
rats at the 2nd time point (Figure 2A). Following 2K+L-NAME treatment, UAV in Rf-1A+4 double congenic 
rats was signifi cantly increased at all time points compared to ACI, Rf-4 and Rf-1A single congenic rats 
(Figure 2B). Following UNX, UAV was at all time points signifi cantly higher in Rf-1A+4 double congenics 
compared to ACI, or Rf-4 and Rf-1A single congenic rats. The level of UAV in Rf-1A single congenic rats 
was signifi cantly higher compared to Rf-4 single congenics at all time points and to ACI rats at the third time 
point (Figure 2C). When treated with UNX+L-NAME, UAV in Rf-1A+4 double congenic rats at all time points 
was signifi cantly increased compared to ACI, Rf-4 and Rf-1A single congenic rats. In Rf-1A single congenics 
rats this treatment led, at the second and third evaluation, to a signifi cantly increased UAV compared to ACI 
and Rf-4 single congenic rats (Figure 2D). Regardless of treatment or time-point, no statistically signifi cant 
differences in UAV were found in the Rf-4 single congenic rats when compared to ACI (Figure 2A-2D). 
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Fig 2. Albuminuria (UAV) after 6, 12, and 18 weeks of follow-up during four treatments ACI (), Rf-1A (), 
Rf-4 (S), and Rf-1A+4 (z) rats. A: 2K (2-kidneys); B: 2K+L-NAME (2K+L-NAME-induced hypertension); 
C: UNX, (unilateral nephrectomy); D: UNX+L-NAME (UNX+L-NAME-induced hypertension). Values (mg/
day per 100 g BW) are given as mean ± SEM, number of rats is given in Table 1. *: p < 0.05 vs. ACI, Rf-1A 
and Rf-4; °: p<0.05 vs. ACI and Rf-4; +: p < 0.05 vs. Rf-4. 
Systolic blood pressure 
Values for SBP are presented in Figure 3A-3D. In the 2K-situation, Rf-1A single congenic rats 
compared to ACI showed a small, but signifi cant increase in SBP at the fi rst and second evaluations (Figure 
3A). After UNX, a slightly higher SBP was present in the Rf-4 single congenics compared to ACI at the second 
time point (Figure 3C). Chronic L-NAME treatment increased SBP in all strains. At the second and third 
evaluations, SBP in Rf-1A+4 double congenic rats with 2K+L-NAME treatment was signifi cantly increased 
compared to ACI and Rf-1A single congenic rats. At the fi rst time point, following 2K+L-NAME treatment, 
Rf-4 single congenic rats had a signifi cantly lower SBP compared to ACI and Rf-1A. This difference was not 
seen at the second and third evaluations (Figure 3B). The Rf-1A+4 double congenics with UNX+L-NAME 
treatment, showed a higher SBP at the fi rst and second evaluations compared to ACI and to Rf-1A single 
congenics at the second evaluation. However, at the fi nal evaluation there was no difference present (Figure 
3D).
D:C:
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Fig 3. Tail-cuff blood pressure at 6, 12, and 18 weeks in ACI (), Rf-1A (), Rf-4 (S), and Rf-1A+4 
(z) rats. A: 2K (2-kidneys); B: 2K+L-NAME (2K+L-NAME-induced hypertension); C: UNX, (unilateral 
nephrectomy); D: UNX+L-NAME (UNX+L-NAME-induced hypertension). Values (mm Hg) are given as 
mean ± SEM; number of rats is given in Table 1. *: p < 0.05 vs. ACI, Rf-1A and Rf-4; +: p < 0.05 vs. ACI and 
Rf-1A; °: p < 0.05 vs. ACI.
Gene-gene and gene-treatment interactions 
The results of the 2x2 factorial ANOVA analyses showed the presence of signifi cant gene-gene 
interactions. While Rf-4 alone showed no effect on UAV when compared to ACI, combining Rf-4 with Rf-1A 
always resulted in a further increase in UAV when compared with Rf-1A single congenics. Furthermore, the 
magnitude of these interactions was signifi cant in all four treatments. However the greater the haemodynamic 
stress upon the kidney, the greater the synergistic effect. 
An example is presented in Figure 4, for the UAV at the second time point, after 12 weeks of 
treatment. It is shown that changing the Rf-1 genotype from homozygous ACI (AA) to homozygous FHH 
(FF), while the Rf-4 genotype remains AA, induced an increase in UAV per 100g BW in all treatment groups. 
In contrast, changing the Rf-4 genotype from AA to FF, while the Rf-1 genotype remains AA, showed 
almost no change in UAV. Assuming an additive effect on UAV when both Rf-1 and Rf-4 change from AA 
to FF, an expected change in UAV can be calculated. In all four situations, the observed changes in UAV 
signifi cantly exceeded the expected change. The difference, being the interactive effect between Rf-1 and 
Rf-4 depended on the experimental situation, but was signifi cant in all treatment groups. The magnitude 
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was small with 2K (+1.5 mg/day/100g BW), intermediate with 2K+L-NAME (+12.5 mg/day/100g BW) and 
UNX (+11.7 mg/day/100g BW) and large in the UNX+L-NAME situation (30.9 mg/day/100g BW). 
Fig 4. The effects of the Rf-1 and Rf-4 (chr. 14) genotype and their interaction of Rf-1 and Rf-4 on UAV after 
12 weeks of treatment (M2). A: 2K (2-kidneys); B: 2K+L-NAME (2K+L-NAME-induced hypertension); C: 
UNX, (unilateral nephrectomy); D: UNX+L-NAME (UNX+L-NAME-induced hypertension); AA, homozygous 
ACI; FF, homozygous FHH. Values for UAV (mg/day per 100 g BW) are mean ± SEM. Statistics are given 
in Table 2.
Additional information about the effects of the Rf-1 and Rf-4 QTLs and their interactions on UAV 
at all three time-points is provided in Table 2. The major fi nding being that the magnitude of the interaction 
between Rf-1 and Rf-4 not only depended on the type of treatment but also on the duration of the treatments, 
i.e. the longer the treatment the larger the interaction.
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Table 2: Effect of the Rf-1 and Rf-4 QTLs and their interaction on albuminuria (UAV). 
6 weeks of 
treatment
2x2 
factorial 
ANOVA P
12 weeks of 
treatment
2x2 
factorial 
ANOVA P
18 weeks of 
treatment
2x2 
factorial 
ANOVA P
2K
Rf-4 effect -0.3±0.9 P=0.476 -0.5±0.4 P=0.234 -0.3±0.6 P=0.178
Rf-1 effect +0.6±0.5 P<0.001 +0.5±0.4 P<0.001 +0.9±0.7 P<0.001
Interaction of
Rf-1 and Rf-4 +0.8±0.8 P=0.072 +1.5±0.8 P=0.009 +1.6±1.3 P=0.045
2K+L-NAME
Rf-4 effect -0.8±1.0 P=0.116 -0.5±0.9 P=0.002 -0.3±2.1 P<0.001
Rf-1 effect +1.6±1.3 P<0.001 +3.4±2.9 P<0.001 +7.1±6.9 P<0.001
Interaction of
Rf-1 and Rf-4 +3.3±1.4 P<0.001 +12.5±5.1 P<0.001 +39.5±10.7 P<0.001
UNX
Rf-4 effect -1.5±1.4 P=0.155 -2.5±1.7 P=0.010 -4.5±2.8 P=0.011
Rf-1 effect +2.2±2.0 P<0.001 +4.2±3.6 P<0.001 +7.4±5.2 P<0.001
Interaction of
Rf-1 and Rf-4 +4.8±2.6 P=0.004 +11.7±4.7 P<0.001 +15.9±5.2 P<0.001
UNX+L-NAME
Rf-4 effect -1.0±1.4 P=0.003 -0.9±3.3 P<0.001 +7.7±13.0 P<0.001
Rf-1 effect +5.1±2.7 P<0.001 +15.7±6.9 P<0.001 +30.9±14.7 P=0.012
Interaction of
Rf-1 and Rf-4 +11.8±6.4 P=0.005 +30.9±11.3 P<0.001 +18.2±16.1 P=0.009
For each treatment and time-point the Rf-4 effect (UAVRf-4 – UAVACI), the Rf-1 effect (UAVRf-1A – UAVACI), and the interaction (UAVRf-1A+4 
– UAVRf-1A – UAVRf-4 + UAVACI) were calculated. Data represent change in UAV (mg/day per 100 g BW) ± SD. Statistical signifi cance 
of the overall (main) effect of Rf-1 and Rf-4 and their interaction were calculated using 2x2 factorial ANOVA. 2K, 2-kidneys; 2K+L-
NAME, 2K+L-NAME-induced hypertension; UNX, unilateral nephrectomy; UNX+L-NAME, UNX+L-NAME-induced hypertension.
Findings at end of experiment
The incidence of focal glomerulosclerosis (%FGS), creatinine clearance per 100 g BW (Cc/100) 
and plasma albumin (Palb) level are summarized in Table 3. The  %FGS was signifi cantly higher in Rf-
1A+4 double congenic rats compared to ACI, Rf-4 and Rf-1A single congenic rats, regardless of treatment. 
Following both 2K+L-NAME and UNX+L-NAME, the %FGS was signifi cantly higher in Rf-1A single congenics 
compared to ACI rats. Irrespective of the treatment no statistically signifi cant differences in %FGS were 
found between Rf-4 single congenics and ACI rats.
As with UAV, a signifi cant interactive effect upon the %FGS was present between the Rf-1 and 
Rf-4 QTLs. The magnitude of the interaction differed per treatment. It was low (+9±6%, p=0.021) for 2K, 
intermediate (+21±10%, p=0.002) for 2K+L-NAME and (+24±10%, p<0.001) for UNX, and most pronounced 
(+49±12%, p<0.001) for UNX+L-NAME treated rats. 
In the 2K- and UNX-situation, Cc/100 level was signifi cantly lower in Rf-1A single congenic and 
Rf-1A+4 double congenic rats compared to Rf-4 single congenics. Following 2K+L-NAME, Cc/100 was 
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lower in Rf-1A+4 double congenics compared to all other strains, while in Rf-1A single congenic rats it was 
lower compared to Rf-4 single congenic rats. After UNX+L-NAME treatment, Cc/100 of Rf-1A+4 double 
congenics and Rf-1A single congenics was lower than that of Rf-4 single congenics and ACI rats. At the 
end of the follow-up, Palb level was signifi cantly decreased in Rf-1A+4 double congenic rats compared to 
all other strains after 2K+L-NAME or UNX treatment, and compared to ACI and Rf-4 single congenics after 
UNX+L-NAME treatment. Following UNX+L-NAME treatment, Rf-1A single congenics also showed a lower 
Palb level in comparison to ACI and Rf-4 single congenic rats.
Table 3: Measurements at end of follow-up 
2K n BW (gram) FGS(% glom.)
Cc/100
(ml/min/100gBW) Palb (g/l)
ACI 6 303 ±  4 10 ±  2 0.55 ± 0.05 28.8 ± 0.9
Rf-4 9 317 ±  7 8 ±  1 0.66 ± 0.05 28.9 ± 0.6
Rf-1A 11 326 ±  5 15 ± 2 ° 0.45 ± 0.03 + 28.9 ± 0.5
Rf-1A+4 12 327 ±  5 #   22 ± 2 * 0.44 ± 0.03 + 28.6± 0.5
ANOVA P = 0.037 P < 0.001 P<0.001 P = 0.977
2K+L-NAME
ACI 6 312 ± 8 14 ± 4 0.54 ± 0.02 29.1 ± 0.2
Rf-4 9 309 ± 4 6 ± 1 0.62 ± 0.03 29.3 ± 0.3
Rf-1A 12 326 ± 4 26 ± 2 ° 0.47 ± 0.02 + 27.7 ± 0.5
Rf-1A+4 10 278 ± 6 *   39 ± 5 * 0.34 ± 0.03 *     25.8 ± 0.8*
ANOVA P < 0.001 P < 0.001 P<0.001 P < 0.001
UNX
ACI 10 309 ± 6 18 ± 2 0.50 ± 0.03 27.8 ± 0.4
Rf-4 10 298 ± 4 6 ± 2 0.56 ± 0.03 28.2 ± 0.3
Rf-1A 12 324 ± 6 ° 26 ± 3 ° 0.46 ± 0.02 + 26.3 ± 0.5
Rf-1A+4 12 331 ± 5 °   38 ± 5 * 0.45 ± 0.02 +     25.0 ± 0.4*
ANOVA P < 0.001 P < 0.001 P=0.014 P < 0.001
UNX+L-NAME
ACI 9 301 ± 10 20 ± 3 0.52 ± 0.03 27.2 ± 0.6
Rf-4 10 283 ± 6 16 ± 6 0.51 ± 0.02 27.2 ± 0.8
Rf-1A 12 320 ± 5 ° 42 ± 3 ° 0.37 ± 0.02 ° 23.2 ± 1.0 °
Rf-1A+4 14 258 ± 10 °   69 ± 3 * 0.34 ± 0.04 ° 23.5 ± 0.7 °
ANOVA P < 0.001 P < 0.001 P<0.001 P < 0.001
Abbreviations: 2K, 2-kidneys; 2K+L-NAME, 2K+L-NAME-induced hypertension; UNX, unilateral nephrectomy; UNX+L-
NAME, UNX+L-NAME-induced hypertension; BW, body weight (gram); FGS, incidence of glomerulosclerosis (% 
glomeruli); Cc/100, creatinine clearance (ml/min per 100gBW); Palb, plasma albumin level (g/l). Values are given as 
mean ± SEM; n is number of rats. #: p<0.05 vs. ACI; + p < 0.05 vs. Rf-4; ° p < 0.05 vs. ACI and Rf-4; * p < 0.05 vs. ACI, 
Rf-4 and Rf-1A.
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Assessment of renal blood fl ow autoregulation 
 No differences were found in the absolute values of the RBF at 100 mm Hg between ACI, Rf-1A, 
Rf-4, and Rf-1A+4 rats. Despite the relatively large variations within each strain, a signifi cantly higher RBF 
at a RPP of 150 mm Hg was present in the Rf-1A and Rf-1A+4 rats in comparison with ACI rats (data not 
shown). After normalizing the RBF, more signifi cant differences were revealed (Figure 5). From 130-150 
mm Hg, mean %RBF values were signifi cantly higher in the Rf-1A single congenics compared to ACI rats. 
At 150 mm Hg, mean %RBF value of Rf-1A+4 double congenics was signifi cantly higher compared to ACI 
rats. This points to an impairment of the RBF autoregulation in Rf-1A and Rf-1A+4 rats. Over the pressure 
range 100-150 mm Hg, the RAIs were in the order of 0.2 –0.3 in ACI as well as in Rf-4 single congenics, 
indicating a normal renal autoregulation in these strains. In contrast, RAI values were signifi cantly increased 
to levels of about 0.4-0.7 in Rf-1A single and Rf-1A+4 double congenic rats, indicating an impaired renal 
autoregulation. 
No marked renal damage was present in the rats used for the autoregulation experiment. In 
all four strains, the average UAV level was about 2-4 mg/day/100g BW, while the percentage of injured 
glomeruli was in the order of 2-6%.
Discussion
The major fi nding of our present study is the presence of a powerful synergistic interaction 
between the Rf-1 and Rf-4 QTLs that is markedly enhancing the susceptibility to renal damage as measured 
by the levels of UAV during and the %FGS at the end of the follow-up. The magnitude of the interactive 
effect differs between the various treatments, and appears to depend on the intensity and the duration of 
the exposure to the various stressors. The largest effect is observed when a reduction in renal mass by 
UNX is combined with L-NAME induced hypertension. A moderate effect is noted following UNX or L-NAME 
induced hypertension. Even in the 2K-situation there appears to be a small synergistic interaction.
The interpretation of the present fi nding of an interaction between the Rf-1 and Rf-4 QTL is 
complicated by the presence of a second part of the FHH chromosome 14 introgressed in the Rf-1A+4 
double congenic rats. However, this extra part located between 36.4-74.0 Mb is way off the 95% C.I. of the 
Rf-4 QTL (i.e. between 5 and 20 Mb).  In theory, a gene or genes in this additional part could account for the 
increased susceptibility of the double congenic strain. Preliminary data, obtained by H.J. Jacob and M.M. 
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Fig 5: Renal blood fl ow autoregulation curves in 
two-kidney ACI (, n=15), Rf-1A (, n=12), Rf-4 
(S, n=15), and Rf-1A+4 (z, n=12) rats. Values 
(as %RBF at RPP of 100 mm Hg) are given as 
means ± SEM (error bars); %RBF, relative renal 
blood fl ow; RPP, renal perfusion; * p < 0.05 vs. ACI 
and Rf-4.
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Lutz (MM Lutz et al, manuscript in preparation), exclude a role of the distal part of chromosome 14. In order 
to narrow down the interval of the Rf-4 QTL, a panel of subcongenic strains was generated from the Rf-
1A+4 and Rf-1A strains tested in the present experiments. One of the subcongenic strains (Rf1A+4_by) was 
identical to the Rf-1A+4 with regard to the distal part of chromosome 14, but the FHH genotype between 
the markers D14Mit11 (4.9 Mb) and D14Mit2 (19.1 Mb) was replaced by ACI. In these strains susceptibility 
to renal damage was compared with Rf-1A single congenics. Following 8 weeks of UNX and L-NAME 
treatment UAV corrected for BW in the Rf-1A+4_by subcongenic (34±6 mg/day, n=6, mean±SEM) was 
signifi cantly less that that of Rf-1A+4 double congenics (98±10 mg/day, n=20), but not different from that 
of Rf-1A single congenics (31±4 mg/day, n=6). These fi ndings indicate that the gene(s) responsible for the 
interaction between the Rf-1 and Rf-4 QTLs is located on chromosome 14 in the 4.9 and 19.1 Mb interval. 
Future studies aim to further reduce the size of the Rf-4 interval and positionally clone the Rf-4 gene(s). 
Nature of the interaction
In recent years, there is an increasing awareness that genetic and environmental factors play 
an important role in common complex diseases in humans, such as diabetes, hypertension, and mental 
disorders.169,246,257 Double congenic rat strains have been studied to establish interactions between blood 
pressure QTLs.167,206 To our knowledge, the present fi ndings are the fi rst to directly show a QTL interaction 
increasing susceptibility to renal damage. Such an interaction between the Rf-1 and Rf-4 QTLs was predicted 
in an F2 population from a cross of FHH and ACI rats subjected to UNX.234 The synergistic interaction is 
extremely powerful in this protective genomic background, particularly in the presence of kidney stressors. 
This observation could be important in understanding the variability found in the human situation.
Gene-gene interactions may have different phenotypic implications.292 For example, the interaction 
could be additive, where the combined effect of Rf-1 and Rf-4 in the double congenic strain would roughly 
be equal to the sum of the effects of Rf-1 and Rf-4 on the phenotype. Irrespective of treatment the effect of 
Rf-4 on UPV and UAV was only marginal, and therefore additivity can be excluded for UPV and UAV, but not 
for FGS. The UPV and UAV results clearly show that the gene-gene interaction has a powerful synergistic 
effect, consistent with epistasis for complex traits.30 Our fi ndings fi t this concept. The effects of changing 
the genotype of Rf-1 and Rf-4 from homozygous ACI to homozygous FHH, has a powerful and signifi cant 
effect on the pathophysiological parameters of renal damage. In addition, the complexity of the gene-gene 
interaction is further distended by the fact that the effects on renal damage of changing the Rf-1 and Rf-4 
genotypes also depends on the severity of the (haemodynamic) strain put upon the kidney and the length 
of the exposure to the harmful stimuli. The renal damage parameters (UAV and FGS) are distant traits, 
i.e. not likely to be directly related to a gene defect. With the generation of the Rf-1A+4 double congenics 
we have constructed a relatively simple two-locus model that results in an increased susceptibility to renal 
damage. One effect of Rf-1 appears to be an impairment of the renal autoregulation, which might result in 
an increased PGC when faced with systemic hypertension and/or reduced renal mass. The effect of Rf-4 
appears to be on a different level and only becomes detectable presence two copies of the Rf-1 QTL from 
FHH.  We can only speculate about possible mechanism(s) of action of Rf-4. It is conceivable that Rf-4 as 
well as other Rf-QTLs play a role in protecting the integrity of the glomerular fi ltration barrier when exposed 
to an increased PGC. Although this limits the number of possible candidates, it still leaves a wide range of 
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molecular pathways important in the biology of the podocyte and the glomerular barrier.9,164,174,191 
Next to fi ve QTLs in FHH, numerous QTLs infl uencing parameters of renal damage have been 
detected in other strains.84,175,195,224,225,235 The Rat Genome Database (http://rgd.mcw.edu) has collected over 
90 QTLs associated with renal damage or renal function components, some of them overlapping with the 
fi ve Rf-QTLs. As far as renal damage is concerned, it looks as if 15-20 different loci might be involved in the 
various rat models.129 Should a similar number of QTLs also play a role in humans, the number of possible 
interacting gene combinations that can be derived from these loci becomes tremendous. Inbred rat models 
remain relevant for gene identifi cation and gene interaction, as the number of gene combinations per strain 
is relatively small. With the detection of an interaction between Rf-1 and Rf-4, we continue to investigate the 
interaction between Rf-1 and the three other Rf-QTLs. The ultimate goal, of course, is to identify the genes 
in the various Rf-QTLs, as recently accomplished for Rf-2204, and establish how they affect susceptibility 
to renal damage and how they interact.116 Subsequently, these genes and gene-gene interactions can be 
tested in humans. With the recent completion of the sequencing of the rat genome87 it has become feasible 
to make a rat, mouse, and human genome comparison.261 Analysis of the genes present in the various Rf-
regions with the Ensembl Genome Browser (http:/www.ensembl.org) indicated that the 25 Mb Rf-1 interval 
on rat chromosome 1 contains about 200 known and predicted genes with homologies in both mouse and 
human. The 25 Mb Rf-4 interval on rat chromosome 14 contains about 130 known and predicted genes. 
Currently, 15-25% of the genes are predicted, novel, genes without a description of the gene product, while 
the description of others is vague. Eventually, shortening the congenic region will further decrease the 
number of candidate genes.
Conclusion
The present studies show that there is an interaction between the Rf-1 and Rf-4 QTL, which 
is markedly enhancing the susceptibility to renal damage in ACI genomic background that is ordinarily 
protective for proteinuria. It appears that the Rf-1 QTL of the FHH rat contains one or more genes directly 
infl uencing renal susceptibility, possibly by impairing the effi cacy of renal autoregulation. The Rf-4 QTL also 
contains one or more genes that infl uence renal susceptibility. However, the effect of the Rf-4 QTL can only 
be observed in the homozygous presence of the Rf-1 QTL from the FHH rat. 
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Abstract
The FHH (Fawn-Hooded Hypertensive) rat is a well established model of hypertension-associated 
chronic kidney damage (CKD). Multiple interacting genes determine the high renal susceptibility in this 
inbred rat strain. Previously we reported a synergistic interaction between Rf-1 and Rf-4. In the present 
study we tested the presence of an interaction between the Rf-1 and Rf-3 QTLs.
The experiments were carried out in ACI.FHH-(D1Rat298-D1Rat90) (Rf-1A for short), ACI.FHH-
(D3Wox2-D3Rat59) (Rf-3 for short), and ACI.FHH-(D1Rat475-D1Rat90)/(D3Rat84-D3Rat59) (Rf-1A+3 for 
short) congenic rats and ACI control rats. Rats were randomly divided over four treatment groups, i.e. 
two-kidney control (2K), 2K plus L-NAME induced hypertension (2K+L-NAME), unilateral nephrectomy 
(UNX), and UNX+L-NAME. Proteinuria (UPV), systolic blood pressure (SBP) were assessed 6, 12 and 
18 weeks after starting treatment. The incidence of focal glomerulosclerosis (%FGS) was assessed at the 
end of the experiment. In the Rf-1 and Rf-3 single congenics, small increases in renal susceptibility were 
found following UNX+L-NAME treatment. However, when Rf-1 and Rf-3 were combined a major synergistic 
increase in renal susceptibility was found with all four treatments.
Autoregulation was assessed in 13-15 week old ACI, Rf-1A, Rf-3 and Rf-1A+3 congenic rats. Both 
Rf-1A and Rf-1A+3 congenic rats had an impaired renal autoregulation. In contrast, the Rf-3 had a normal 
autoregulation, similar to that of the ACI rat.
In conclusion, this study provides evidence that both Rf-1 and Rf-3 slightly increase the 
susceptibility to the development of renal damage. However, a synergistic interaction between these two 
QTLs is markedly enhancing renal susceptibility. Also, the Rf-3 region does not carry any genes infl uencing 
renal autoregulation.
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Introduction
Chronic kidney disease (CKD) is an important risk factor for the progression to end-stage renal 
failure (ESRF), cardiovascular disease, and overall mortality.44,161,177 A large majority of CKD and ESRF is 
not associated with primary renal disease, but with systemic conditions like diabetes and hypertension.263 
However, only a minority of patients with diabetes and/or hypertension develops CKD, indicating that other 
aspects, such as genetic factors, also determine susceptibility to progressive renal disease.220 Finding genes 
involved in these complex forms of nephropathy in humans has been more arduous. Linkage analysis has 
identifi ed several chromosomal regions possibly involved in diabetic and non-diabetic forms of nephropathy, 
while candidate gene analyses have tested several genes with limited success.38,81,219
Inbred rat strains also vary widely in their susceptibility to develop renal damage and may be 
helpful to elucidate the genetics of progressive nephropathy. Our studies involve the FHH (Fawn-Hooded 
Hypertensive) rat, a well characterized model of hypertension-associated proteinuria and ESRF.133,198,238, 
239,272,273,279 Crosses between FHH and the renal resistant ACI (August x Copenhagen Irish) rat revealed the 
presence of fi ve QTLs, named renal-failure-1 (Rf-1) to Rf-5, linked to proteinuria (UPV) and other parameters 
of renal damage.25,234 It is surmised that each of these QTLs contains gene(s) infl uencing the susceptibility 
to progressive renal damage in the FHH rat.
Although the nature of the genes is still unknown, the role of each QTL can be studied in congenic 
rat strains that have an Rf-region of the FHH rat introgressed in the genomic background of the renal-
resistant ACI rat. Next, interactions between QTLs can be studied in double and multiple congenic strains. 
Since ACI is resistant to UPV even when made hypertensive, we stress the kidney to initiate the renal failure 
phenotype and be able to study the effect of a single QTL in the ACI genomic background. Previously, we 
reported about the susceptibility to renal damage in strains of ACI.FHH-Rf1, ACI.FHH-Rf4, and ACI.FHH-
Rf5 single congenics.199,267,270 Following unilateral nephrectomy (UNX) combined with L-NAME induced 
hypertension, ACI.FHH-Rf1 congenic rats developed signifi cantly more UPV and albuminuria (UAV) than 
the ACI progenitor strain. In contrast, the ACI.FHH-Rf4 and –Rf5 single congenic rats showed no signifi cant 
increase in renal susceptibility. In Rf-1 congenic rats, renal autoregulation was impaired to the same extent 
as the parental FHH rat, while a normal renal blood fl ow (RBF) autoregulation was present in Rf-4 and Rf-5 
single congenics.267,270,272 
Despite the lack of a direct effect on renal susceptibility in the Rf-4 single congenic rats, the 
combined presence of both the Rf-1 and Rf-4 QTLs increased renal damage susceptibility.270 The scale 
of interaction depended on the experimental treatment. It was small in the normotensive two-kidney (2K) 
situation, intermediate following L-NAME treatment in 2K rats and in normotensive rats following UNX. 
The largest interaction was noted in the L-NAME treated UNX rats.270 These experiments provided direct 
evidence for an interaction between the Rf-1 and Rf-4 QTLs, already suggested in the linkage analysis.234 
In the present experiments we tested the presence of an interaction between the Rf-1 and Rf-3 
QTLs. Therefore, we compared the renal susceptibility between the ACI progenitor strain and three congenic 
strains, i.e. ACI.FHH-Rf1A, ACI.FHH-Rf-3 single congenics, and ACI.FHH-Rf-1A+3 double congenic, in four 
experimental situations. Similar to the combination of Rf-1 and Rf-4, we found evidence for a signifi cant 
synergistic gene-gene interaction between Rf-1 and Rf-3 increasing the susceptibility to renal damage. 
Again, the magnitude of the interaction depended on the experimental treatment. We also examined the 
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renal autoregulation in two-kidney ACI, ACI.FHH-Rf1A, ACI.FHH-Rf3 single congenics, and ACI.FHH-
Rf1A+3 double congenic rats. Results showed that renal autoregulation was impaired in ACI.FHH-Rf1A 
single congenics and ACI.FHH-Rf1A+3 double congenic rats. Renal autoregulation was normal in ACI.
FHH-Rf3 single congenics, similar to the ACI rats.
Methods
Congenic and control rat strains
For the experiments, ACI.FHH-(D1Rat298-D1Rat90) (Rf-1A for short), ACI.FHH-(D3Wox2-
D3Rat59) (Rf-3 for short), and ACI.FHH-(D1Rat475-D1Rat90)/(D3Rat84-D3Rat59) (Rf-1A+3 for short) 
congenic rats and ACI control rats were used. All breeding was performed at the Animal Research Center at 
Erasmus MC, Rotterdam, the Netherlands. Animals were housed in individually-ventilated cages under SPF-
conditions180 as previously described.267 The protocol received approval from the animal ethical committee 
of the Erasmus University.
Congenic rat strains were generated using a speed congenic strategy as described for the Rf-1B 
strain by Provoost et al.199 Since the single and double congenic strains were generated in parallel, the 
size of the introgressed congenic regions (homozygous for FHH) slightly differs between the strains. A 
schematic view of the introgressed Rf-regions of the various congenic strains is presented in Figure 1. The 
introgressed Rf-1 region in the double congenic rats is about 13 Mb shorter than in the single congenic. 
The introgressed Rf-3 region in the double congenic rats is about 7 Mb shorter than in the single congenic. 
A whole genome scan with 150 genetic markers on these three congenic strains showed that there was no 
FHH genomic contamination on other chromosomes.
Renal damage susceptibility
Experiments for assessment of renal damage susceptibility were performed on 184 animals 
starting from the age of 6-7 weeks. Per strain, the animals were randomly divided over four treatments 
(Table 1). The fi rst received no treatment, remaining with two kidneys (2K), and was considered to be the 
control situation. The second remained with 2K and was chronically treated with Nω-nitro-L-arginine methyl 
ester (L-NAME, Sigma-Aldrich Chemicals, Zwijndrecht, the Netherlands) (2K+L-NAME) to induce systemic 
hypertension. The third treatment consisted of UNX to reduce renal mass (UNX), while the fourth treatment 
consisted of UNX and receiving L-NAME (UNX+L-NAME).
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Figure 1: Genetic maps of rat chromosomes 1 and 3 depicting the homozygous FHH regions introgressed on 
the ACI background in the Rf-1A, Rf-3 single, and Rf-1A+3 double congenic strains. The areas homozygous 
FHH in the congenic strains are indicated by the solid and striped lines. The arrows indicate the locations 
of the Rf-1 and Rf-3 QTL peaks found in previous studies, i.e. D1Mgh12 for Rf-1, and D3Mit4 for Rf-3.25,234 
Distances are given in mega-base pairs (Mb). The 95% C.I. represents the 95% confi dence interval of the 
QTLs.
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Table 1: Number of rats studied in the renal susceptibility experiments.
2K 2K+L-NAME UNX UNX+L-NAME
ACI 12 12 12 12
Rf-3 10 10 9 11
Rf-1A 12 12 12 12
Rf-1A+3 12 12 12 12,10,5*
* Number of rats at fi rst, second and third follow-up, respectively.
Surgery for UNX and L-NAME treatment were performed as previously described.274 Actual L-
NAME intake was calculated in mg/kg from the fl uid intake after 6, 12 and 18 weeks of treatment. The 
L-NAME intake was in the order of 8-12 mg/day/kg BW in the 2K+L-NAME situation, and 9-17 mg/day/kg 
BW in the UNX+L-NAME situation. 
Urine of individual rats was collected after 6, 12, and 18 weeks of treatment. The animals were 
housed in metabolic cages (Tecniplast, Buggugiate, Italy). Urine was collected during two consecutive 
days after a three-day adaptation period. Besides the amount of urine excretion, food and fl uid intake was 
also measured. Following the urine collection, systolic blood pressure (SBP) was measured by the tail-cuff 
method, using a photoelectric oscillatory detection device (IITC Life Science, Woodland Hills, CA) in awake, 
restrained rats, as described previously.199 
Shortly after the last series of urine collections and SBP measurements, the rats were sacrifi ced as 
previously described.267 Both kidneys were weighed, and left kidneys were used for histological examination. 
In a PAS-stained slide a total of 50 glomeruli were examined to determine the incidence of focal glomerular 
sclerosis (%FGS) as previously described.267
Renal blood fl ow autoregulation
Experiments for assessment of renal blood fl ow autoregulation were performed on 64 animals 
(21 ACI, 12 Rf-1A, 15 Rf-3, and 16 Rf-1A+3 rats) with an age of 13-15 weeks. To get an indication of 
the presence of renal damage, UPV and UAV were assessed using a 24-hr sample obtained before the 
autoregulation experiments, while at the end of the evaluation both kidneys were collected and weighed and 
the left kidney was used to determine the %FGS, as previously described.267
Animals were anaesthetized with a mixture of 3% Isofl urane®, 30% N2O, and 60% O2 and 
surgically prepared for autoregulation studies.272,273 After surgery and a 10-min equilibration period, the 
relationship between the left kidney RBF and the renal perfusion pressure (RPP) was determined. The 
RBF was recorded as the RPP was lowered from 150 to 80 mm Hg in 10 mm Hg steps by tightening a 
clamp around the aorta, followed by a 3-min equilibration period. To normalize the outcome of the individual 
rats, the RBF at a RPP of 100 mm Hg (RBF100) was considered to be 100%. Renal autoregulatory indexes 
(RAIs) over the range of pressures from 80 to 150 mm Hg were calculated by the method of Semple and 
de Wardener.228 A RAI of 0 indicates perfect autoregulation of RBF, and a RAI of 1 indicates that there is no 
autoregulation present due to a fi xed renal vascular resistance.
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Analytical procedures 
Plasma and urinary samples were analysed with an ELAN system (Eppendorf-Merck, Hamburg, 
Germany) using colorimetric assays. Total urinary protein was determined colorimetrically with pyrogallol 
red-molybdate complex.286 Plasma albumin was determined with bromocresol green.62 Plasma and urinary 
creatinine levels were determined with the Jaffé method without deproteinisation.240
Statistics
Data are presented as mean ± SEM. Statistical differences in mean values between groups 
were compared using one-way ANOVA. In both studies the ANOVA was followed by the Bonferroni test 
to determine which pairs were signifi cantly different. The experimental design was also analysed as a 2x2 
factorial analysis of variance (ANOVA) providing an evaluation of main effects and the interaction between 
the genotypes of Rf-1 and Rf-3, being either homozygous ACI or homozygous FHH. In all tests, a p-value 
<0.05 was considered statistically signifi cant. One-way ANOVA, followed by Bonferroni test were performed 
using the Primer of Biostatistics for Windows program (Version 4.0, McGraw Hill, 1996). The 2x2 factorial 
ANOVA was performed by using the statistics program at http://faculty.vassar.edu/lowry/anova2x2.html.
Results
Animal survival
All 2K, 2K+L-NAME, and UNX rats survived the 18-week follow-up period. Following UNX+L-NAME 
treatment, two of the twelve Rf-1A+3 double congenic rats did not survive up to the second measurement, 
and another three of the remaining ten Rf-1A+3 double congenics did not survive to complete the third 
measurement. Another two did not eat and suffered from severe weight loss, and were excluded from the 
analysis.
Proteinuria
Mean values for UPV during follow-up from the various treatments are presented in Figure 2A-2D. 
At all time points, regardless of treatment, UPV was signifi cantly higher in Rf-1A+3 double congenic rats 
compared to ACI, Rf-1A and Rf-3 single congenic rats. In the 2K situation, Rf-3 single congenics show an 
increased UPV compared to ACI at the second measurement. At the fi nal measurement following L-NAME 
treatment in 2K-rats, a slight albeit not signifi cant increase in UPV was found in Rf-1A and Rf-3 single 
congenics compared to ACI. In the UNX model, Rf-1A single congenics showed an increase in UPV at the 
third time point compared to ACI and Rf-3 congenic rats. After UNX+L-NAME treatment, both Rf-1A and Rf-3 
single congenics have a signifi cantly higher UPV compared to ACI at the third time point. 
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Figure 2. Proteinuria in ACI (), Rf-1A (), Rf-3 (S), and Rf-1A+3 (z) rats after 6, 12, and 18 weeks 
of follow-up during four treatments, values are given as mean ± SEM; A: 2K (2 kidneys); B: 2K+L-NAME 
(2K + L-NAME induced hypertension); C: UNX, (unilateral nephrectomy); D: UNX+L-NAME; +: P<0.05 
compared to ACI; *: P<0.05 compared to ACI, Rf-1A, and Rf-3; °: P<0.05 compared to ACI and Rf-3; #: 
P<0.05 compared to ACI, Rf-1A, and Rf-1A+3.
SBP 
Values for SBP are presented in Figure 3A-3D. In the 2K-situation all four rat strains remained 
normotensive. At the fi rst measurement, the congenic strains showed a small but signifi cantly higher SBP 
compared to ACI. However, this difference was no longer present in the second and third measurements. 
After UNX all strains remained normotensive (Figure 3C), but a slightly higher SBP was present in the 
Rf-1A+3 double congenics compared to the Rf-1A and Rf-3 single congenic rats at the third time point. 
In the 2K-situation, chronic L-NAME treatment increased SBP in all strains. At the fi rst time point, SBP in 
Rf-1A+3 double congenic rats, and Rf-1A and Rf-3 single congenic rats with 2K+L-NAME treatment were 
signifi cantly increased compared to ACI rats. At the second and third time point, following 2K+L-NAME 
treatment, Rf-1A+3 double congenic rats had a signifi cantly higher SBP compared to ACI, Rf-1A, and Rf-3 
single congenic rats. Following UNX+L-NAME treatment, the Rf-1A+3 double congenics had a higher SBP 
compared to the other strains at the fi rst and second time points. 
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Figure 3. Systolic blood pressure in ACI (), Rf-1A (), Rf-3 (S), and Rf-1A+3 (z) rats after 6, 12 and 
18 weeks of follow-up during four treatments; values are given as mean ± SEM; number of rats are the 
same as given in Figure 2 A: 2K (2 kidneys); B: 2K+L-NAME (2K + L-NAME induced hypertension); C: UNX, 
(unilateral nephrectomy); D: UNX+L-NAME; +: P<0.05 compared to ACI; *: P<0.05 compared to ACI, Rf-1A, 
and Rf-3; °: P<0.05 compared to ACI and Rf-3; #: P<0.05 compared to Rf-1A, and Rf-3.
Gene-gene and gene-treatment interactions  
The results of the 2x2 factorial ANOVA analyses showed the presence of signifi cant gene-gene 
interactions. The Rf-1 and Rf-3 QTLs each showed to have an effect on UPV compared to ACI. Combining 
Rf-3 with Rf-1A always resulted in a further increase in UPV when compared to Rf-1A and Rf-3 single 
congenics. Furthermore, the magnitude of these interactions was signifi cant in all four treatment groups, 
however the greater the haemodynamic stress upon the kidney, the greater the synergistic effect. (Table 
2)
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An example is presented in Figure 4, for UPV at the second time point, after 12 weeks of treatment 
at the age of about 18 weeks. It is shown that changing the Rf-3 genotype from homozygous ACI (AA) to 
homozygous FHH (FF), while the Rf-1A genotype remains AA, induced a slight increase in UPV per 100g 
BW in all four treatment groups. Changing the Rf-1A genotype from AA to FF, while the Rf-3 genotype 
remains AA, also an increase in UPV is seen. Assuming an additive effect on UPV when both Rf-1A and Rf-
3 change from AA to FF, an expected change in UPV can be calculated. In all four situations, the observed 
changes in UPV induced by changing both Rf-1A and Rf-3 from AA to FF, signifi cantly exceeded the expected 
calculated change in UPV. The difference, being the interactive effect of Rf-1A and Rf-3 depended on the 
experimental situation, but was signifi cant in all four situations. The magnitude of the interaction was small 
with 2K (+6.1 mg/day/100g BW), intermediate with 2K+L-NAME (+15.4 mg/day/100g BW) and UNX (+21.1 
mg/day/100g BW) and large in the UNX+L-NAME situation (50.0 mg/day/100g BW). 
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Figure 4: The effects of the Rf-1 and Rf-3 (chr. 3) genotype and their interaction of Rf-1 and Rf-3 on UPV 
after 12 weeks of treatment (M2). A: 2K (2 kidneys); B: 2K+L-NAME (2K + L-NAME induced hypertension); 
C: UNX, (unilateral nephrectomy); D: UNX+L-NAME; AA, homozygous ACI; FF, homozygous FHH. Values 
for UPV (mg/day per 100 g BW) are mean ± SEM. Statistics are given in Table 2.
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Findings at end of experiment
Body weight (BW), the incidence of focal glomerulosclerosis (%FGS), the creatinine clearance 
(Cc/100), and plasma albumin level (Palb) are summarized in Table 3. The %FGS was signifi cantly higher 
in Rf-1A+3 double congenic rats compared to ACI rats, following 2K+L-NAME, UNX, or UNX+L-NAME 
treatment. Following UNX+L-NAME treatment %FGS in Rf-1A+3 double congenics was also signifi cantly 
increased compared to Rf-1A and Rf-3 single congenics. Following UNX+L-NAME treatment, the incidence 
of FGS was signifi cantly higher in Rf-1A and Rf-3 single congenic rats compared to ACI rats. 
In Rf-3 single congenic rats, Cc/100 was signifi cantly increased compared to ACI and Rf-1A single 
congenics in all treatment groups. Following UNX, Rf-1A+3 double congenics also showed an increased 
Cc/100 compared to ACI and Rf-1A single congenics. Plasma albumin (Palb) levels were slightly higher 
in Rf-3 single congenic rats in the 2K, 2K+L-NAME and UNX treatment groups. Following 2K+L-NAME, 
UNX, or UNX+L-NAME treatment, Palb levels were decreased in Rf-1A+3 double congenic rats. In the 
UNX situation, Cc/100 in Rf-1A+3 double congenics is slightly increased compared to ACI rats. Following 
UNX+L-NAME treatment, Rf-1A single congenics have a decreased Palb compared to ACI and Rf-3 single 
congenics.
Renal blood fl ow autoregulation
After normalizing the RBF, signifi cant differences were revealed (Figure 5). From 110-150 mm 
Hg, mean %RBF values were signifi cantly higher in the Rf-1A single congenics compared to ACI rats. From 
130-150 mm Hg, mean %RBF value of Rf-1A+3 double congenics were signifi cantly higher compared 
to ACI rats. This points to an impairment of the RBF autoregulation in Rf-1A and Rf-1A+3 rats. Over the 
pressure range 100-150 mm Hg, the RAIs were 0.25±0.02 in ACI and 0.28±0.03 in Rf-3 single congenics, 
indicating a normal renal autoregulation in these strains. In contrast, RAI values were signifi cantly increased 
in Rf-1A single (0.57±0.08) and Rf-1A+3 double (0.49±0.05) congenic rats, indicating an impaired renal 
autoregulation. 
No marked renal damage was present in the rats used for the autoregulation experiment. In 
all four strains, the average UAV level was about 2-7 mg/day/100g BW, while the percentage of injured 
glomeruli was in the order of 2-6%.
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Figure 5: Renal blood fl ow autoregulation curves in 
two-kidney ACI (, n=21), Rf-1A (, n=12), Rf-3 
(S, n=15), and Rf-1A+3 (z, n=16) rats. Values (as 
%RBF at RPP of 100 mm Hg) are given as means 
± SEM (error bars); %RBF, relative renal blood fl ow; 
RPP, renal perfusion; * p < 0.05 vs. ACI and Rf-3, °: 
p < 0.05 vs. ACI. 
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Table 3: Measurements at end of follow-up.
n BW (gram) FGS(% glom.)
Cc/100
(ml/min/100gBW) Palb (g/l)
2K
ACI 12 309±4 9±2 0.46±0.03 28.6±0.4
Rf-3 10 316±3 13±2 0.72±0.04 ° 31.7±0.3 °
Rf-1A 12 333±7 # 14±2 0.51±0.03 29.0±0.6
Rf-1A+3 12 311±3 14±2 0.56±0.02 27.9±0.4
ANOVA P=0.002 P=0.238 P<0.001 P<0.001
2K+L-NAME
ACI 12 319±5 11±1 0.50±0.02 28.0±0.3
Rf-3 10 321±4 18±2 0.81±0.03 ° 29.7±0.4 °
Rf-1A 12 328±3 23±2 0.49±0.01 28.0±0.4
Rf-1A+3 12 296±6 * 31±6 + 0.52±0.04 26.4±0.5 *
ANOVA P<0.001 P=0.001 P<0.001 P<0.001
UNX
ACI 12 315±3 15±2 0.41±0.01 27.8±0.2
Rf-3 9 304±3 20±2 0.58±0.02 z 28.6±0.4 
Rf-1A 12 330±6  23±3 0.46±0.02 26.3±0.4
Rf-1A+3 11 304±5 27±3 + 0.58±0.02 z 23.6±0.6 *
ANOVA P<0.001 P=0.015 P<0.001 P<0.001
UNX+L-NAME
ACI 12 314±6 15±1 0.46±0.05 27.3±0.3
Rf-3 11 301±6 39±5 + 0.63±0.04 ° 27.2±0.4
Rf-1A 12 319±6 37±4 + 0.40±0.03 25.6±0.3 S
Rf-1A+3 5 263±12 * 64±11 * 0.31±0.06 23.0±0.4 *
ANOVA P<0.001 P<0.001 P<0.001 P<0.001
Abbreviations: 2K, 2-kidneys; 2K+L-NAME, 2K + L-NAME-induced hypertension; UNX, unilateral nephrectomy; 
UNX+L-NAME, UNX + L-NAME-induced hypertension; BW, body weight (gram); FGS, incidence of glomerulosclerosis 
(% glomeruli); Cc/100, creatinine clearance (ml/min per 100gBW); Palb, plasma albumin level (g/l). Values are given 
as mean ± SEM; n is number of rats; +: P<0.05 compared to ACI; z: P<0.005 compared to ACI and Rf-1A; #: P<0.05 
compared to ACI and Rf-1A+3; : P<0.05 compared to Rf-1A and Rf-1A+3; : P<0.05 compared to Rf-3 and Rf-1A+3  
°: P<0.05 compared to ACI, Rf-1A, and Rf-1A+3; *: P<0.05 compared to ACI, Rf-1A, and Rf-3; S: P<0.05 compared 
to ACI and Rf-3.
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Discussion
The major fi nding of the present study is that introgression of the Rf-1 and Rf-3 QTLs on the 
ACI genomic background have a synergistic effect markedly increasing susceptibility to renal damage. 
This synergistic interaction between the Rf-1 and Rf-3 QTLs found in the Rf-1A+3 double congenic rat is 
quantitatively comparable with the synergistic effect of Rf-1 and Rf-4 QTLs found earlier in Rf-1A+4 double 
congenics.270 Synergistic interactions between Rf-1 and other Rf-regions suggested by Shiozawa et al.234 
were based on linkage analyses in an ACIxFHH F2-cross following UNX.234 Our studies have now provided 
direct evidence for gene-gene interaction between Rf-1 and Rf-3, as well as Rf-1 and Rf-4. Interestingly, 
the magnitude of the interaction depended on the experimental situation, i.e. the presence or absence of 
hypertension and/or reduced renal mass.
In contrast to the parental FHH strain, the single and double congenics in the 2K-control group 
are normotensive, providing evidence that the Rf-1 and Rf-3 loci do not carry genes responsible for 
hypertension. To detect changes in renal susceptibility resulting from the introgression of the Rf-QTLs on the 
ACI background, we had to raise systemic blood pressure. Based on our earlier experience we used chronic 
L-NAME treatment to raise systemic blood pressure.274,276 As indicated in our previous studies, using chronic 
L-NAME treatment has some disadvantages. It is diffi cult to match SBP between the various strains at a 
level normally present in the FHH rat. Chronic L-NAME treatment may directly affect the vascular structure 
in the kidney, independent of its blood pressure effects.306 Furthermore, reducing endothelial NO-synthase 
activity by L-NAME may have a negative effect on the protective action of NO in organs that are targets of 
hypertensive injury.101  Thus, differences in renal damage between Rf-1A, Rf-3 single congenics, and Rf-
1A+3 double congenics and ACI rats may be partly due to an increased susceptibility to L-NAME. 
Loss of functional renal mass is another way to induce progressive renal damage.21 Therefore, 
we also tested if the renal disease was simply the result of a decrease in renal mass, mimicked by UNX. It 
should be noted that the ACI was almost completely protected from renal damage, despite the reduction in 
renal mass and/or presence of hypertension. Therefore, any change in renal damage found in the congenic 
rats must be the result of FHH genomic regions introgressed into the ACI genome.
A surprising fi nding was the presence of an increased Cc/100 in the Rf-3 single congenic rats. 
This would indicate the presence of one or more genes in this region infl uencing the glomerular fi ltration 
rate. However, an increased Cc/100 in the Rf-1A+3 double congenics was only seen following UNX and not 
in the 2K-situation and L-NAME treated rats. No good explanation is yet available, and further studies using 
better GFR methodologies need to be performed.
In previous studies we found that rats carrying the Rf-1 QTL had an impaired renal autoregulation.267,270 
The Rf-1A+3 double congenics also showed to have an impaired renal autoregulation, similar to that of the 
Rf-1A single congenic rat. In contrast, the Rf-3 single congenic has a normal autoregulation, similar to 
that of the ACI rat. These fi ndings indicate that the Rf-3 region of the FHH rat does not infl uence renal 
autoregulation.
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With the completion of the sequencing of the human, mouse and rat genome, genomic comparisons 
between these three species are greatly facilitated.87,135,278,287 The 95% confi dence interval of the Rf-3 region 
(3: 117-146 Mb) is homologous to a part of human chromosome 20 (~1-33 Mb) and mouse chromosome 2 
(126-155 Mb)(http:/www.ncbi.nlm.nih.gov/projects/Homology). Surprisingly, the Rf-3 homologous region in 
human and mouse appear both to be involved in renal disease. Linkage studies in Pima Indians suggest 
the presence of a gene on chromosome 20 infl uencing diabetic nephropathy.111 The homologous region 
in the mouse has recently been linked to albuminuria in KK/Ta mice.233 The presence of QTLs linked to 
nephropathy in rat, mouse and human make the Rf-3 region very interesting for further investigation.
In conclusion, this study provides evidence that Rf-1 and Rf-3 alone slightly increase the 
susceptibility to the development of renal damage. However, a synergistic interaction between these two 
QTLs does markedly enhance renal susceptibility.
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Abstract
Previous studies in Rf-double congenic rats showed an increase in renal damage susceptibility 
when compared to Rf-1 single congenics. Combining the Rf-1 and Rf-3 or Rf-1 and Rf-4 regions of the FHH 
on the ACI genomic background induced synergistic interactions markedly enhancing renal susceptibility. In 
the present study we wanted to determine whether such an interaction was also present between the Rf-1 
and Rf-5 QTLs.
Renal damage susceptibility was assessed in Rf-1B+5 and Rf-1B+4 double congenics and 
compared to Rf-1B single congenics in four situations, i.e. two-kidney control (2K), unilateral nephrectomy 
(UNX), L-NAME induced hypertension (2K+L-NAME) and UNX+L-NAME. Albuminuria (UAV) and systolic 
blood pressure (SBP) were regularly measured. In a separate experiment renal autoregulation was assessed 
in 2K Rf-1B, Rf-1B+5, and Rf-1B+4 rats.
The Rf-1B+4 rats developed more UAV than the Rf-1B and Rf-1B+5 rats following UNX, 2K+L-
NAME and UNX+L-NAME. No differences were found in UAV between Rf-1B and Rf-1B+5 rats regardless 
of treatment or time. Following UNX and 2K+L-NAME treatment no differences in SBP were noted between 
the three strains. With UNX+L-NAME treatment, the SBP in both double congenic strains was increased 
compared to Rf-1B single congenics. Autoregulation was impaired to a similar extent in the three strains. 
We conclude that the Rf-5 region does not infl uence renal damage susceptibility, neither alone 
nor in the presence of Rf-1B. We therefore assume that the Rf-5 region does not contain genes infl uencing 
renal susceptibility. 
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Introduction
 Chronic kidney disease (CKD) is assumed to be a complex polygenic disease19, limiting the rate of 
success in fi nding genes involved in the development of CKD in human studies.292,136,90 Multiple interacting 
genes may enhance the susceptibility to renal disease, as well as interactions between genes and the 
environment. Therefore, single gene mutations could be present in humans without showing an increased 
susceptibility to renal disease.292 
Inbred rat strains also vary in their development of renal damage. The FHH (Fawn-hooded 
hypertensive) rat develops severe renal damage and hypertension at a relatively young age. Linkage 
analysis of crosses of FHH and the renal-resistant ACI (August x Copenhagen Irish) rat revealed fi ve QTLs, 
named Renal failure-1 (Rf-1) through Rf-5.25,234
Several congenic rats were generated carrying a single Rf-QTL region of the FHH onto an ACI 
genomic background. Previously we reported that transfer of the Rf-1 region of the FHH onto the ACI 
genomic background increases susceptibility to renal damage, while transfer of Rf-4 or Rf-5 alone did 
not.267,270 Furthermore, we reported synergistic interactions between the Rf-1 and Rf-4 as well as the Rf-1 
and Rf-3 region of the FHH rat. In the Rf-1A+4 and the Rf-1A+3 double congenic rat susceptibility to renal 
failure was markedly, compared to the various single congenic strains.269,270
 Infl uences of the Rf-5 region on renal susceptibility still remain to be discovered. This can be 
done by studying the presence or absence of an interaction between the Rf-5 and Rf-1 regions in a double 
congenic rat. For this we generated double congenic rats carrying the Rf-1 region and Rf-5 regions.  In the 
present study we investigated the susceptibility to the development of renal damage in Rf-1B+5 and Rf-
1B+4 double congenics compared to Rf-1B single congenics. Renal susceptibility was tested as previously 
described.267,269,270  In a separate experiment the effi cacy of the renal blood fl ow (RBF) autoregulation was 
assessed in the three strains. 
Methods
Congenic rat and control strains
For the experiments, ACI.FHH-(D1Rat384-D1Rat156) (Rf-1B for short), ACI.FHH-(D1Mit18-
D1Mit8)/(D14Mit11-D14Hmgc14b/D14Rat65-D14Rat90) (Rf-1B+4 for short), and ACI.FHH-(D1Rat324-
D1Rat452)/(D17Rat61-D1Arb5)(D17Rat51) (Rf-1B+5 for short) congenic rats were used. All breeding was 
performed at the Animal Research Centre at Erasmus MC, Rotterdam, the Netherlands. Animals were 
housed in individually-ventilated cages under SPF-conditions180 as previously described.267 The protocol 
received approval from the animal ethical committee of the Erasmus University.
Congenic rat strains were generated using a speed congenic strategy as described for the Rf-1B 
strain.199 Since the single and double congenic strains were generated in parallel, the size of the introgressed 
congenic regions (homozygous for FHH) differs between the strains. A schematic view of the introgressed 
Rf-regions of the various congenic strains is presented in Figure 1. A whole genome scan with 150 genetic 
markers on these three congenic strains showed that there was no FHH genomic contamination on other 
chromosomes.
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Figure 1: Congenic regions (homozygous FHH) in the Rf-1B, Rf-1B+4, and Rf-1B+5 strains. The whole 
genomic background of these congenic rats is ACI, except for the areas shown at the right hand side 
above with the different markers. These areas are homozygous for FHH, and contain the QTL peak. 
The arrows at the left hand side indicate the locations of the QTL peaks plus 95% C.I. found in previous 
studies, i.e. D1Mgh12 for the Rf-1 QTL, D14Mgh7 for the Rf-4 QTL, and D17Mit12 for the Rf-5 QTL.25,234
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Renal damage susceptibility
Experiments for assessment of renal damage susceptibility were performed on 132 animals 
starting from the age of 6-7 weeks. Per strain, the animals were randomly divided over four treatments 
(Table 1). The fi rst received no treatment, remaining with two kidneys (2K). This was considered to be the 
control situation. The second remained with 2K and was chronically treated with Nω-nitro-L-arginine methyl 
ester (L-NAME, Sigma-Aldrich Chemicals, Zwijndrecht, the Netherlands) (2K+L-NAME) to induce systemic 
hypertension. The third treatment consisted of UNX to reduce renal mass (UNX), while the fourth treatment 
consisted of UNX and receiving L-NAME (UNX+L-NAME). 
Table 1: Number of rats studied in the renal susceptibility experiments.
2K 2K+L-NAME UNX UNX+L-NAME
Rf-1B 12 12 12 12,12,11*
Rf-1B+4 12 12 12 12, 10, 2*
Rf-1B+5 8 10,10,9* 9,8,7* 9,9,7*
* Number of rats at fi rst, second and third follow-up, respectively.
Surgery for UNX and chronic L-NAME treatment were performed as previously described.274 
Urine of individual rats was collected after 6, 12, and 18 weeks of treatment. The animals were housed in 
metabolic cages (Tecniplast, Buggugiate, Italy). Urine was collected during two consecutive days after a 
three-day adaptation period. Besides the amount of urine excretion, fl uid intake was also determined. Actual 
L-NAME intake was calculated in mg/kg from the fl uid intake after 6, 12 and 18 weeks of treatment. The 
L-NAME intake was in the order of 9-16 mg/day/kg BW in the 2K+L-NAME situation, and 10-21 mg/day/kg 
BW in the UNX+L-NAME situation.
Following the urine collection, SBP was measured by the tail-cuff method, using a photoelectric 
oscillatory detection device (IITC Life Science, Woodland Hills, CA) in awake, restrained rats, as described 
previously.199
The rats were sacrifi ced shortly after the last series of urine collections and SBP measurements as 
previously described.267 Kidneys were weighed, and left kidneys were used for histological examination. In a 
PAS-stained slide a total of 50 glomeruli were examined to determine the incidence of focal glomerulosclerosis 
(%FGS) as previously described.274
Renal blood fl ow autoregulation
Experiments for assessment of renal blood fl ow autoregulation were performed on 37 animals (13 
Rf-1B, 12 Rf-1B+4, and 12 Rf-1B+5 rats) at the age of 13-15 weeks. To get an indication of the presence of 
renal damage, UAV was assessed using a 24-hr sample obtained before the autoregulation experiments. 
The determination of renal blood fl ow autoregulation was performed as previously described.269,270,272 
Renal autoregulatory indexes (RAI) over the range of pressures from 130 to 150 mm Hg were calculated by 
the method of Semple and de Wardener.228 
At the end of the autoregulation evaluation, both kidneys were weighed, and left kidneys were 
used for histological examination, as previously described.274
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Analytical procedures 
 Plasma and urinary samples were analysed with an ELAN system (Eppendorf-Merck, Hamburg, 
Germany) using colorimetric assays. Plasma and urinary albumin was determined with bromocresol green.62 
Plasma and urinary creatinine was determined with the Jaffé method without deproteinisation.240
Statistical analysis
Data are presented as mean ± SEM. Statistical differences in mean values between groups were 
compared using one-way analysis of variance (ANOVA), followed by the Bonferroni test to determine which 
pairs were signifi cantly different. These tests were performed using the Primer of Biostatistics for Windows 
program (Version 4.0, McGraw Hill, 1996). In all tests, a p-value <0.05 was considered to be statistically 
signifi cant.
Results
Animal survival
All 2K and UNX rats survived the 18-week follow-up period. Following 2K+L-NAME treatment, one 
Rf-1B+4 double congenic rat did not survive the total follow-up period. Following UNX+L-NAME treatment, 
two of the twelve Rf-1B+4 double congenic rats did not survive up to the second measurement, and another 
eight of the remaining ten Rf-1B+4 double congenics did not survive up to the third measurement. One 
of the Rf-1B single congenics did not survive the follow-up period after UNX+L-NAME treatment. Data 
obtained from these twelve rats are included in the results for the fi rst and, if measured, for the second 
measurements.
Albuminuria 
Mean values for UAV during follow-up from the various treatments are presented in Figure 2A-
2D. In the 2K-situation, Rf-1B+4 showed an increase in UAV compared to Rf-1B at all time points, however 
it was only statistically signifi cant at the fi rst measurement. After both 2K+L-NAME and UNX, UAV was 
signifi cantly increased in Rf-1B+4 double congenic rats compared to Rf-1B rats at all time points. Following 
UNX+L-NAME treatment, Rf-1B+4 double congenics developed signifi cantly more UAV compared to Rf-1B 
single congenics rats at the fi rst and second time point. At the third time-point, only two Rf-1B+4 double 
congenics survived, not allowing a statistical analysis. No differences were found in UAV in the Rf-1B+5 
double congenic rat compared to Rf-1B single congenic rats, regardless of treatment or time. 
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Figure 2. Albuminuria in Rf-1B (z), Rf-1B+4 () and Rf-1B+5 (S) rats after 6, 12, and 18 weeks of 
follow-up during four treatments; values are given as mean ± SEM; A: 2K (2 kidneys); B: 2K+L-NAME (2K 
+ L-NAME induced hypertension); C: UNX, (unilateral nephrectomy); D: UNX+L-NAME, statistical analysis 
at third time point only between Rf-1B and Rf-1B+5; *: p < 0.05 versus Rf-1B.
Systolic blood pressure 
Values for SBP are presented in Figure 3A-3D. In the 2K-situation, the Rf-1B+4 double congenic 
rats showed a small but signifi cantly lower SBP compared to Rf-1B at the fi rst measurement. This difference 
was not present in the second and third measurements. After UNX (Figure 3C), no signifi cant differences 
were found in SBP between the three strains. Chronic L-NAME treatment increased SBP. No differences 
were found following 2K+L-NAME treatment. However, following UNX+L-NAME treatment SBP was 
signifi cantly increased in Rf-1B+4 (fi rst and second time point) and Rf-1B+5 (at all time points) double 
congenic rats compared to Rf-1B single congenic rats. 
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Figure 3. Systolic blood pressure (SBP) in Rf-1B (z), Rf-1B+4 () and Rf-1B+5 (S) rats after 6, 12, 
and 18 weeks of follow-up during four treatments; values are given as mean ± SEM; A: 2K (2 kidneys); B: 
2K+L-NAME (2K + L-NAME induced hypertension); C: UNX, (unilateral nephrectomy); D: UNX+L-NAME, 
statistical analysis at third time point only between Rf-1B and Rf-1B+5; *: p < 0.05 versus Rf-1B.
Measurements at end of follow-up
No differences were found in body weight (BW), %FGS, and plasma albumin (Palb) in the 
2K-situation. Creatinine clearance (Cc/100) was slightly decreased in the Rf-1B+4 and Rf-1B+5 double 
congenics compared to Rf-1B single congenics. Following 2K+L-NAME treatment an increase in %FGS was 
found in Rf-1B+4 double congenics compared to Rf-1B single congenics. After UNX, %FGS was increased 
in Rf-1B+4 double congenics, and Palb was increased in Rf-1B+5 double congenics compared to Rf-1B 
single congenics. Following UNX+L-NAME treatment, Palb was decreased in Rf-1B+4 double congenics 
compared to Rf-1B single congenics (Table 2).
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Table 2: Measurements at end of follow-up.
n BW (gram) FGS(% glom.)
Cc/100
(ml/min/100gBW) Palb (g/l)
2K
Rf-1B 12 311±6 16±2 0.67±0.03 28.5±0.4
Rf-1B+4 12 305±2 21±3 0.52±0.04* 25.5±1.8
Rf-1B+5 8 312±5 8±2 0.54±0.03* 28.7±0.6
ANOVA P=0.516 P=0.006 P<0.001 P=0.151
2K+L-NAME
Rf-1B 11 294±5 20±3 0.55±0.05 27.7±0.9
Rf-1B+4 11 287±8 33±3* 0.46±0.04 26.2±0.6
Rf-1B+5 9 286±7 15±3 0.53±0.03 28.8±0.5
ANOVA P=0.672 P<0.001 P=0.407 P=0.051
UNX
Rf-1B 12 305±8 13±2 0.54±0.04 26.4±0.6
Rf-1B+4 12 304±4 30±3* 0.50±0.03 25.3±0.5
Rf-1B+5 7 303±2 12±2 0.50±0.07 28.8±0.3*
ANOVA P=0.997 P<0.001 P=0.738 P<0.001
UNX+L-NAME
Rf-1B 11 272±11 39±6 0.47±0.04 25.5±0.4
Rf-1B+4 2 286±0.4 59±11 0.37±0.04 23.6±0.4
Rf-1B+5 7 276±7 36±5 0.40±0.04 25.0±1.0
ANOVA P=0.742 P=0.666 P=0.160 P=0.511
Values are given as means ± SEM.  2K, 2 kidneys; 2K+L-NAME, 2K + L-NAME induced hypertension; UNX, 
unilateral nephrectomy; UNX+L-NAME, unilateral nephrectomy with L-NAME induced hypertension; BW, body 
weight; FGS, incidence of glomerulosclerosis; Pcreat, plasma creatinine level; Palb, plasma albumin level; 
*: p < 0.05 compared to Rf-1B.
Renal blood fl ow autoregulation 
The RBF autoregulation curves are presented in Figure 4. No statistical differences in RBF were 
present between the three rat strains. In addition, no statistical differences were found in RAI indexes for the 
130-150 mm Hg RPP range. The RAI values amounted to 0.59±0.05 in Rf-1B, 0.45±0.07 in Rf-1B+4, and 
0.45±0.03 in Rf-1B+5 rats. The magnitude of the RAI values indicated that autoregulation is impaired to a 
similar extent in Rf-1B single and Rf-1B+4 and Rf-1B+5 double congenic rats.
No marked renal damage was present in the rats used for the autoregulation experiment. In all 
three strains, the average UAV were ~1-3 mg/day/100g BW, while the percentage of injured glomeruli was 
in the order of 4-10%.
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Discussion
The present study fails to demonstrate an effect of the Rf-5 QTL on the susceptibility to develop 
renal damage. Renal susceptibility in the Rf-1B+5 double congenic rats did not differ from that observed 
in Rf-1 single congenics. It is therefore likely that the Rf-5 QTL does not contain genes infl uencing renal 
damage susceptibility. In contrast, the Rf-1B+4 double congenic rats show an increased susceptibility to 
renal damage, comparable with the previously reported results in the Rf-1A+4 double congenic strain.270
Following UNX+L-NAME treatment, Rf-1B+4 double congenics did develop signifi cantly more 
renal damage than the Rf-1B single congenics. Because of this increased susceptibility to renal damage, 
the majority of the Rf-1B+4 double congenics did not survive the complete 18-week follow-up period. Based 
on the similarities of the present fi ndings in the Rf-1B+4 and our previous fi ndings in the Rf-1A+4 double 
congenic rats, we confi rm the presence of a synergistic interaction between the Rf-1 and Rf-4 QTLs.270  
No differences in the severity of renal damage induced by the various procedures could be 
detected when comparing the Rf-1B+5 double congenics to the Rf-1B single congenics. While studies 
demonstrated that the presence of the Rf-3 or Rf-4 QTL besides the Rf-1 increases renal susceptibility, the 
Rf-5 QTL fails to do so. Following 2K, UNX, and 2K+L-NAME, no marked differences in SBP were found 
between the three strains. Thus the absence of an effect of Rf-5 cannot be explained by difference in SBP. 
To the contrary, following UNX+L-NAME the SBP was signifi cantly higher in the Rf-1B+5 double congenics 
compared to Rf-1B single congenics, but no differences in renal damage susceptibility were present. The 
differences in SBP were due to an increased L-NAME intake in Rf-1B+5 double congenics. The results also 
indicate that differences in L-NAME intake by itself have little effect on the development of renal damage.
We reported earlier that congenic rats carrying the Rf-1 QTL region from the FHH on the ACI 
background do have an impaired renal autoregulation similar to FHH parental rats.267,270 This study shows 
that renal autoregulation is also impaired in the Rf-1B+4 and Rf-1B+5 double congenic rats. Despite similar 
degrees of impaired renal autoregulation renal damage varies markedly between the different strains, 
underscoring that an impaired renal autoregulation alone is not suffi cient to induce severe renal damage. 
Even in the presence of hypertension or reduced renal mass renal damage is limited in the absence of 
other Rf-QTLs, i.e. additional susceptibility genes. We surmise that the genes play a role in maintaining the 
integrity of the glomerulus or the glomerular fi ltration barrier when facing an increased hemodynamic stress. 
On the other hand, they could be involved in the renal handling of fi ltered proteins, like albumin. Further 
0
2
4
6
8
60 80 100 120 140 160
RPP (mm Hg)
R
B
F
(m
l/m
in
/g
L
K
W
)
Figure 4: Relationship between renal blood fl ow 
(RBF) and renal perfusion pressure (RPP) in Rf-
1B (z, n=13), Rf-1B+4 (, n=12) and Rf-1B+5 
(S, n=12) rats; Values are given as means ± SEM 
(error bars). No signifi cant differences were present.
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studies will be needed to substantiate these assumptions, and eventually explain the mechanisms of the 
high susceptibility to develop renal damage seen in the FHH rat.
The evidence for a role of the Rf-5 QTL in renal damage susceptibility remains meagre. The 
present study does not present any evidence, while a previous study showed that the Rf-5 region alone 
does not infl uence renal susceptibility. Furthermore, the LOD-score of the Rf-5 QTL was only suggestive 
for linkage (2.99).234 Currently, a panel of consomic rat strains is being generated at the Medical College of 
Wisconsin (http://pga.mcw.edu). In these consomic strains each FHH chromosome is, one by one replaced 
by the corresponding chromosome of the BN strain. In the FHH-17BN strain, FHH chromosome 17 containing 
the Rf-5 QTL is substituted. The FHH-17BN rats showed no difference in either UAV or SBP when compared 
to FHH rats. The results of the consomic studies strengthen our conclusion that the Rf-5 QTL of the FHH 
does not contain genes infl uencing renal damage susceptibility. However, the situation might be different 
in other rat strains. Yagil et al. reported that chromosome 17 of the SBH/y carried genes infl uencing the 
development of proteinuria in the salt-susceptible Sabra rat strain.299 
In conclusion, the present study confi rms that the Rf-4 region interacts with the Rf-1 region to 
enhance renal susceptibility. The Rf-5 region does not infl uence renal damage susceptibility when combined 
with Rf-1. We therefore assume that the Rf-5 QTL from FHH does not contain genes infl uencing the 
susceptibility to develop renal damage.
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Abstract
Linkage analysis of a cross of FHH and the renal-resistant ACI (August x Copenhagen Irish) rats 
revealed fi ve QTLs, named Rf-1 through Rf-5. A double congenic rat was generated carrying Rf-1 and Rf-2, 
the ACI.FHH-(D1Mit34-D1Rat90)(D1Rat101-D1Rat120) or (Rf-1A+2) for short. 
Renal damage susceptibility was assessed in Rf-1A+2 double congenic, FHL and FHH rats in two 
situations, i.e. two-kidney control (2K), and unilateral nephrectomy (UNX). After 6, 12, and 18 weeks after 
treatment, albuminuria (UAV) and systolic blood pressure (SBP) was measured. Renal autoregulation was 
assessed in two-kidney Rf-1A+2, FHL and FHH rats at an age of 13-15 weeks. A global genome scan on 
FHH and FHL was performed.
The FHH develops signifi cantly more UAV (2K: 51.4±5.3, UNX: 166.8±9.2) compared to Rf-
1A+2 and FHH, regardless of treatment or time. Following UNX an increase in UAV is found in Rf-1A+2 
and FHL (33.8±4.6 and 52.8±5.2, respectively). The FHH are hypertensive (SBP ~160 mmHg), FHL are 
normotensive (SBP ~130 mm Hg), and SBP of the Rf-1A+2 is intermediate (~145 mm Hg). The Rf-1A+2, 
FHL and FHH all have an impaired renal autoregulation. In the Rf-regions, FHH and FHL rats are identical 
for 86%, over all chromosomes it is 75%.
The Rf-1 and Rf-2 regions carry genes that infl uence renal susceptibility, and the Rf-2 region 
carries a gene that increases blood pressure. Differences in renal damage found between FHH and FHL 
can be partly explained by the differences in SBP, and partly by differences in genotype of the Rf-regions. 
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Introduction
The FHH (fawn-hooded hypertensive) rat is an inbred rat strain that is well characterized as a 
model for hypertension-associated renal failure. The FHH rat is a result of inbreeding of a random-bred FH 
strain. The FHH rats develop hypertension, progressive proteinuria (UPV), focal glomerulosclerosis (FGS), 
and fi nally end-stage renal failure (ESRF) at a relatively young age.198,200,238 During inbreeding of the FHH 
rat, another strain was selected for its low blood pressure and relatively low proteinuria, i.e. the FHL (fawn-
hooded low blood pressure) rat. This FHL rat showed to be less susceptible to the development of ESRF, 
which could be partly explained by the absence of hypertension.198,275 
Linkage analysis of crosses of FHH and the renal-resistant ACI (August x Copenhagen Irish) rat 
revealed the presence of fi ve QTLs, named Renal failure-1 (Rf-1) through Rf-5.25,234 It is surmised that each 
of these QTLs contain genes that infl uence the susceptibility to the development of renal damage. The Rf-1 
QTL had by far the highest LOD-score (16.9) for albuminuria (UAV), and was therefore the most promising 
QTL. The Rf-2 QTL peak had a LOD-score of 5.4 for UAV. In the Rf-2 region, a QTL was embedded 
suggestively linked to blood pressure, which was named Blood pressure fawn-hooded (Bpfh-1).25,234 A recent 
study by Matsson et al describes a consomic rat strain with chromosome 1 of the FHH, carrying Rf-1, Rf-2 
and Bpfh-1, being replaced by that of the BN (Brown Norway) strain. This FHH.BN1 strain had a signifi cantly 
lower blood pressure and less renal damage than he FHH parental strain after L-NAME treatment.158 These 
results support our previous linkage results, indicating that FHH chromosome 1 carries genes infl uencing 
blood pressure and the development of renal damage. 
Previously we reported that the transfer of just Rf-1 from FHH onto the genetic background of 
the ACI rat, increased renal damage susceptibility after UNX+L-NAME treatment.267 The effect of Rf-1 
alone was small, but when Rf-1 was combined with either Rf-3 or Rf-4, a signifi cant interaction was found 
to markedly increase renal damage susceptibility.269,270 Thus it appears that next to Rf-1 the presence of 
another QTL is needed to enhance renal susceptibility. Therefore, we studied the effect of the combined 
presence of Rf-1 and Rf-2 on blood pressure and the development of renal damage. We therefore generated 
a congenic rat strain carrying both QTLs from FHH on the ACI background. This double congenic strain, 
ACI.FHH-(D1Mit34-D1Rat90)(D1Rat101-D1Rat120) or (Rf-1A+2) for short, was studied in the two-kidney 
(2K) situation and following unilateral nephrectomy (UNX). The effects in the Rf-1A+2 strain were compared 
to those of FHH and FHL rat. We also performed a global genome scan comparing the inbred FHH and 
FHL strains to fi nd genetic differences that might help to explain the difference in blood pressure and renal 
damage susceptibility between these two strains.
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Methods
Congenic rat and control strains
For the experiments, Rf-1A+2 double congenic rats, FHH, and FHL rats were used. All breeding 
was performed at the Animal Research Centre at Erasmus MC, Rotterdam, the Netherlands. Animals were 
housed in individually-ventilated cages under SPF-conditions180 as previously described.267 The protocol 
received approval from the animal ethical committee of the Erasmus University. It was anticipated that in 
some strains the experimental procedures could induce severe distress demanding to end the experiment. 
Criteria to remove animals were severe weight loss (>15% within a week), paralysis or the presence of 
glaucoma.
The congenic rat strain was generated using a speed congenic strategy as described for the Rf-1B 
strain by Provoost et al.199 A schematic view of the introgressed Rf-regions of the Rf-1A+2B congenic strain 
is presented in Figure 1. The congenic generated here encompass the earlier reported 95% C.I. for Rf-1 
and Rf-2 and a major part of the Bpfh-1 QTL.25,234 A whole genome scan with 150 genetic markers on the 
congenic strain showed that there was no detected FHH genomic contamination on other chromosomes.
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Figure 1: Congenic regions (homozygous FHH) in the Rf-1A+2 strain. 
The whole genomic background of these congenic rats is ACI, except for 
the areas shown at the right hand side above with the different markers. 
These areas are homozygous for FHH, and contain the QTL peak. The 
arrows at the left hand side indicate the locations of the QTL peaks plus 
95% C.I. found in previous studies, i.e. D1Mgh12 for the Rf-1 QTL, and 
D1Mit3 for the Rf-2 QTL, and in gray, Mt1pa for Bpfh-1. 25,234
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Genetic heterogeneity between FHH and FHL rats
 Genomic DNA was extracted from spleens of FHH and FHL rats. Genotyping with simple-sequence 
length polymorphisms (SSLPs) was performed.115 Randomly divided over all rat chromosomes, 124 SSLPs 
were tested on DNA obtained from FHH an FHL. Of these 124 SSLPs, 21 were located in the fi ve Rf-regions 
of the FHH rat.
Susceptibility to L-NAME in Rf-1A+2 double congenics
 Previously we observed that both FHH and FHL rats suffered a high mortality following chronic 
L-NAME treatment, especially following UNX.275,276 Based on these fi ndings, susceptibility to L-NAME of 
the Rf-1A+2 double congenic rats was also tested in the 2K-situation (n=5) and in combination with UNX 
(n=6). 
Renal damage susceptibility in two-kidney rats and following UNX
Experiments for assessment of renal damage susceptibility in 2K and UNX were performed on 
61 animals starting from the age of 6-7 weeks. Per strain, the animals were randomly divided over two 
treatments (Table 1). The fi rst received no treatment, remaining with two kidneys (2K), which was considered 
to be the control situation. The second treatment consisted of UNX to reduce renal mass (UNX). UNX was 
performed as previously described.274 
Table 1: Number of rats studied in the 
renal susceptibility experiments.
2K UNX
Rf-1A+2 11 12
FHL 10 9
FHH 10 9,9,6*
* Number of rats at fi rst, second and third follow-
up, respectively.
Urine of individual rats was collected after 6, 12, and 18 weeks of treatment. The animals were 
housed in metabolic cages (Tecniplast, Buggugiate, Italy). Urine was collected during two consecutive 
days after a three-day adaptation period. Besides the amount of urine excretion, fl uid intake was also 
determined. 
Following the urine collection, SBP was measured by the tail-cuff method, using a photoelectric 
oscillatory detection device (IITC Life Science, Woodland Hills, CA) in awake, restrained rats, as described 
previously.199 
The animals were sacrifi ced shortly after the last series of urine collections and SBP 
measurements as described previously.267 Kidneys were weighed and left kidneys were used for histological 
examination. In a PAS-stained slide a total of 50 glomeruli were examined to determine the incidence of 
focal glomerulosclerosis (%FGS) as previously described.267 
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Renal autoregulation experiment 
Experiments for assessment of renal blood fl ow autoregulation were performed on 24 animals (8 
Rf-1A+2, 8 FHH, and 8 FHL rats) with an age of 13-15 weeks. To get an indication of the presence of renal 
damage, UAV was assessed using a 24-hr sample obtained before the autoregulation experiments. 
The determination of renal blood fl ow autoregulation was performed as previously described.267,270,272 
Renal autoregulatory indexes (RAI) over the range of pressures from 80 to 150 mm Hg were calculated by 
the method of Semple and de Wardener.228 
At the end of the autoregulation evaluation, both kidneys were weighed, and left kidneys were used for 
histological examination, as previously described.274 
Analytical procedures 
 Plasma and urinary samples were analysed with an ELAN system (Eppendorf-Merck, Hamburg, 
Germany) using colorimetric assays. Plasma and urinary albumin was determined with bromocresol green.62 
Plasma and urinary creatinine was determined with the Jaffé method without deproteinisation.240
Statistical analysis
Data are presented as mean ± SEM. Statistical differences in mean values between groups were 
compared using one-way analysis of variance (ANOVA), followed by the Bonferroni test to determine which 
pairs were signifi cantly different. These tests were performed using the Primer of Biostatistics for Windows 
program (Version 4.0, McGraw Hill, 1996). 
Results
Genetic heterogeneity between FHH and FHL rats
 Genetic heterogeneity in FHH and FHL rats was tested in order to reveal differences between 
these two strains. In total, 124 SSLPs were tested, of which 31 (25%) had different lengths in FHL compared 
to FHH. Of the 21 SSLPs located in the Rf-regions of the FHH rat, only three had a different length in FHL 
(14%). In the Rf-1 and Rf-3 regions no polymorphisms were found between FHH and FHL. In the Rf-2, Rf-4 
and Rf-5 regions only one SSLP in each region was different in FHL compared to FHH. Overall, 75% of the 
SSLPs are identical in FHL and FHH, while in the Rf-region identity increases to 86%.
Susceptibility to L-NAME and survival 
 Mean survival time of the Rf-1A+2 double congenic rats on L-NAME in the 2K-situation was 
18.7±1.7 weeks, i.e. after ~12 weeks of treatment. The mean survival time on L-NAME when combined with 
UNX was reduced to 14.0±4.0 weeks of age, i.e. after about 7 weeks of treatment.
Survival of animals in the 2K and UNX situation
 All rats survived the follow-up period of the 2K-control situation. After UNX, all FHL and Rf-1A+2 
double congenic rats survived the entire follow-up period. Three out of nine FHH rats did not survive the 
entire follow-up period after UNX. Data obtained from these three rats are included in the results of the fi rst 
and second measurements.
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Albuminuria and systolic blood pressure
 In the 2K-situation the Rf-1A+2 double congenic rats develop slightly more UAV than the FH. 
However this is not statistically signifi cant. The FHH rats develop considerably more UAV compared to both 
FHL and Rf-1A+2 double congenics. Following UNX, the Rf-1A+2 double congenic rats developed UAV than 
FHL rats. However this difference was again not statistically signifi cant. The FHH rats develop a progressive 
increase in UAV values, being signifi cantly different from both FHL and Rf-1A+2 double congenics (Figure 
2).
Figure 2. Albuminuria in FHH (z), FHL (S) and Rf-1A+2 () rats after 6, 12, and 18 weeks of follow-up 
during two treatments, values are given as mean ± SEM; A: 2K (2 kidneys); B: UNX, (unilateral nephrectomy); 
*: P<0.05 compared to Rf-1A+2 and FHL. 
The FHL rats showed to have a normal blood pressure of around 120-125 mm Hg, regardless 
of treatment or time. In the 2K-control situation and following UNX, SBP in FHH rats averaged at about 
150-160 mm Hg. The SBP of Rf-1A+2 double congenic rats was above that of FHL and below that of FHH, 
averaging at 140-145 mm Hg. With one exception, differences in SBP between FHL, FHH, and Rf-1A+2 
were statistically signifi cant (Figure 3).
Figure 3. Systolic blood pressure (SBP) in FHH (z), FHL (S) and Rf-1A+2 () rats after 6, 12 and 18 
weeks of follow-up during two treatments; values are given as mean ± SEM; A: 2K (2 kidneys); B: UNX, 
(unilateral nephrectomy); *: P<0.05 compared to Rf-1A+2 and FHL; +: P<0.05 compared to FHL.
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To enable a comparison between the outcome of the present experiment with the UAV and SBP 
values of the ACI parental strain and Rf-1A single congenic strains data at 18 weeks of follow-up are 
presented in Table 2. The UAV and SBP values for ACI and UAV are derived from a previous study. The 
comparison shows that in the 2K situation and following UNX the UAV and SBP values of Rf-1A+2 double 
congenics are signifi cantly higher than those of ACI and Rf-1A single congenics rats.
 
Table 2: Comparison of UAV and SBP values at 18 weeks of follow-up.
n BW (gram) UAV(mg/day/100 g BW)
SBP
(mm Hg )
2K
ACI
Rf-1A
Rf-1A+2
12
12
11
305±4
329±7*
301±4
1.9±0.1
2.7±0.2
15.7±2.5#
122±1
125±2
148±2#
ANOVA 0.005 <0.001 <0.001
UNX
ACI
Rf-1A
Rf-1A+2
12
11
12
310±3
325±6
299±7
5.4±0.6
16.5±2.0+
35.5±4.8#
126±2
123±2
145±2#
ANOVA 0.041 <0.001 <0.001
Values are given as means ± SEM. 2K, 2 kidneys; UNX, unilateral nephrectomy; BW, body 
weight; UAV, urinary albumin excretion; SBP, systolic blood pressure; * P<0.05 compared to 
ACI, Rf-1A+2; # P<0.05 compared to ACI and Rf-1A; + P<0.05 compared to ACI.
Measurements at end of follow-up
Data obtained at the end of the follow-up are depicted in Table 3. The BW of the Rf-1A+2 double 
congenics is signifi cantly lower compared to FHH and FHL. After UNX, BW of FHH rats is also have a lower 
than that of FHL. The %FGS is signifi cantly lower in FHL rats in the 2K-control situation compared to FHH 
and Rf-1A+2 double congenic rats. Following UNX the %FGS in FHH signifi cantly higher compared to FHL 
and Rf-1A+2 double congenics rats. The %FGS in Rf-1A+2 is signifi cantly higher compared to FHL. Plasma 
albumin is signifi cantly lower in FHH rats in both the 2K as the UNX situation. In the 2K-situation, creatinine 
clearance (Cc/100) in Rf-1A+2 double congenics is signifi cantly lower compared to FHH and FHL rats. In 
the UNX-situation, Cc/100 in Rf-1A+2 double congenics is signifi cantly lower compared to FHL rats
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Table 3: Measurements at end of follow-up. 
n BW (gram) FGS(% glom.)
Cc/100
(ml/min/100gBW) Palb (g/l)
2K
Rf-1A+2 11 303±3 35±3 0.52±0.02 26.0±0.4
FHL 10 388±6* 11±1* 0.89±0.06* 29.6±0.8*
FHH 10 385±8* 26±2# 0.91±0.03* 24.5±0.4+
ANOVA P<0.001 P<0.001 P<0.001 P<0.001
UNX
Rf-1A+2 12 300±6 48±5 0.44±0.02 24.0±0.5
FHL 9 384±5* 30±3* 0.70±0.03* 26.6±0.6*
FHH 6 323±14+ 95±3# 0.51±0.18 19.8±1.4#
ANOVA P<0.001 P<0.001 P=0.034 P<0.001
Values are given as means ± SEM. 2K, 2 kidneys; UNX, unilateral nephrectomy; BW, body weight; FGS, 
incidence of glomerulosclerosis; Cc/100 creatinine clearance; Palb, plasma albumin level; *: P<0.05 compared 
to Rf-1A+2; +: P<0.05 compared to FHL; # P<0.05 compared to Rf-1A+2 and FHL
Assessment of renal blood fl ow autoregulation 
Renal autoregulation curves depicting the relative RBF against the RPP are presented in Figure 
4. The RBF at an RPP of 150 mm Hg was increased by 25-27% compared to the RBF measured at 100 
mm Hg. No signifi cant differences were found between the Rf-1A+2, FHL, and FHH rats. The RAI values 
over the 100-150 mm Hg pressure range were 0.55±0.03 for FHH (n=8), 0.51±0.06 for FHL (n=8), and 
0.49 ±0.06 for Rf-1A+2 (n=8) congenic rats. There were no statistically signifi cant differences in RAI values 
between the strains. The magnitude of the RAI values indicated that all three strains do have an impaired 
renal autoregulation. 
In the Rf-1A+2 double congenic and FHL rats used for the autoregulation experiment no marked 
renal damage was present. The average UAV was ~5-7 mg/day/100g BW, while the %FGS was in the order 
of 3-11%. The FHH rat used for the renal autoregulation did show some degree of renal damage, UAV ~29 
mg/day/100g BW and ~14%FGS. 
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Discussion
The present studies shows that Rf-1A+2 double congenics rats show an increased susceptibility 
to renal damage and a higher level of SBP in comparison with ACI and Rf-1A single congenic rats. This 
indicates that the additional presence of the Rf-2 and Bpfh1 QTL from FHH on top of the Rf-1 QTL affects 
both renal susceptibility and SBP. However, compared to the FHH parental strain renal susceptibility and 
SBP are less Rf-1+2 double congenics. Compared to FHL rats, that share about 75% of the FHH genome, 
SBP is higher in the double congenics. Remarkably, UAV levels in Rf-1A+2 double congenic rats are higher 
than FHL in the 2K-situation, but lower following UNX. Similar to FHH, RBF autoregulation was impaired in 
Rf-1A+2 double congenic and FHL rats.
In contrast to our previous studies in Rf-1A+3 and Rf-1A+4 double congenic rats, renal susceptibility 
could not be tested in Rf-1A+2 double congenics following L-NAME-induced hypertension. All Rf-1A+2 rats 
died prematurely during L-NAME treatment. This was not a complete surprise, as we previously reported 
high mortality rates in L-NAME treated FHH and FHL rats.237,275,276 Such a high early mortality during L-
NAME treatment was not present in Rf-1, Rf-3, Rf-4, and Rf-5 single congenics or Rf-1+3 and Rf-1+4 double 
congenic rats.199,267,269,270 It is highly likely that the high mortality during L-NAME is due to the presence of 
the Rf-2 QTL, probably related to bleeding disorder gene located in that region.50 The bleeding disorder 
found in FH rats resembles the platelet-storage pool defi ciency in humans.50,204 The gene responsible for the 
bleeding disorder is also responsible for the coat color dilution in FH rats.197 This gene was recently reported 
to be the Rab38 gene.187 Rab38 is a member of the Rab family of small GTPases that regulate intracellular 
vesicle formation and traffi cking.192 In addition, Rab38 is a strong candidate for the Rf-2 gene affecting 
proteinuria and albuminuria in the FHH rat.204
Interestingly, SBP in intact Rf-1A+2 double congenics is about 15-20 mm Hg higher compared 
to FHL but still about 10-15 mm Hg below that of FHH. The effect on SBP is most likely due to the 
simultaneous introgression of the Bpfh1 QTL that is embedded in the Rf-2 QTL. The SBP level in the Rf-
1A+2 double congenics equals that of rats homozygous for Bpfh1 or Rf-2 in our original linkage analysis 
of an FHHx(ACIxFHH)F1 backcross.25 The lower SBP in FHL might indicate that Bpfh1, present in FHH 
and Rf-1A+2 double congenics, is lacking in FHL. Comparing the genotypes of FHH and FHL indicated 
that all 5 SSLP markers in the Rf-1 and 4 out of 5 markers in the Rf-2 region were identical in the two 
Figure 4: Relationship between percentage of renal 
blood fl ow and renal perfusion pressure in 13 to 15 
week old FHH (z, n=8), FHL (S, n=8) and Rf-1A+2 
(, n=8); Values (as %RBF at RPP of 100 mm Hg) 
are given as means ± SEM (error bars); %RBF, 
relative renal blood fl ow; RPP, renal perfusion; no 
signifi cant differences were present.
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strains. However, one marker in the Rf-2 and Bpfh-1 region was different between FHL and FHH, i.e. 
D1Mit2. Extensive genotyping of the region surrounding this marker should give more detailed information 
about the genetic differences between FHH and FHL and be helpful to fi nd the gene(s) responsible for the 
differences in SBP between these strains. Our present fi ndings support the supposition that Rf-2 infl uencing 
renal damage and Bpfh-1 infl uencing SBP are separate genes, a distinction that could not be defi nitively 
made in our previous linkage analyses.25,234 Studies in different rat strains support our fi ndings. Crosses of 
WKY with SHRSP, BN/SsNHsd with SS/JrHsdMcwi, and SBH/Ygl with SBN/Ygl all had a blood pressure 
QTL with a peak at marker D1Mit2.73,156,176,216,249 This indicates that most likely the region around D1Mit2 on 
rat chromosome 1 carries a gene that infl uences blood pressure. Further research should be conducted to 
reveal the actual gene.
Autoregulation of the RBF is infl uenced by the Rf-1 QTL. We previously reported that RBF 
autoregulation in Rf-1 carrying single congenic rats is impaired to the same extent as in FHH parental 
rats.267,270 Our present fi ndings show no differences in RBF autoregulation between FHH, FHL, and Rf-1A+2 
double congenics, indicating that the functional aspects of Rf-1 are also present in FHL. These fi ndings 
together with the equal genotype of 5 SSLP markers in FHL and FHH made us conclude that Rf-1 is also 
present in FHL.  
Comparing the differences in renal susceptibility between Rf-1A+2 double congenics, FHH and 
FHL shows that the FHH rats are the most susceptible strain.  The difference between the Rf-1A+2 double 
congenics and FHH may be partly due to the difference in SBP. However, it is more likely that it due to the 
absence of the Rf-3, Rf-4, and Rf-5 QTLs that are expected to further increase renal susceptibility in the FHH 
strain. Additional studies in multiple congenic strains are needed to provide evidence for this assumption. 
A comparison between the Rf-1A+2 double congenics and FHL rats is complicated. In the 2K-situation the 
level of UAV and FGS is higher in the double congenic. This may be due to the difference in SBP that in 
the presence of an impaired renal autoregulation would result in a higher intra-glomerular pressure and 
eventually more renal damage. On the other hand, based on the genotype comparison between FHL and 
FHH it is likely that FHL also carries the Rf-3 QTL from FHH, as no genotype differences in the Rf-3 region 
were present between both strains. Since genotype differences were present between FHL and FHH in the 
Rf-4 and Rf-5 regions we cannot be certain about the presence of the Rf-4 or Rf-5 QTL in FHL. However, 
the additional presence of Rf-3 in the FHL rat is likely to augment renal susceptibility. An augmented UAV 
response is seen in FHL following UNX. Although SBP is lower than that of the Rf-1A+2 double congenics 
the level of UAV is higher. Strangely enough this is not mirrored by a similar difference in FGS. To the 
contrary, the incidence of FGS in the Rf-1A+2 double congenics is signifi cantly higher than that of FHL. This 
points to a discrepancy between the severity of the functional damage (albuminuria) and structural damage 
(glomerulosclerosis). Further studies will be needed to explain such a discrepancy.
The combination of the Rf-1 and Rf-2 QTL is the third combination that results in an augmentation 
in renal susceptibility when compared with Rf-1 single congenic rats. Previously we reported that combining 
Rf-1 with Rf-3 or Rf-4 also increases renal susceptibility. Remarkably, the levels of renal damage seen 
in the three combinations are of the same order of magnitude.269,270 In contrast, renal susceptibility the 
combination of Rf-1 and Rf-5 did not differ from that of Rf-1 single congenics, indicating that the contribution 
of Rf-5 in determining the renal susceptibility in FHH is probably small.266 Future studies, will involve multiple 
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congenic strains carrying three or more of the Rf-QTL, in order to reconstruct the full renal susceptibility of 
the parental FHH strain.
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Abstract 
Renal damage susceptibility varies among inbred rat strains. The FHH (Fawn-Hooded 
Hypertensive) is a well-characterized inbred rat strain, which develops hypertension and end-stage renal 
failure at a relatively young age. Linkage studies in crosses of FHH and renal-resistant ACI (August x 
Copenhagen Irish) revealed fi ve QTLs linked to proteinuria (UPV), named Renal failure-1 (Rf-1) through 
Rf-5.
In previous studies we determined renal damage susceptibility in FHL, FHH, ACI rats, and ACI.
FHH-Rf congenics using unilateral nephrectomy (UNX) and L-NAME induced hypertension. Our goal was 
to determine if remnant kidney model (RKM) is a suitable model to test renal susceptibility in ACI, FHH, FHL 
and ACI.FHH-Rf congenic rats.
Three experiments were performed. Firstly, FHH and FHL were compared to ACI. In the second 
set-up, Rf-1B and Rf-5 single congenics were compared to ACI rats. In the third set-up, Rf-1A and Rf-4 
single and Rf-1A+4 double congenics were compared with ACI. At the age of 6 weeks, RKM started. After 
three and six weeks proteinuria levels (UPV) and systolic blood pressure (SBP) were measured. 
In the fi rst set-up, none of the FHH survived for to the fi rst evaluation. FHL developed severe renal 
damage. In the second set-up, Rf-1B developed signifi cantly more UPV than ACI and Rf-5, although both 
ACI and Rf-5 already developed considerable renal damage. The Rf-1A+4 developed signifi cantly more 
UPV compared to only ACI and Rf-4 rats.
 In conclusion, our fi ndings question the suitability of the RKM as a model to rapidly assess 
differences in susceptibility to develop renal damage. Although it could still be useful in strains that markedly 
differ in susceptibility, its value to detect differences between congenic rat strains was poor. The UNX model 
either alone or in combination with L-NAME induced hypertension, despite the longer duration, appears 
better suitable. 
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Introduction
The incidence and progression of kidney damage, eventually resulting in end-stage renal 
failure (ESRF) forms an increasing health care burden.103,160,244,263,285 To reveal pathophysiological 
mechanisms behind the development of ESRF, experimental research using various animal models may 
be helpful.25,84,175,195,224,225,234,235 Susceptibility to develop progressive renal damage varies among inbred rat 
strains. This can be used to identify genes involved in renal damage susceptibility via linkage analyses. 
Through rat-human homology this may lead to the identifi cation of genes involved in human forms of 
ESRF.11,78,220,226 
There are several ways to assess susceptibility to renal damage in rat. Differences can be 
spontaneously present, when comparing strains of inbred rats.10,20,66,95,99,215,238,245,283 In addition, renal mass 
reduction, hypertension and diabetes, well-known risk factors to develop renal damage in humans, have 
been used to induce or accelerate chronic renal damage in rats. Unilateral and subtotal nephrectomy are 
methods to reduce renal mass.16,97,130,239,291  Hypertension and diabetes may occur spontaneously or can be 
induced chemically or pharmacologically.119,275,276 We previously applied four treatments to detect differences 
in renal susceptibility between various rat strains.267,270,275,276 Next to the two-kidney (2K) control situation, 
they included 2K rats with L-NAME-induced hypertension, renal mass reduction by unilateral nephrectomy 
(UNX), and the combination of UNX and L-NAME induced hypertension. Recently, these models have been 
successfully applied to detect differences in renal susceptibility between the relatively resistant (August 
x Copenhagen Irish hooded) ACI rat and various ACI.FHH-Rf congenic rats.267,270  However, it did take a 
considerable time to detect signifi cant differences between these strains, markedly slowing the research 
progress.199,275,276,274,267,270   
The remnant kidney model (RKM), produced by the removal of over 75% of the functional renal 
mass, is a frequently used model to induce chronic renal failure in rats.16,97,130  The RKM has been generated 
by two means, i.e. ligation of renal artery branches or resection of the upper and lower kidney poles.32,68,173 
In contrast to the resection model, the ligation model also induces a marked increase in systemic blood 
pressure31,93,118, thus combining renal mass reduction and hypertension.
The aim of our present studies was to test the effi cacy of the RKM to more rapidly detect differences 
in renal susceptibility between inbred strains. We therefore mimicked previous experiments comparing the 
effect of the RKM in ACI and other rat strains that were previously shown to differ or not to differ in their 
susceptibility to develop renal damage.199,267,270,275,276
Methods
Animals
 For the different experiments we used 11 ACI, 7 FHH (Fawn Hooded Hypertensive), 12 FHL 
(Fawn Hooded Low blood pressure), 13 ACI.FHH-(D1Rat384-D1Rat156) (Rf-1B) congenics, 11 ACI.FHH-
(D17Rat112-D17Arb5/D17Rat180-D17Rat51) (Rf-5) congenics, 12 ACI.FHH-(D1Rat298-D1Rat90) (Rf-1A) 
congenics, 11 ACI.FHH-(D14Mit11-D14Rat82) (Rf-4) congenic, and 11 ACI.FHH-(D1Mit18-D1Rat90)/
(D14Mit11-D14Rat33/D14Rat65-D14Rat90)(Rf-1A+4) double congenic rats. Congenic rat strains were 
generated using a speed congenic strategy, as described for the Rf-1B strain by Provoost et al.199 The 
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congenic regions introgressed from the FHH into the ACI genomic background in the various ACI.FHH-Rf 
congenic rats have been previously described.267,270
All breeding was performed at the Animal Research Centre at the Erasmus MC, Rotterdam, the 
Netherlands. Animals were housed in micro-isolators under SPF-conditions.180 Lights were on from 7.00 a.m. 
to 7.00 p.m. Standard commercial rat chow containing 44% carbohydrates, 29% digestible animal protein, 
7% fat, 4% fi bre and 8% minerals (SRM-A; Hope Farms, Woerden, the Netherlands) and drinking fl uid (tap 
water, acidifi ed to pH 2.4-2.8) were provided ad libitum. The protocol received approval from the animal 
ethical committee of Erasmus MC. It was anticipated that in some strains the RKM could induce severe 
distress demanding to end the experimental procedures. Criteria to remove animals from the experiment 
were severe weight loss (>15% within a week), paralysis or the presence of glaucoma.
Experimental set-up
Three previously published experimental set-ups were mimicked. In the fi rst, we compared the 
ACI, the FHL, and FHH strains known to markedly differ in renal damage susceptibility.275,276 In the second, 
we compared ACI controls and Rf-1B and Rf-5 single congenic rats. We previously showed that renal 
susceptibility was somewhat increased in Rf-1B congenics rats following UNX+L-NAME treatment, while 
Rf-5 congenics did not differ from ACI.199,267 In the third experiment we compared ACI controls with Rf-1A, 
Rf-4 single congenics and Rf-1A+4 double congenic rats. We previously showed that renal susceptibility 
was somewhat increased in Rf-1A congenics rats while Rf-4 congenics did not differ from ACI. In addition 
renal susceptibility was markedly enhanced in Rf-1A+4 double congenic rats indicating a synergistic gene-
gene-interaction between Rf-1 and Rf-4.270
Surgical procedure
 For the surgical procedure, rats were anaesthetized with a mixture of 3% isofl urane®, about 30% 
N2O, and about 60% O2, and were placed on a heated surgical table to maintain the body temperature 
at approximately 36ºC. The RKM was produced by total removal of the right kidney and ligaturing two 
branches of the left renal artery with a silk suture (8.0, Braun AG, Melsungen, Germany). The wound was 
closed using a dissolvable suture (4.0, Braun AG, Melsungen, Germany). The rats were allowed to recover 
from surgery in a warmed cage for half an hour.
Urine collection, proteinuria and systolic blood pressure measurement
Urine of individual rats was collected at 3 and 6 weeks after surgery to determine the level of 
UPV. The animals were housed in metabolic cages (Tecniplast, Buggugiate, Italy). Urine was collected 
during two consecutive days after a three-day adaptation period. Total urinary protein was determined using 
an ELAN system (EppendoRf-Merck, Hamburg, Germany) with the with pyrogallol red-molybdate complex 
colorimetric method.286
 Following the urine collection, systolic blood pressure (SBP) was measured by the tail-cuff 
method, using a photoelectric oscillatory detection device (IITC Life Science, Woodland Hills, CA) in awake, 
restrained, but trained rats, as described previously.275,276 
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Statistics
 Data are presented as mean ± SEM. Statistical differences in mean values between ACI and 
FHL were compared by Students-t-test. Statistical differences in mean values between rat strains within the 
two other experimental set-ups were compared using one-way analysis of variance (ANOVA). The ANOVA 
test was followed by the Bonferroni test to determine whether strains were signifi cantly different from each 
other. In all tests, a p-value <0.05 was considered statistically signifi cant. All tests were peRformed using 
the Primer of Biostatistics for Windows program (Version 4.0, McGraw Hill, 1996).
Results
Experiment 1
Survival
All seven FHH rats died prior to the fi rst evaluation. Mean survival time was only 10±1 days 
after inducing the RKM. Out of the 12 FHL rats, ten could be measured at the fi rst and nine at the second 
evaluation. All 11 ACI rats did not survive the complete 6-week follow-up period. 
Proteinuria and systolic blood pressure
Values for UPV and SBP during follow-up are presented in Figure 1. Because of differences in 
BW between strains, UPV values are presented as mg/day/100g BW. Both at 3 and 6 weeks, UPV and SBP 
values were signifi cantly higher in FHL compared to ACI. 
Figure 1: Proteinuria (UPV) and systolic blood pressure (SBP) after 3 and 6 weeks of follow-up in ACI and 
FHL rats. Values (mg/day per 100 g BW) are given as mean ± SEM, number of rats is given in Table 1. A: 
UPV B: SBP; *: P<0.05 compared to ACI.
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Experiment 2
Survival, proteinuria and systolic blood pressure
 All ACI, Rf-1B, and Rf-5 single congenics survived the entire follow-up period. Values for UPV and 
SBP during follow-up of all the rats are presented in Figure 2. At 3 weeks mean UPV level in Rf-1B congenic 
rats was signifi cantly higher compared to ACI rats, while at 6 weeks mean UPV level in Rf-1B was higher 
compared to both ACI and Rf-5 single congenic rats. No signifi cant differences in mean UPV level were 
noted between ACI and Rf-5 single congenic rats. No signifi cant differences in mean SBP level were noted 
between the three strains. 
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Figure 2: Proteinuria (UPV) and systolic blood pressure (SBP) after 3 and 6 weeks of follow-up in ACI, Rf-
1B and Rf-5 rats. Values (mg/day per 100 g BW) are given as mean ± SEM, number of rats is given in Table 
1. A: UPV B: SBP; *: P<0.05 compared to ACI and Rf-5; +: P<0.05 compared to ACI.
Experiment 3
Survival, proteinuria and systolic blood pressure
All Rf-1A, and Rf-4 single and Rf-1A+4 double congenics survived the entire follow-up period. 
Values for UPV and SBP during follow-up are presented in Figure 3. At 3 weeks mean UPV level was 
signifi cantly higher in Rf-1A+4 double congenics compared to ACI rats, while at 6 weeks mean UPV 
level in Rf-1A+4 double congenics was higher compared to both ACI and Rf-4 single congenic rats. No 
signifi cant differences in mean UPV level were noted between Rf-1A+4 double and Rf-1A single congenics 
and between ACI and Rf-4 single congenic rats. No signifi cant differences in mean SBP level were noted 
between the four strains. 
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Figure 3: Proteinuria (UPV) and systolic blood pressure (SBP) after 3 and 6 weeks of follow-up in ACI, 
Rf-1A, Rf-4 and Rf-1A+4 rats. Values (mg/day per 100 g BW) are given as mean ± SEM, number of rats is 
given in Table 1. A: UPV B: SBP; *: P<0.05 compared to ACI and Rf-4; +: P<0.05 compared to ACI.
Discussion
This study shows that the RKM is extremely powerful in inducing chronic renal damage. Even the 
ACI rat, shown to be relatively resistant to other procedures 199,267,270,275,276, rapidly develops severe renal 
damage. The severity of the renal damage observed in ACI will infl uence the ability to detect differences in 
renal susceptibility in other strains. Besides, we observed a large variability in the degree of renal damage 
induced by the RKM. Comparing the outcome of the present experiments with that of our previous studies 
shows that some fi ndings, but not all, could be reproduced by the RKM. This makes the RKM not better 
suitable than the ones we previously applied to detect differences in renal susceptibility between inbred rat 
strains.
In the fi rst experiment, we confi rmed the high renal susceptibility of the FHH and FHL strains. 
Mean survival time after surgery of the FHH rats was only 10 days. The FHL strain is less susceptible than 
FHH and the majority of the FHL rats did survive the complete follow-up period. However, severe renal 
damage developed in this very short period. These fi ndings are in line with previous studies looking at the 
effects of UNX and UNX+L-NAME treatment in FHH and FHL rats, where severe renal damage rapidly 
developed. Therefore, RKM is suitable to assess differences in renal susceptibility between the ACI and the 
two FH rat strains.
In the second, a study was mimicked that had shown that Rf-1B single congenics do develop 
more renal damage than ACI rats, especially when haemodynamic stress is put upon the kidney by the 
combination of UNX and L-NAME induced hypertension. In contrast, renal damage in Rf-5 single congenics 
following this procedure did not differ from that of ACI parental rats.267 Similar differences were observed in 
the present study, employing the RKM. Signifi cantly more renal damage was found in Rf-1B single congenic 
rats when compared to ACI rats. In contrast, the renal damage in Rf-5 single congenics did not differ 
from that in ACI rats. The level of SBP was not signifi cantly different between the three strains. Thus, 
differences in renal damage cannot be explained by differences in systemic blood pressure. The absence 
of any difference in SBP and renal damage between ACI and Rf-5 single congenic rats also indicates that 
the introgressed FHH congenic regions in the Rf-5 congenic strain apparently do not contain genes directly 
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infl uencing SBP or renal damage susceptibility. Taken together, the RKM appears suitable to rapidly assess 
differences in renal susceptibility between single congenic rat strains.
In the third experiment, another study was mimicked that had revealed the presence of a synergistic 
interaction between Rf-1A and Rf-4 markedly increasing the susceptibility to develop renal damage. The 
presence of a synergistic interaction could not be confi rmed in the RKM. Although a similar trend was 
present, i.e. the highest level of renal damage in Rf-1A+4 double congenics, followed by Rf-1A single 
congenics. In contrast, renal damage in Rf-4 damage did not differ from that of ACI parental rats. The level 
of SBP was not signifi cantly different between the four strains. Thus, differences in renal damage cannot 
be explained by differences in systemic blood pressure. Similar to the fi ndings in Rf-5 single congenics, the 
absence of any difference in SBP and renal damage between ACI and Rf-4 single congenic rats indicates 
that the introgressed FHH congenic regions in the Rf-4 congenic strain apparently do not contain genes 
directly infl uencing SBP or renal damage susceptibility. In contrast to our previous fi ndings, the presence of 
a synergistic interaction between Rf-1A and Rf-4 was not detected with the RKM. At 6 weeks, renal damage 
in Rf-1A+4 double congenics was signifi cantly different from that of ACI and Rf-4 single congenics, but not 
from that of Rf-1A single congenics. Furthermore, in the present set-up no signifi cance difference in renal 
damage was found between Rf-1A and Rf-4 single congenics, thus failing to confi rm our previous fi ndings 
in less severe models of chronic renal damage.270 To our opinion, the failure to detect the earlier found 
interaction between Rf-1A and Rf-4 can be explained by large variation in UPV value within each rat strain, 
weakening the power of the statistical analysis. From this experiment we may conclude that the RKM is not 
suitable to rapidly assess differences in renal susceptibility between single and double congenic rat strains 
and to reveal the presence of synergistic interactions between congenic regions. 
The RKM has been an important, widely used model to study the mechanisms of progressive 
renal damage110,148,182, the consequences of chronic renal failure16,96, as well as the effects of pharmacologic 
interventions to prevent or treat the development of chronic renal damage.41,153,162 To detect differences 
in susceptibility between strains, the RKM has major disadvantages compared to the previously studied 
UNX or UNX+L-NAME models. The main disadvantage is the poor reproducibility of the model. In contrast 
to the UNX where 50% of the renal mass is reduced, the amount of renal mass reduction in the RKM is 
quite variable. This is mainly due to differences in the anatomy of the renal blood supply between individual 
rats. Tying of two or three branches of the renal artery, will infarct different amounts of renal tissue. While 
this is anticipated, it is hard to reliably estimate how much renal tissue is actually excluded. One can look 
at the colour change of the kidney surface, but it could well be that the surface has a good blood supply 
while the inner part is infarcted. Therefore, a visual estimation of the renal mass reduction could be entirely 
wrong. A second disadvantage is the poor control of the systemic blood pressure. The RKM rats uniformly 
develop marked hypertension shortly after surgery. However, large individual differences were present. 
These differences may, at least partly, be related to differences in the amount of infracted renal tissue. 
Previous studies have shown that an increase in blood pressure often occurs in RKM with branch ligation, 
but is less seen with the pole resection method.92 The consequence of the poor reproducibility of RKM is 
the large variability of the degree of renal damage induced within each strain, resulting in large standard 
deviations, markedly reducing the chances of fi nding statistically differences between rat strains.
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Effi cacy of remnant kidney model in ACI, FH rats and ACI.FHH-Rf congenic rats
In conclusion, our fi ndings question the suitability of the RKM as a model to rapidly assess 
differences in susceptibility to develop renal damage. Although it could still be useful in strains that markedly 
differ in susceptibility, its value to detect differences between congenic rat strains was poor. The UNX model 
either alone or in combination with L-NAME induced hypertension, despite the longer duration, appears 
better suitable.
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9. General discussion
Human chronic kidney disease (CKD) is an international health care burden.263 Several studies 
indicate that CKD in humans is a polygenic disease.292,129 Experimental studies in rats and mice may be 
helpful to unravel the complex genetics of CKD.17,25,69,82,84,88,100,109,130,152,172,175,185,195,224,225,234,235,249,307  Linkage 
analysis of a cross of ACI and FHH rats revealed fi ve QTLs linked to renal damage, named Renal failure-1 
(Rf-1) through Rf-5. The Rf-1 QTL had by far the highest LOD-score and was our main interest.25,234 We 
have studied the role of the Rf-1 to Rf-5 QTLs in congenic rat strains. Congenic strains are useful for 
studying the effects of specifi c genes or genomic regions against a common inbred background. The use of 
congenic strains has evolved during the past decade as the major working algorithm used by researchers 
in their attempts to narrow down the span of QTLs.136,300 Several congenic rats were generated carrying 
one or two Rf-regions of the FHH rats onto an ACI genomic background.271 The experiments described in 
this thesis study the susceptibility to the development of renal damage in ACI.FHH-Rf single and double 
congenic rats. 
Previous studies have shown that the FHH rat has an impaired renal autoregulation. An impaired 
renal autoregulation is thought to contribute to the susceptibility to renal damage in FHH rats. The impaired 
renal autoregulation allows the increased systemic pressure present in FHH rats to enter the glomeruli, 
which increases hemodynamic stress upon the glomeruli. Therefore, renal autoregulation has also been 
tested in the ACI.FHH-Rf congenic rats.
 In the general discussion the major fi ndings presented in this thesis will be reviewed. In addition, 
an attempt is made to translate the experimental fi ndings to the human situation, and perspectives are given 
to further unravel the genetic mechanism behind the development of renal damage. This chapter ends with 
the overall conclusion derived from the different studies.
9.1 Difference in susceptibility to develop renal damage
For the various experiments presented in this thesis renal susceptibility has been tested in 13 
different rat strains. To allow for a comparison between these strains, indices of renal damage obtained after 
18 weeks of treatment are summarized in Table 1-4. Table 1 and 2 summarize the fi ndings of renal damage 
indices in ACI, fi ve ACI.FHH-Rf single congenics, fi ve ACI.FHH-Rf double congenics, as well as FHL and 
FHH rats in 2K controls and following UNX. Table 3 and 4 summarize the renal damage indices in ACI and 
ACI.FHH-Rf single congenics rats following 2K+L-NAME or UNX+L-NAME treatment.
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9.1.1 Differences in renal susceptibility between ACI, FHL, and FHH
The FHH rat is a well-characterized model of hypertension associated renal damage and together 
with the renal resistant ACI strain they form the foundation of the present studies. The FHL rat, like the FHH 
generated during the inbreeding process from a random bred FH strain, was selected for its normal blood 
pressure and lower level of UPV. In the 2K-control situation, the FHH develops mild hypertension of about 
160 mmHg and signifi cant amounts of UPV and UAV. Glomerulosclerosis is present, but still mild. Despite 
a similar level of SBP, UPV and UAV are higher in FHL compared to ACI rats, demonstrating that the FHL 
strain is more susceptible to renal damage than the ACI strain. Interestingly, compared to ACI both FHL and 
FHH show glomerular hyperfi ltration indicated by the increased creatinine clearance. 
When hemodynamic stress upon the kidney is increased by reducing renal mass, a marked 
further increase in UPV, UAV and FGS is seen in FHH. The FHL strain too shows marked increases in 
renal damage following UNX. In contrast, only a small increase in UPV and UAV is seen in ACI. In all three 
strains the level of SBP is similar to the levels found in the 2K-situation.268 Thus, clear differences in renal 
susceptibility are present. The FHH strain is clearly the most susceptible followed by the FHL strain, while 
the ACI strain is quite resistant to develop renal damage.
The origin of the differences in susceptibility to develop progressive renal damage between the 
FHH and FHL strain are not clear yet. Five Rf-QTLs are thought to contribute to the increased susceptibility 
to renal damage in the FHH rat. A crude genome scan revealed that FHH and FHL were genetically identical 
for 75%. When looking at the fi ve Rf-regions, they were identical for 86%. Markers tested in the Rf-1 and 
Rf-3 regions were identical in FHL and FHH, while marker differences were present in the Rf-2, Rf-4 and Rf-
5 regions. 268 Thus, differences in Rf-2, Rf-4, and Rf-5 may account for the difference in renal susceptibility 
between FHL and FHH.
Differences in systemic blood pressure between FHH and FHL may also play a role. Interestingly, 
the Rf-2 region also includes the Bpfh-1 QTL, previously linked to SBP in the FHH rat.25,234 A marker difference 
in the Bpfh-1 QTL could explain the difference in SBP between the FHH and FHL rats. Unfortunately, the 
effects of L-NAME-induced hypertension could not be tested. Induction of hypertension by administering L-
NAME leads to a high mortality rate in both FHL and FHH.275,276 Whether this is linked to the high renal damage 
susceptibility, the bleeding disorder that resembles the platelet-storage pool defi ciency in humans50,204, or 
another mechanism still remains unclear and should be further studied. 
In summary, the difference in susceptibility to renal damage between FHL and FHH rat can be 
partly explained by difference in SBP, but also partly by genetic differences in some of the Rf-regions. A 
detailed genome scan comparing the FHH and FHL rats in the fi ve Rf-regions will delineate the genetic 
differences between the stains and may be helpful to further narrow down the regions involved in determining 
the differences in SBP and renal susceptibility.
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9.1.2 Differences in renal susceptibility between ACI and single congenics
Congenic rat strains give us an unique opportunity to detect an effect of a QTL-region linked 
to a disease trait on a genomic background that does not develop the disease trait.154,300 Where human 
studies fail because of the huge genetic heterogeneity, studies in congenic animals are more successful 
because of their genetic homogeneity.292 The congenic rats carry the QTL region of the FHH but are for over 
95% genetically identical to the renal resistant ACI progenitor strain.271 In this thesis, we described the fi rst 
congenic rats generated for unraveling the mechanisms behind the development of renal damage. It was 
surmised that each of the fi ve Rf-QTLs had a role in the development of renal damage. This assumption has 
been tested in single Rf-congenic rats. 
Single congenic rats were generated carrying the Rf-1, Rf-3, Rf-4 or Rf-5 QTL of the FHH on an 
ACI genomic background. Each of these single congenic rats have been studied for their susceptibility to 
renal damage using four models. The control model consisted of two-kidney rats. In another model, renal 
mass was reduced by unilateral nephrectomy (UNX). Since all tested single congenics were normotensive, 
an increase in SBP was needed to compare the results with the hypertensive FHH. The 2K+L-NAME model 
consisted of two-kidney rats with L-NAME induced hypertension, and the last model was a combination of 
UNX and L-NAME induced hypertension. 
Following UNX, 2K+L-NAME, or UNX+L-NAME, both Rf-1 and Rf-3 single congenics had 
signifi cantly higher UPV and UAV values when compared to ACI rats.267,269 In contrast, rats carrying either 
the Rf-4 or the Rf-5 QTL did not show to have an increased renal susceptibility.267,270 It is clear that the 
Rf-4 and Rf-5 regions do not have a direct effect on renal susceptibility. In contrast, both the Rf-1 and 
Rf-3 regions appear to directly infl uence renal damage susceptibility. The role of the Rf-2 region on the 
renal susceptibility has not been established yet since the Rf-2 single congenic rat only recently has been 
generated.
9.1.3 Differences in renal susceptibility between Rf-1 single congenics and double congenics
 Chronic kidney damage is thought to be a polygenic disease, where multiple genes are interacting 
to increase renal susceptibility.129,292 The presence of fi ve QTLs linked to renal damage susceptibility 
underscores the complexity of CKD. Linkage studies revealed that Rf-1 had by far the highest LOD-
score and studies in Rf-1 single congenics showed that this region must contain genes infl uencing renal 
susceptibility.25,234 To fi nd out if interactions are present between the different Rf-QTLs, double congenics 
were generated carrying besides the Rf-1 region, also another Rf-region. In this thesis we describe the fi rst 
double congenics created for unraveling the mechanism behind the development of CKD.
 Renal damage susceptibility was assessed in fi ve ACI.FHH-Rf double congenic rat strains, i.e. 
Rf-1A+2, Rf-1A+3, Rf-1A+4, Rf-1B+4, and Rf-1B+5 double congenics. The Rf-1A+2 double congenic was 
the only double congenic with an increased blood pressure.268 The induction of hypertension by L-NAME 
led to an increased mortality rate in all double congenics. Especially in combination with UNX survival, 
was low. In this discussion only a comparison is made between the double congenics and the Rf-1B single 
congenics using the 2K and UNX model. Following UNX, increased UPV and UAV values were found in 
the Rf-1A+2, Rf-1A+3, Rf-1A+4 and Rf-1B+4 double congenics when compared with ACI and Rf-1 single 
congenics.266,268,269,270 Also in the two-kidney model, differences in UPV and UAV values were found between 
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double congenics and ACI rats. Statistical analysis of the Rf-1A+3 and Rf-1A+4 revealed signifi cant 
interactions between the Rf-1 and Rf-3, and Rf-1 and Rf-4 QTLs, explaining the markedly increase in renal 
damage susceptibility.269,270 Remarkably, the levels of renal damage seen in the Rf-1A+2, Rf-1A+3, Rf-1A+4 
and Rf-1B+4 combinations are of the same order of magnitude.266,268,269,270 In contrast, renal susceptibility in 
the Rf-1B+5 double congenics did not differ from Rf-1B single congenics, indicating that the contribution of 
Rf-5 in determining the renal susceptibility in FHH is probably small.266 
9.2 Assessment of renal susceptibility 
9.2.1 Comparison of renal damage parameters
Comparing UPV and UAV values is an often used method to compare renal susceptibility.52,274,276,299 
These values will give an assessment of renal function. In a normal situation, glomeruli are relatively 
impermeable for proteins. However, when renal failure is present, the glomerular membrane becomes more 
permeable and proteins will leak through to the urine, resulting in elevated levels of UPV and UAV.258 The 
incidence of glomerulosclerosis (%FGS) can be assessed at the end of the experiment and will give an 
indication of structural damage present in the kidney.52,133 Another renal damage parameter is creatinine 
clearance (Cc/100). The Cc/100 will give an estimation of the glomerular fi ltration rate (GFR).42 These four 
parameters are often related to each other. The majority of proteins leaking through the membranes are 
albumin, therefore UAV values are close to the UPV values. Increased UPV and UAV values is often linked 
to an increased %FGS. In the end, a decrease in functioning glomeruli can lead to a decreased Cc/100. 
In most of the tested congenic rats a relation between the renal damage parameters is seen. 
However, in the Rf-1A+2 double congenic rat it appears that this relation is absent. Compared to FHL, 
Rf-1A+2 double congenic rats develop less UAV following UNX. Strangely enough this is not mirrored 
by a similar difference in FGS. To the contrary, the incidence of FGS in the Rf-1A+2 double congenics is 
signifi cantly higher than that of FHL.268 This points to a discrepancy between the severity of the functional 
damage (albuminuria) and structural damage (glomerulosclerosis). Further studies will be needed to explain 
such a discrepancy.
9.2.2 Role of systemic blood pressure
The FHH rat develops hypertension at a relatively young age. The hypertension present in this rat 
contributes to the development of renal damage. Three possibilities exist regarding the role of hypertension 
in CKD: (1) hypertension is necessary and suffi cient to produce CKD; (2) hypertension is necessary but 
not suffi cient to produce CKD, other risk factors are also needed; (3) hypertension is neither necessary nor 
suffi cient to produce CKD, but increases the risk in individuals who are otherwise predisposed or increases 
the rate of progression of CKD. In the fi rst situation, CKD is hypertension-induced, while in the latter two 
situations CKD will be hypertension-associated.25
Since hypertension is a very important risk factor for developing CKD, congenic rats should be 
tested in both a normotensive as well as a hypertensive situation. Based on our earlier experience we used 
chronic L-NAME treatment to raise systemic blood pressure.275,276 As indicated in our previous studies, 
using chronic L-NAME treatment has some disadvantages. It is diffi cult, if not impossible, to match SBP 
between the various strains at a level normally present in the FHH rat. Chronic L-NAME treatment may 
Chapter 9
128
directly affect the vascular structure in the kidney, independent of its blood pressure effects.305 Furthermore, 
reducing endothelial NO-synthase activity by L-NAME may have a negative effect on the protective action 
of NO in organs that are targets of hypertensive injury.101 Thus, differences found in renal damage between 
Rf-1B congenics and ACI may be partly due to an increased susceptibility to L-NAME. However, when 
comparing the Rf-1B single and Rf-1B+5 double congenics, results suggest that L-NAME is not infl uencing 
renal susceptibility. Following UNX+L-NAME, Rf-1B+5 double congenics had a signifi cantly higher SBP 
compared to Rf-1B, caused by an increase in L-NAME intake. Despite the increase in SBP, renal damage 
susceptibility in Rf-1B+5 double congenics was the same as in the Rf-1B single congenics, indicating that 
an increase in SBP alone is not likely to increase renal damage susceptibility. 
Renal susceptibility could not be tested in Rf-1A+2 double congenics following L-NAME-induced 
hypertension. All Rf-1A+2 rats died prematurely during L-NAME treatment. This was not a complete surprise, 
as we previously reported high mortality rates in L-NAME treated FHH and FHL rats.237,275,276 Such a high 
early mortality during L-NAME treatment was not present in Rf-1, Rf-3, Rf-4, and Rf-5 single congenics or 
Rf-1A+3, Rf-1+4, and Rf-1B+5 double congenic rats.199,267,269,270 It is highly likely that the high early mortality 
during L-NAME is due to the presence of the Rf-2 QTL. In conclusion, although L-NAME has disadvantages, 
it is good way to induce hypertension in congenic rats not carrying the Rf-2 region.
 In this thesis we also described a study where we tried to fi nd out if renal damage susceptibility 
can be assessed using RKM. We mimicked our previous studies where rats were treated with UNX+L-
NAME induced hypertension. With RKM the FHH rats did not survive for more than two weeks because 
of total renal failure. The FHL rats did survive but developed severe renal damage. Differences could be 
found between the normally renal resistant ACI rat strain and the FHL rat, although it should be taken into 
account that the ACI rat also developed a considerable amount of renal damage. In earlier studies we 
demonstrated that Rf-1 increases renal susceptibility to renal damage, and Rf-5 did not have an effect at 
all. When using RKM, the difference between ACI, Rf-5 and Rf-1B is found, although ACI and Rf-5 both 
developed considerable renal damage using RKM. While following UNX+L-NAME, both ACI and Rf-5 rats 
showed to be resistant to the development of renal damage. Comparing Rf-1A+4 double congenics with 
ACI, and Rf-1A and Rf-4 single congenics in the RKM, differences in susceptibility to renal damage were 
not as clear as when using the UNX+L-NAME model. The synergistic interaction between Rf-1A and Rf-4 
could not be detected in RKM, mainly because of huge variations within each rat strain.
To detect differences in susceptibility between strains, the RKM has major disadvantages 
compared to the UNX or UNX+L-NAME models. The main disadvantage of RKM is the poor reproducibility 
of the model. In contrast to the UNX model where 50% of the renal mass is reduced, the amount of renal 
mass reduction in the RKM is quite variable. This could be due to differences in the anatomy of the renal 
blood supply between individual rats. Another disadvantage is the poor control of the systemic blood 
pressure. The RKM rats uniformly develop marked hypertension shortly after surgery. However, large 
individual differences were present. 
Our fi ndings question the suitability of the RKM as a model to rapidly assess differences in 
susceptibility to develop renal damage. The RKM is extremely powerful in inducing chronic renal damage. 
Even the ACI rat, shown to be relatively resistant to other procedures 199,267,270,275,276, rapidly develops severe 
renal damage. Although it could still be useful in strains that markedly differ in susceptibility, its value to 
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detect differences between congenic rat strains was poor. The UNX model either alone or in combination 
with L-NAME induced hypertension, despite the longer duration, appears better suitable.
9.3 Renal physiology
9.3.1 Renal blood fl ow autoregulation
In a normal situation, an adequate autoregulation of the renal blood fl ow (RBF) is able to protect the 
glomerular capillary structures from injury due to systemic hypertension. Impaired autoregulation increases 
susceptibility for renal damage in various rat models including FHH.15,35,94,272,273 Because of the impaired 
renal autoregulation, hypertension increases intraglomerular pressure. A high PGC is the predominant cause 
of UPV and FGS in the FHH rat.237 When the renal perfusion pressure (RPP) in FHH rats is increasing, the 
PGC is increasing in the same extent because of an increased efferent arteriolar resistance and a decreased 
afferent arteriolar resistance.273 In another study it was found that UPV was directly dependent on the 
changes in RPP in FHH rats. The mechanism involved in this unusual pressure proteinuric response may be 
dependent on the GFR in response to elevations in RPP. Thus the high baseline fi ltered load of protein and 
the increase seen when RPP is elevated likely increased the delivery load of protein to a level that exceeds 
the transport maximum for reabsorption for protein in the proximal tubule.279
Two mechanisms contribute importantly to the regulation of preglomerular tone: the 
tubuloglomerular feedback and the myogenic response. Besides a reduced regulation of preglomerular 
tone, an increased tone of the efferent arterioles (EAs) may also contribute to the increased susceptibility 
of FHH rats to develop renal disease. A high tone of the EAs will retain an elevated glomerular pressure in 
the capillary network.210 The fi rst observation of Verseput et al.279 was that the TGF system in the FHH rat is 
intact, despite the fact that the FHH rat has a characteristically low afferent arteriolar resistance as compared 
to other hypertensive rats. Their second observation was that the FHH rat has a normal or even enhanced 
TGF system following prolonged administration of an ACE inhibitor (ACE-i). These latter fi ndings indicate 
that the reduction of PGC achieved by ACE-i is not offset by a concomitant attenuation of TGF function. The 
results of another study by van Dokkum et al.273 indicated that the myogenic response of preglomerular renal 
arteries is impaired in FHH rats and that they exhibit an impaired ability to buffer changes in intraglomerular 
pressure, especially in response to rapid fl uctuations in arterial pressure. This defect in the myogenic 
response of the preglomerular vasculature in combination with the previously reported increased efferent 
vascular resistance that elevated baseline PGC237,238, and the tendency of these animals to develop systolic 
hypertension promote the transmission of elevated pressures to the glomerulus.
Renal blood fl ow autoregulation has been tested two-kidney ACI, FHH, FHL, four ACI.FHH-Rf 
single congenics and fi ve ACI.FHH-Rf double congenics and results are depicted in Table 5. It shows the 
average RBF at a RPP of 100 mm Hg, and renal autoregulatory index (RAI) of RPP ranges of 130-150 mm 
Hg and 100-150 mm Hg. The RAI gives an indication of the renal autoregulation function of the depicted 
renal perfusion pressure range. A RAI of 0 indicates perfect autoregulation of RBF, and a RAI of 1 indicates 
that there is no autoregulation present due to a fi xed renal vascular resistance. Previous studies were not 
able to localize impaired autoregulation to a particular chromosomal region. Table 5 shows that all rats 
carrying the Rf-1 QTL have an increased RAI, indicating an impaired renal autoregulation. In this thesis 
we demonstrate that the Rf-1 region of rat chromosome 1 contains one or more gene(s) responsible for 
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impairing autoregulation of the RBF before the development of severe renal damage.267 It still remains to be 
determined if it is the same gene that is responsible for both a lack of autoregulation and renal disease. In 
contrast to the fi ndings in congenic rats carrying Rf-1, the Rf-3, Rf-4 and Rf-5 single congenics were shown 
to have a normal autoregulation, comparable to that of ACI rats (Table 5). Therefore, we can conclude that 
the Rf-3, Rf-4 and Rf-5 regions do not contain genes that infl uence renal autoregulation. The role of Rf-2 on 
renal autoregulation has not yet been investigated.
Table 5: Renal blood fl ow autoregulation of two-kidney (2K) 
ACI, FHH, FHL, and ACI.FHH single and double congenics 
at the age of 13-15 weeks.
n RBF100 RAI130-150 RAI100-150
ACI 21 4.63±0.24 0.26±0.04 0.25±0.02
Rf-1A 12 5.22±0.36 0.69±0.10 0.57±0.08
Rf-1B 13 4.58±0.25 0.59±0.05 0.53±0.05
Rf-3 15 4.58±0.36 0.24±0.02 0.28±0.03
Rf-4 15 5.36±0.43 0.21±0.03 0.23±0.04
Rf-5 15 5.90±0.28 0.17±0.02 0.17±0.02
Rf-1A+2 8 4.64±0.31 0.51±0.07 0.49±0.06
Rf-1A+3 16 4.97±0.23 0.63±0.07 0.49±0.05
Rf-1A+4 12 5.45±0.27 0.47±0.03 0.44±0.50
Rf-1B+4 12 4.28±0.30 0.45±0.07 0.42±0.05
Rf-1B+5 12 4.82±0.35 0.45±0.03 0.36±0.03
FHH 8 5.50±0.34 0.73±0.04 0.55±0.03
FHL 8 4.11±0.20 0.36±0.03 0.51±0.06
9.3.2 Creatinine clearance
Creatinine clearance (Cc/100) is used a measurement of GFR.42 Previous studies demonstrated 
that FHH and FHL rats are hyperfi ltrating, indicated by an increased Cc/100.51 Renal susceptibility studies 
in single ACI.FHH-Rf congenics revealed the presence of an increased Cc/100 in the Rf-3 single congenic 
rats.269 This would indicate the presence of one or more genes in this region infl uencing the GFR. However, 
an increased Cc/100 in the Rf-1A+3 double congenics was only seen following UNX and not in the 2K-
situation and L-NAME treated rats (Table 1-4). No good explanation is yet available, and further studies 
using better GFR methodologies need to be performed to unravel the genetics behind the increased GFR.
n: amount of rats; RBF100: renal blood fl ow (ml/min/gKW) at a renal perfusion 
pressure of 100 mm Hg; RAI130-150: Renal Autoregulatory Index at renal 
perfusion pressure range of 130 to 150 mm Hg; RAI100-150: Renal Autoregulatory 
Index at renal perfusion pressure range of 100 to 150 mm Hg; Rf: congenic 
strains; ACI: August x Copenhagen Irish; FHH: Fawn Hooded Hypertensive; 
FHL: Fawn Hooded Low blood pressure.
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9.4 Translation from rat to human
9.4.1 Complexity
The results from the numerous genomic studies in humans as well as rodent models together 
indicate that differences in renal susceptibility result from complex interactions between genes and the 
environment. In humans and rats multiple chromosomal regions have been linked with parameters of renal 
damage. However, studies with different forms of nephropathy in humans and different rat models yield 
different QTLs infl uencing renal susceptibility (Table 4, 5, 6 and Figure 1 of Chapter 1), suggesting an 
enormous genetic heterogeneity. Studies in congenic rats indicate that the effects of single QTLs may be 
small or absent. However, when various QTLs are combined in double congenic strains, strong gene-gene 
(epistatic) interactions do occur, markedly enhancing renal susceptibility. The complexity of the gene-gene 
interaction is further distended by the fact that the renal damaging effects of changing the genotypes also 
depends on the severity of the hemodynamic stress put upon the kidney, as well as the duration of the 
exposure. 
Epistasis is an old term to describe a masking effect whereby a variant or allele at one locus 
prevents the variant at another locus from manifesting its effect. Others defi ned it as a deviation from adding 
up the effects of alleles at different loci with respect to their contribution to a quantitative phenotype. More 
recent approaches dealing with epistasis have focused on the concept that the effect of a gene needs to be 
estimated in a specifi c context.193 The idea is to have a specifi c model of how genes function and interact 
and then construct a building-block description of the phenotype based on the genetic composition, as 
suggested by Cheverud and Routman36, in what they call physiological epistasis. 
Proteinuria, albuminuria, and glomerulosclerosis are all distant traits, i.e. not directly related to a 
single gene effect. With the generation of the different double congenics we have constructed a relatively 
simple two-locus model that resulted in an increased susceptibility to renal damage. Next to QTLs in FHH, 
numerous QTLs infl uencing parameters of renal damage have been detected in other strains (Table 5 of 
Chapter 1). It may well be that 10-15 candidate loci are involved in the various rat models of renal damage. 
Should a similar number of QTLs also play a role in humans, the number of possible gene pairs, trios or 
quartets that can be derived from these loci becomes tremendous. With n loci, there are [n(n-1)/2] gene 
pairs, [n(n-1)(n-2)/6] trios, and [n(n-1)(n-2)(n-3)/24] quartets. With 5 loci, the number of pairs, trios and 
quartets will be 10, 10, and 5 respectively. With 10 loci, these numbers increase to 45, 120, and 210, while 
with 15 loci there will already be 105, 455, 1365 possible combinations. As the various combinations may 
also interact, the number of partitions that one has to deal with statistically becomes gigantic. 
It may still be feasible to dissect and reconstruct the genetic components of inbred rat models 
with a limited number of homozygous QTLs involved. However, unraveling the genetic components of 
susceptibility to renal damage in humans becomes a tremendous task. With a large number of candidate 
genes and gene combinations involved, it might well be that each of them contributes only marginally to the 
total ESRF population. For instance, if diabetic nephropathy results from a three-locus model involving 12 
candidate genes with equal disease allele frequencies, than 220 possible three-gene combinations account 
for 30-35% of diabetics that eventually develop diabetic nephropathy. Each three-gene combination, 
however, only has to account for 0.45% of the cases. Even with a simpler two-locus model, there are 66 
possible two-gene combinations and each of them only has to account for 1.5% of the cases.
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The involvement of many loci may be one of the reasons that so many human studies fail to 
replicate animal fi ndings.292 Consider the testing of one gene polymorphism out of twelve candidate genes 
in a three-locus model. Supposing equal frequencies of the various possibilities, the gene tested will be 
present in 55 of the 220 (25%) possible trios. Thus, in 75% of the cases, the disease allele of the tested 
candidate gene will not be involved. Furthermore, the susceptibility allele of the tested gene may also be 
found in the control population. If disease alleles or other candidate genes are not present, or if harmful 
environmental conditions, like hypertension, diabetes, etc., are absent, the disease allele of the tested gene 
will have a high frequency also in the controls. The involvement of many candidate genes may also account 
for the inconsistencies in replicating genetic linkage and association studies in humans.292 
The presence of gene-gene interactions calls for new approaches to analyze the genetics 
underlying complex diseases in humans.168,178,292 Recent studies have analyzed the involvement in coronary 
heart disease of 18 polymorphisms in six candidate susceptibility genes178, or the role in hypertension of 
13 polymorphisms in eight candidate genes that play a role in blood pressure regulation.293 Both studies 
indicated that combinations of loci better predicted the trait variation than the marginal single locus effects. 
However, the computational burden of the analyses was considerable. Multigene approaches also emerge 
in studying CKD in humans.70 To achieve enough statistical power, however, future studies should strive 
for large collaborations to enable sample sizes that are suffi cient to simultaneously analyze multiple gene 
loci.163
9.4.2 Comparative genomics 
The enormously expanding collection of data generated from genetic and genomic research 
efforts in human, mouse, and rat emphasizes the fundamental need for integrating bioinformatics 
systems. Such systems are under permanent development in the USA as well as Europe/UK.260,28 The Rat 
Genome Database (RGD, http:/rgd.mcw.edu) is an NIH-funded collaboration between the Bioinformatics 
Research Center at the Medical College of Wisconsin, the Jackson Laboratory and the National Center for 
Biotechnology Information. The aims of RGD are to collect, consolidate and integrate data generated from 
ongoing rat genetic and genomic research efforts and make these data widely available to the scientifi c 
community. The rat is uniquely suited to its role as a model of human disease and the primary focus of 
RGD is to aid researchers in their study of the rat and in applying their results to studies in a wider context. 
This is achieved by providing a high-quality disease-centric resource, applicable to human, mouse, and 
rat via comparative tools. Thus, RGD is not only a valuable resource for those working with the rat but 
also for researchers in other model organisms wishing to harness the existing genetic and physiological 
data available in the rat to complement their own work. Integrating rat physiology with mouse genetics 
and clinical results from human by using the respective genomes provides a novel route to capitalize on 
comparative genomics and the strengths of model organism biology.116,260,261
RGD is continuously expanding and improving its activities. Recent developments can be 
categorized into three groups. (i) Improved data collection and integration to match increased volume 
and biological scope of research. (ii) Knowledge representation augmented by the implementation of a 
new ontology and annotation system. (iii) The addition of quantitative trait loci data, from rat, mouse and 
human to our advanced comparative genomics tools, as well as the creation of new, and enhancement of 
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existing, tools to enable users to effi ciently browse and survey research data. The emphasis is on helping 
researchers fi nd genes responsible for disease through the use of rat models.55
The T1DBase (http://T1Dbase.org) is a public website and database that is currently focused on 
the molecular genetics and biology of type 1 diabetes (T1D) susceptibility and pathogenesis. It includes 
annotated genome sequence for human, rat and mouse; information on genetically identifi ed T1D 
susceptibility regions in human, rat and mouse, and genetic linkage and association studies pertaining to 
T1D. Although the site is focused on T1D, the system is applicable to any genetic study of complex disease, 
of either large or small scale.28,241
A recent development is the Human Phenome Database (HPD, http://hpd.mcw.edu), which was 
created to help researchers identify the underlying genetics responsible for complex multifactorial human 
diseases. Their aims is to consolidate and integrate phenotype data generated from ongoing research 
efforts and make these data widely available to the scientifi c community. Data from model organisms, 
specifi cally rat and mouse, for comparative analysis as well as a suite of tools that integrate the data and 
allow interspecies comparisons are provided by HPD to facilitate analysis. The development of HPD will be 
very helpful for comparative genomics.
The search for genetic factors infl uencing susceptibility to renal damage in humans and rodent 
studies has revealed that multiple genes are involved acting in complex gene-gene and gene-environment 
interactions. Despite the progress, this has not yet resulted in a better understanding of the mechanisms 
of renal susceptibility. The state of affairs mimics the search for the genetic basis of hypertension56,301 and 
diabetes91,124,190 two important risk factors for CKD.  
However, with the completion of the sequencing of the human, mouse and rat genome, genomic 
comparisons between these three species are greatly facilitated.87,135,278,287 A linkage study in humans has 
revealed the presence of QTL linked to renal damage on chromosome 10q, which is homologous to the 
rat Rf-1 QTL.78 The 95% confi dence interval of the Rf-3 region (3: 117-146 Mb) is homologous to a part 
of human chromosome 20 (~1-33 Mb) and mouse chromosome 2 (126-155 Mb) (http://ncbi.nlm.nih.gov/
projects/Homology). Surprisingly, the Rf-3 homologous region in human and mouse appear both to be 
involved in renal disease. Linkage studies in Pima Indians suggest the presence of a gene on chromosome 
20 infl uencing diabetic nephropathy.111 The homologous region in the mouse has recently been linked to 
albuminuria in KK/Ta mice.233 The presence of QTLs linked to nephropathy in rat, mouse and human make 
the Rf-3 region very interesting for further investigation.
9.5 Perspectives
9.5.1 Additional model systems
Genetic manipulations (i.e. reporter-gene constructs, gene transfer, transgenic models, gene 
knockouts, consomics and congenics) can generate new strains of animals that are important not only for 
physiological genomics, but also for targeted functional study at the protein level.
At the moment, we have assessed renal susceptibility in Rf-1, Rf-3, Rf-4 and Rf-5 single 
congenics, and Rf-1+2, Rf-1+3, Rf-1+4 and Rf-1+5 double congenics. For future studies, the Rf-2 congenic 
rat strain should be phenotyped. Results showed that Rf-5 alone or in combination with Rf-1 did not have 
any infl uence on renal susceptibility. Since Rf-5 does not have a role in renal damage susceptibility, the 
focus will be on generating multiple congenic rats of the Rf-1, Rf-2, Rf-3 and Rf-4 regions. At the moment, 
triple congenic rats are being generated by crossing double congenic rats. The Rf-1+3+4 triple congenic rat 
is now ready to be phenotyped. The other two triple congenics, Rf-1+2+3, and Rf-1+2+4 are currently being 
generated. Our fi nal goal would be generating a quadruple congenic strain carrying Rf-1, Rf-2, Rf-3 and 
Rf-4. Ideally, this congenic rat strain should be studied physiologically with four models, i.e. the 2K control 
situation, UNX, and 2K+L-NAME induced hypertension. The UNX+L-NAME model will not be used because 
of the high mortality rate in double congenics.
Using the congenic rats described in this thesis, subcongenics can be generated. By making 
overlapping subcongenics, the QTL region can be narrowed down to a few Mb. By narrowing down the QTL 
region, the chance of fi nding genes increases. At the moment, several subcongenics have been generated 
for the Rf-1 and Rf-4 regions and are being tested for their renal damage susceptibility.
Consomic rats are yet another tool to help identifying genes infl uencing complex traits. The main 
principle of consomic rats is that the phenotype might be rescued by replacing an entire chromosome from a 
disease model by one from a healthy control strain.45 Further, the consomic rats can be used for generating 
congenic strains. In this way, the generation of congenic rats takes less time compared to the conventional 
method. Single consomic strains are also useful for generating multiple consomics, which can be used to 
reveal interactions between genes on different chromosomes. 
The Program for Genomic Applications (PGA) generates two panels of consomic rat strains by 
replacing each individual chromosome of either the FHH or the SS strain by that of the BN strain. Currently, 
19 SS.BN and 19 FHH.BN consomics have been generated and tested for several disease traits. Of the 
available SS.BN consomics, the SS.BN5, SS.BN6, SS.BN7, SS.BN8, SS.BN13 and SS.BN18 strains are the 
most promising as they all confer protection from renal damage (Chapter 1, Table 6). Currently, the SS.BN13 
strain is being studied to unravel the mechanisms behind the protection from salt induced hypertension and 
renal damage.47,146 
With regard to our studies, it will be interesting to compare the results obtained with the ACI.
FHH-Rf congenics with those from the FHH.BN1, FHH.BN3, FHH.BN14 and FHH.BN17 consomic strains. 
Replacement of chromosome 1 of FHH by BN led to a partial rescue of the renal damage phenotype. These 
results underscore the signifi cance of chromosome 1 of the FHH, harboring both Rf-1 and Rf-2. Replacing 
chromosome 14 of the FHH by BN results in a signifi cant decrease in UPV, confi rming a possible role for 
Rf-4 in infl uencing renal susceptibility. Finally, the replacement of chromosome 17 did not have any effect 
on the renal damage phenotype. This fi nding is in line with our results indicating that the Rf-5 region did 
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not signifi cantly infl uence renal damage susceptibility. An FHH.BN3 consomic strain to confi rm a role for the 
Rf-3 region has not been tested yet. The PGA data support the fi ndings of the ACI.FHH-Rf congenic rats 
presented in this thesis. In the future, double consomics, i.e. FHH.BN1,3, FHH.BN1,14, and FHH.BN3,14 can 
be generated and compared to the ACI.FHH-Rf double congenics. The generation of a multiple consomic 
where chromosome 1, 3, and 14 of the FHH are replaced by BN could be very interesting. It is expected that 
the renal damage phenotype in this triple consomic will be totally rescued.
Several genomic studies are carried out in mice. Currently, the total number of knockout mice 
described in the literature corresponds to about 10% of the ~25-30,000 mouse genes. Large consortia plan 
to generate comprehensive series of mouse gene knockout strains5, strains with ENU-mutated genes6,208, 
and a Collaborative Cross40 to speed up biomedical discovery. The aim of the Knockout Mouse Project is “to 
produce and phenotype knockouts for all mouse genes, and place these resources in the public domain”.5 An 
academic/industry consortium in the UK has initiated a phenotype-driven mutagenesis program to generate 
new mouse models of human disease and for gene function assignment.208 The objective of the European 
Mouse Mutagenesis Consortium is “to establish and integrate mutagenesis platforms, gene expression 
resources and phenotyping units, and bioinformatics resources” in order to “accelerate our understanding 
of gene function and of human health and disease”.6 The Collaborative Cross is an initiative of the Complex 
Trait Consortium aiming “to promote the development of resources that can be used to understand, treat 
and ultimately prevent pervasive human diseases.” The Collaborative Cross in itself is a panel of eight-
way recombinant inbred (RI) mouse strains, derived from a genetically diverse set of founder strains and 
designed specifi cally for complex trait analysis.40 The long-term expectations of all these initiatives are 
huge. Whereas the knockout and mutagenesis consortia aim at mutating all ~ 28,000 mouse genes, the 
collaborative cross thinks “of a set of 1,000 fully phenotyped RI strains and more than one million potential 
isogenic and completely defi ned F1 hybrids”.40
The transgenic and knockout technology that has been fl ourishing in the mouse has been less 
successful in the rat. Only a few transgenic rat strains are of interest to study the mechanisms of progressive 
renal damage. One of them is a strain of rats overexpressing the mouse ren-2 gene (TGR[mREN2]27). This 
strain was developed to study primary renin-dependent hypertension, but they also develop proteinuria 
associated with glomerulosclerosis as early as 8 weeks of age.7,137,214 Deterioration of renal function is 
accelerated in subtotally nephrectomized (remnant kidney) transgenic rats [TGR(mREN2)27] compared 
with that in comparably hypertensive stroke-prone SHR.284 A transgenic rat overexpressing the angiotensin 
II type 1 (AT1) receptor in podocytes was recently developed. It was found that increased AT1 receptor 
signaling in podocytes leads to protein leakage and structural podocyte damage progressing to focal and 
segmental glomerulosclerosis.105
The embryonic stem cell technology to produce knockout rats is not yet established. Methods 
to produce gene-disrupted knockout rats are greatly needed. Recently protocols have been developed for 
creating ENU-induced germline mutagenesis.242,304 The ENU mutagenesis technology has been successful 
in generating knockout rats as well as rats with mutations in genes of interest. No studies related to kidney 
damage employing this technology have yet been published. However, a program is being developed to 
generate gene knockouts in the SS, BN, and FHH strains that may be of interest for the renal research 
community (http://pga.mcw.edu).
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9.5.2 More physiology
In order to totally unravel the mechanisms behind the development of renal damage, more renal 
physiological studies must be conducted. For instance, in Chapter 5 an increased creatinine clearance 
(Cc/100) is described in single congenic rats carrying the Rf-3 region. This may point to the presence of 
an increased GFR. However, the 24-hour creatinine clearance is a rather crude estimate of the real GFR. 
Other, more GFR specifi c methods should be used to identify the presence of real differences in GFR 
between ACI, FHH and Rf-3 single congenic rats. 
 The Rf-4 region is most likely responsible for an increased glomerular permeability.231 Further 
studies into glomerular permeability, including electron microscopic pictures of glomeruli should be made to 
detect differences in glomerular structure, which might explain the differences in glomerular permeability.
 Previously, it was reported that the impaired renal autoregulation in FHH was caused by an 
impaired myogenic response, whereas the TGF was normal.272,273 Therefore, renal micropuncture studies 
should be performed in Rf-1 single congenics to fi nd out if the impaired renal autoregulation in this congenic 
rat is also due to an impaired myogenic response.
9.5.3 Transcriptome analysis
In the current era, it is not all about genomics. Several other “omics” have been created to help 
reveal the mechanisms behind a disease trait. Genomics looks at DNA level, while at mRNA level it is 
called transcriptomics, based on mRNA being the transcript of DNA. Another very important development 
is proteomics, where levels of proteins are defi ned. Genomics, transcriptomics and proteomics are “omics” 
that have been extensively used to several areas of biomedical research. All these techniques combined 
may contribute to a better understanding of the pathogenesis and pathophysiology of new therapeutic 
targets, biomarker discovery, prediction of therapeutic response, personalized treatment regimens, better 
therapeutic outcome and ultimately prevention of a disease.145,150,255 
Transcriptome analysis, a high-throughput analysis of gene expression at the mRNA level in a 
(near)-genome scale has become one of the most widely used approached in biomedical research. Gene 
expression studies are used to detect differences in gene activity between two different samples. The 
microarray technique is the most often used transcriptome technique. In the last few years, an enormous 
amount of data has been collected in kidney research using transcriptome techniques. Besides microarray, 
other techniques like serial analysis of gene expression (SAGE), sequencing of expressed sequence tags 
(EST) and real-time polymerize chain reaction (RT-PCR) give an estimation of the absolute or relative 
mRNA levels for all genes. The suppressive subtractive hybridization and differential display techniques are 
different because they will only identify mRNA that differs quantitatively between the tested samples.145 
In summary, the sequence of a gene can be assessed by genomics. The expression of a gene, 
i.e. the mRNA level can be assessed by transcriptomics. Analysis of proteins is called proteomics. It should 
be noted that one should be cautious when extrapolating mRNA to protein. Especially when mRNA and/or 
protein abundance is low it could give different quantitative estimates. Transcriptomic analysis alone will 
not be suffi cient for characterizing complex networks of biological regulation. Measurement of proteins will 
complement mRNA data or provide a validation of the mRNA data.145 
For future studies, it would be very interesting to fi nd out if there are genes that are differentially 
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expressed (up or down-regulated) in the kidneys of the FHH rat compared to the ACI rat. Since ACI and 
FHH are two different inbred rat strains, it is expected that a lot of genes will be different in their activity. 
Results should be focused on genes that lie within the Rf-regions of the FHH rats. A better option would be 
to compare kidney tissue of ACI with ACI.FHH-Rf congenic rats. The ACI.FHH-Rf congenic rats are for 95-
99% identical to the ACI rat, therefore limiting the total number of genes that will be differentially expressed. 
The specifi c changes in gene expression of each Rf-QTL can be measured by comparing the various ACI.
FHH-Rf single congenic strains with the ACI parental strain. Comparing single and double congenics could 
reveal alterations in gene expression caused by gene-gene interactions. These gene expression studies will 
result in the discovery of candidate genes that can be linked to the development of renal damage.
9.5.4 Gene discovery
 Discovering a gene causing or infl uencing the susceptibility to develop a disease is not simple. 
Genetic mapping of QTLs has resulted in several CKD-related QTLs, however a specifi c set of genes 
causing CKD has not been established yet. One of the reasons is that QTLs include large areas of a 
chromosome, incorporating a large set of genes. Congenic animals are most often generated in order to 
reduce this huge set of genes.205 The disadvantage of congenic animals is that it is time-consuming and will 
cost a lot to generate and maintain these animals. Transcriptomic analysis is another strategy to reveal the 
genetic basis of complex diseases. It will generate massive amount of data, where most of the genes do not 
have any relevance to the disease. When integrating the genomic strategy with the transcriptomic strategy, 
it is most likely to fi nd genes that are involved in the pathophsyiology of the disease.298 This method was 
used by Yagil et al, who were able to narrow down the number of candidate genes for salt-susceptibility and 
hypertension in the rat from 1102 to 7 genes.298 
 Integrating transcriptomic, genomic and proteomic analysis in studying the Rf-QTLs will most 
likely yield interesting fi ndings. Such studies should also be performed with the various single and multiple 
ACI.FHH-Rf congenic rats. The ACI.FHH-Rf congenic rat strains could be compared to the ACI rat. 
Differences in gene expression between the congenics and ACI could help explain the mechanism behind 
the development of CKD. Hopefully, this type of research will hopefully lead to the identifi cation of genes 
infl uencing differences in susceptibility to develop CKD. 
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9.6 Overall conclusions
Four aims were formulated in Chapter 1.4. The fi rst aim was to directly assess the role of each 
of the fi ve Rf-QTLs in determining susceptibility to renal damage. The second aim was to directly assess 
the interaction between Rf-1 and the four other Rf-QTLs. The third aim was to assess whether the effects 
if the individual Rf-QTLs depended on treatment model. The fourth aim was to establish the role of the 
Rf-QTLs in the autoregulation of the renal blood fl ow. The outcome of the various physiological genomic 
studies presented in this thesis regarding the rat renal failure QTLs Rf-1 through Rf-5 leads to the following 
conclusions:
1. The Rf-1 region of the FHH contains one or more genes directly infl uencing renal susceptibility and 
impairing renal autoregulation. Whether these genes are the same needs to be further investigated.
2. The direct effect of the Rf-2 region could not yet be tested. When the Rf-2 region is combined with 
the Rf-1 region, a signifi cant increase in renal damage is seen when compared with Rf-1 alone. 
Furthermore, the Rf-2 region, harboring Bpfh-1, increases blood pressure.
3. The Rf-3 region contains genes directly infl uencing renal susceptibility. Renal damage susceptibility 
in Rf-3 single congenics is similar to that of Rf-1 single congenics. When Rf-1 and Rf-3 are combined 
a signifi cant synergistic interaction is present. The Rf-3 congenic rats do have a normal renal 
autoregulation. The mechanisms of how Rf-3 infl uences the development of renal damage still remains 
to be detected.
4. Genes in the Rf-4 region do not directly infl uence renal susceptibility. However, when combined 
with Rf-1 a signifi cant synergistic interaction is present. The Rf-4 congenic rats do have a normal 
autoregulation. The mechanisms of how Rf-4 indirectly infl uences the development of renal damage is 
still unknown and should be further investigated.
5. The Rf-5 region does not contain genes that directly infl uence renal susceptibility. In addition, the Rf-5 
region shows no synergistic interaction with the Rf-1 region. 
6. The Remnant Kidney Model (RKM) is not a very suitable model to analyze renal susceptibility in rats 
carrying Rf-regions of the FHH rats. The four models we used, especially the UNX and 2K+L-NAME 
model appear more suitable to assess differences in susceptibility to develop renal damage.
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Summary
Chapter 1 introduces the reader into this thesis and gives an overview on the present knowledge of 
the role of genetic factors in the development of chronic kidney disease (CKD). It also describes the rat renal 
failure QTLs Rf-1 through Rf-5 and the possibilities to test their role in the susceptibility to develop CKD. In 
this chapter, four aims are formulated. The fi rst aim is to directly assess the role of each of the fi ve Rf-QTLs 
in determining susceptibility to renal damage. The second aim is to directly assess the interaction between 
Rf-1 and the four other Rf-QTLs. The third aim is to assess whether the effects if the individual Rf-QTLs 
depends on treatment model. The fourth aim is to establish the role of the Rf-QTLs in the autoregulation of 
the renal blood fl ow.
Chapter 2 describes the generation of the various ACI.FHH-Rf congenic rat strains that are used 
for this thesis. These congenic rats carry one or more chromosomal region(s) of the FHH harboring one or 
more Rf-QTLs, on an ACI genomic background. Studies in congenic rats can provide direct evidence for an 
effect of a single QTL or the interaction between two QTLs on the development of CKD. 
Chapter 3 describes the susceptibility to develop of renal damage in ACI, Rf-1B, and Rf-5 congenic 
rats using four test-models. The fi rst was the two-kidney control model (2K), and in the second model 
hypertension was induced by L-NAME. The third model consisted of unilateral nephrectomy (UNX), while 
the fourth was a combination of UNX and L-NAME induced hypertension. The renal damage-resistant ACI 
rat develops little renal damage, regardless of treatment. The Rf-1B single congenic developed signifi cantly 
more renal damage compared to ACI, which was most pronounced following UNX+L-NAME. In contrast, in 
the Rf-5 congenic rats renal damage did not differ from that of ACI. Studies of the renal blood fl ow (RBF) 
autoregulation revealed that it was impaired in Rf-1B single congenics. In contrast, renal autoregulation in 
Rf-5 single congenics was normal, similar to that of the ACI rat. From this study it is concluded that the Rf-1 
region contains one or more genes directly infl uencing renal susceptibility and renal autoregulation, while 
the Rf-5 region has no direct effect.
 
Chapter 4 describes the renal susceptibility in ACI, Rf-1A and Rf-4 single and Rf-1A+4 double 
congenic rat, using the four renal damage models mentioned above. regardless of treatment, renal damage 
in the Rf-4 single congenic did not differ from that of ACI rats. However, the Rf-1A+4 double congenic 
developed signifi cantly more renal damage compared to Rf-1A single congenics. Statistical analysis 
revealed a signifi cant interaction between the Rf-1 and Rf-4 region of the FHH rat. Renal autoregulation 
studies showed that Rf-1A+4 and Rf-1A congenic rats had a similarly impaired renal autoregulation. In this 
study it is reconfi rmed that the Rf-1 region carries one or more genes infl uencing renal susceptibility and 
renal autoregulation. In addition, the Rf-4 region carries a gene(s) indirectly infl uencing renal susceptibility 
by interacting with the Rf-1 region.
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Chapter 5 describes the effect of the Rf-3 region alone and in combination with Rf-1 on renal 
damage susceptibility. Again, four models were used to assess renal damage susceptibility as previously 
described. Following UNX+L-NAME, both Rf-1A and Rf-3 single congenics developed signifi cantly more 
renal damage compared to ACI. However, in the Rf-1A+3 double congenics a signifi cant further increase in 
renal damage was found compared to the Rf-1 and Rf-3 single congenics. Statistical analysis revealed the 
presence of an interaction between Rf-1 and Rf-3 with all treatments, similar to the interaction found between 
Rf-1 and Rf-4. This study concludes that the Rf-3 region also carries genes infl uencing renal susceptibility, 
and that an interaction is present between the Rf-1 and Rf-3 regions of the FHH rat, augmenting renal 
susceptibility.
Chapter 6 describes renal damage susceptibility and renal autoregulation experiments in Rf-1B+5 
and Rf-1B+4 double congenic rats compared to Rf-1B single congenic rats. Renal damage susceptibility 
was assessed by using the 2K, UNX, 2K+L-NAME and UNX+L-NAME models. Results showed that Rf-
1B+5 double congenics did not develop more renal damage than the Rf-1B single congenics, regardless 
of treatment. The Rf-1B+4 double congenic developed signifi cantly more renal damage than the Rf-
1B single congenic rat, similar to the Rf-1A+4 double congenics. This study and the data presented in 
Chapter 3 indicate that the Rf-5 region does not infl uence renal damage susceptibility, neither alone nor in 
combination with Rf-1. We therefore assume that the Rf-5 region does not contain genes infl uencing renal 
susceptibility.
Chapter 7 describes the renal damage susceptibility of Rf-1A+2 double congenic, FHH, and FHL 
rats. In addition, a global genome scan was performed on FHH and FHL rats to look for genetic differences. 
Administration of L-NAME led to a high mortality rate in FHH, FHL and Rf-1A+2 rats and therefore only 
the 2K and UNX models were used.. The Rf-1A+2 double congenics developed signifi cantly more renal 
damage than the Rf-1A single congenics. The Rf-1A+2 double congenic had an elevated blood pressure 
at a level between the normotensive FHL and hypertensive FHH rats. Some renal damage was present in 
FHL, but not as severe as in the FHH rat. A global genome scan revealed polymorphisms between FHL and 
FHH in the Rf-2, Rf-4 and Rf-5 regions. The Rf-1 and Rf-3 regions in FHL are identical to the FHH rats. We 
conclude that the Rf-1 and Rf-2 regions carry genes that infl uence renal susceptibility, while the Rf-2 region 
also carries a gene that increases blood pressure, confi rming a direct role of Bpfh-1. Differences in renal 
damage between FHH and FHL can be partly explained by the differences in SBP, and partly by differences 
in genotype of the Rf-regions.
Chapter 8 describes the suitability of the remnant kidney model (RKM) to rapidly assess differences 
in renal susceptibility between rat strains. The RKM was tested in several Rf-congenic rat strains, ACI, FHH 
and FHL rats. The FHH did not survive this severe model for more than a week. Comparison of ACI and FHL 
rats showed that differences in renal susceptibility between the renal resistant ACI and renal susceptible 
FHL rats could easily be detected. A second comparison between ACI, Rf-1B and Rf-5 single congenic 
rats indicated that signifi cantly more renal damage was present in Rf-1B compared to ACI and Rf-5, thus 
confi rming the fi ndings of Chapter 3. However, both ACI and Rf-5 developed a considerable amount of 
.
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renal damage. A third comparison was made between ACI, Rf-1A, Rf-4 and Rf-1A+4 double congenics. The 
Rf-1A and Rf-1A+4 developed signifi cantly more renal damage. However, the previously found interaction 
between Rf-1 and Rf-4 (Chapter 4) could not be detected when using RKM. We concluded that our fi ndings 
question the suitability of the RKM as a model to rapidly assess differences in susceptibility to develop renal 
damage. Although it could still be useful in strains that markedly differ in susceptibility, its value to detect 
differences between congenic rat strains was poor. The UNX, 2K+L-NAME and even the UNX+L-NAME 
models appear better suitable, despite the longer duration.
Chapter 9 contains the general discussion, some perspectives for further research and overall 
conclusions of this thesis. The outcome of the various physiological genomic studies presented in this thesis 
regarding the rat renal failure QTLs Rf-1 through Rf-5 leads to the following conclusions:
1. The Rf-1 region of the FHH contains one or more genes directly infl uencing renal susceptibility and 
impairing renal autoregulation. Whether these genes are the same needs to be further investigated.
2. The direct effect of the Rf-2 region could not yet be tested. When the Rf-2 region is combined with 
the Rf-1 region, a signifi cant increase in renal damage is seen when compared with Rf-1 alone. 
Furthermore, the Rf-2 region, harboring Bpfh-1, increases blood pressure.
3. The Rf-3 region contains genes directly infl uencing renal susceptibility. Renal damage susceptibility 
in Rf-3 single congenics is similar to that of Rf-1 single congenics. When Rf-1 and Rf-3 are combined 
a signifi cant synergistic interaction is present. The Rf-3 congenic rats do have a normal renal 
autoregulation. The mechanisms of how Rf-3 infl uences the development of renal damage still remains 
to be detected.
4. Genes in the Rf-4 region do not directly infl uence renal susceptibility. However, when combined 
with Rf-1 a signifi cant synergistic interaction is present. The Rf-4 congenic rats do have a normal 
autoregulation. The mechanisms of how Rf-4 indirectly infl uences the development of renal damage is 
still unknown and should be further investigated.
5. The Rf-5 region does not contain genes that directly infl uence renal susceptibility. In addition, the Rf-5 
region shows no synergistic interaction with the Rf-1 region. 
6. The Remnant Kidney Model (RKM) is not a very suitable model to analyze renal susceptibility in rats 
carrying Rf-regions of the FHH rats. The four models we used, especially the UNX and 2K+L-NAME 
model appear more suitable to assess differences in susceptibility to develop renal damage.
Samenvatting
De FHH (Fawn Hooded Hoge bloeddruk) rat is een rattenstam die een matig verhoogde bloeddruk 
en ernstige nierschade ontwikkelt op een relatief jonge leeftijd. Koppelingsonderzoek in een kruising van 
de FHH rat en de nierschade-resistente ACI (August x Copenhagen Irish) rat heeft 5 “quantitative trait 
loci” (QTLs) opgeleverd die gekoppeld zijn aan parameters van nierschade. Deze QTLs hebben we Renal 
failure-1 (Rf-1) tot en met Rf-5 genoemd. Met behulp van enkel congene ratten kan de rol van ieder QTL 
afzonderlijk bekeken worden. Dubbel congene ratten worden gebruikt om eventuele gen-gen interacties 
aan te tonen. De congene ratten bestudeerd in dit proefschrift hebben de genetische achtergrond van de 
ACI rat waarvan een klein gedeelte vervangen is door het genoom van de FHH rat waarin een of meerdere 
QTLs zitten. 
Het ontstaan van nierschade wordt beïnvloedt door verschillende risicofactoren. Een verminderde 
niermassa en een hoge bloeddruk zijn twee van deze risicofactoren. Het onderzoek naar de gevoeligheid 
van nierschade is uitgevoerd met behulp van vier modellen die rekening houden met de bovengenoemde 
risicofactoren. Het eerste model is het controle model waarbij geen interventie plaatsvindt. Deze ratten 
hebben twee nieren en een normale bloeddruk (2K). Het tweede model bestudeert het effect van een hoge 
bloeddruk, wat geïnduceerd wordt door L-NAME (2K+L-NAME). Bij het derde model wordt de niermassa 
verminderd door middel van een eenzijdige verwijdering van de nier (unilaterale nefrectomie, UNX). Als 
laatste wordt de combinatie van UNX en L-NAME geïnduceerde hoge bloeddruk uitgevoerd (UNX+L-
NAME).
Eerder onderzoek heeft aangetoond dat de FHH rat een verminderde autoregulatie van de 
nierdoorbloeding heeft. De nierdoorbloeding wordt door twee systemen geregeld, t.w. de myogene respons 
en de tubuloglomerulaire feedback (TGF). De TGF bleek normaal in de FHH rat, maar de myogene respons 
was verminderd, resulterend in een verminderde autoregulatie van de nierdoorbloeding. In de FHH rat 
leidt een verhoogde bloeddruk in combinatie met een verminderde autoregulatie tot een verhoogde druk in 
de glomeruli, de fi ltereenheden van de nier. De glomeruli kunnen deze verhoogde druk niet aan en dit zal 
uiteindelijk leiden tot ernstige schade van de glomeruli (glomerulosclerose, FGS)
In Hoofdstuk 1 wordt beschreven wat er op dit moment bekend is over de invloed van genetische 
factoren op het ontstaan en de ontwikkeling van nierschade. De Rf-1 tot en met Rf-5 QTLs worden hier 
besproken en daarmee de mogelijkheden om de gevoeligheid voor het ontstaan van nierschade te testen. 
In dit hoofdstuk zijn vier doelstellingen geformuleerd. De eerste doelstelling is het aantonen van een directe 
rol van ieder QTL in de gevoeligheid voor het ontstaan voor nierschade. De tweede doelstelling is het 
aantonen van een interactief effect tussen Rf-1 en een van de andere vier Rf-QTLs. Het derde doel is uit te 
zoeken of de effecten van alle individuele Rf-QTLs afhankelijk is van de behandeling. De vierde doelstelling 
is het vaststellen van de rol van Rf-QTLs in de autoregulatie van de nierdoorbloeding.
Congene ratten geven de unieke mogelijkheid om de rol van een QTL in het ontstaan van een 
ziekte te testen. In de ACI.FHH-Rf congene ratten wordt een gedeelte van het FHH genoom met het 
desbetreffende Rf-QTL overgebracht naar de nierschade resistente genetische achtergrond van de ACI rat. 
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Dit proefschrift beschrijft de gevoeligheid voor het ontstaan voor nierschade in ACI.FHH-Rf congene ratten. 
Hiervoor zijn enkel congene ratten voor het Rf-1, Rf-3, Rf-4 en Rf-5 QTL gegenereerd en dubbel congene 
ratten die naast het Rf-1 QTL ook het Rf-2, Rf-3, Rf-4 of Rf-5 QTL bevatte. In Hoofdstuk 2 is beschreven 
hoe de verschillende congene stammen gefokt zijn en welke chromosomale gebieden van de FHH naar de 
ACI zijn overgebracht. 
In Hoofdstuk 3 wordt een studie beschreven die het ontstaan en de ontwikkeling van nierschade 
bestudeerd in Rf-1B en Rf-5 enkel congene ratten met behulp van de bovengenoemde vier modellen. 
De Rf-1B congene rat liet een verhoogde gevoeligheid tot het ontstaan van nierschade zien ten opzichte 
van de ACI rat. De Rf-5 congene rat daarentegen had geen verhoogde gevoeligheid tot het ontwikkelen 
van nierschade. Onderzoek naar de autoregulatie functie toonde aan dat de Rf-1B enkel congene rat een 
verminderde autoregulatie heeft, vergelijkbaar met de eerder aangetoonde verminderde autoregulatie van 
de FHH rat. De Rf-5 congene rat had een normale autoregulatie functie, vergelijkbaar met die van de ACI 
rat. Uit deze studie kan geconcludeerd worden dat het Rf-1B gebied een of meerdere genen bevat die 
autoregulatie van de nierdoorbloeding en de gevoeligheid voor het ontstaan van nierschade beïnvloeden. 
In Hoofdstuk 4 zijn de Rf-1A en Rf-4 enkel congenen en Rf-1A+4 dubbel congeen bestudeerd ten 
opzichte van de ACI rat. Hierbij werd aangetoond dat de Rf-1A enkel congeen gevoelig is voor het ontstaan 
van nierschade. De Rf-4 enkel congeen daarentegen ontwikkelde geen nierschade. De gevoeligheid voor 
nierschade in de Rf-1A+4 dubbel congene rat bleek verrassend hoger te liggen dan verwacht. Statistische 
analyse toonde aan dat er een interactie aanwezig was tussen het Rf-1 en Rf-4 gebied, wat leidde tot 
een verhoogde gevoeligheid voor het ontstaan van nierschade. Autoregulatie studies toonde aan dat de 
autoregulatie functie was verminderd in zowel de Rf-1A als de Rf-1A+4 congenen. De Rf-4 congeen had 
net als de ACI rat een normale autoregulatie. De conclusies uit deze studies waren dat Rf-1 genen bevat 
die direct de gevoeligheid voor het ontstaan van nierschade kan beïnvloeden. Het Rf-4 gebied bevat genen 
die alleen indirect, in de aanwezigheid van Rf-1, de nierschade gevoeligheid beïnvloedt. 
De nierschade gevoeligheid van de Rf-3 enkel congenen en de Rf-1A+3 dubbel congenen wordt 
beschreven in Hoofdstuk 5. Net als in voorgaande hoofdstukken werd de gevoeligheid voor nierschade 
getest met de vier eerder genoemde modellen. De Rf-3 enkel congene rat bleek net als de Rf-1 rat gevoelig 
te zijn voor het ontstaan van nierschade. De Rf-1A+3 dubbel congene rat ontwikkelde veel meer nierschade 
en statistische analyse toonde aan dat er sprake was van een interactie tussen het Rf-1 en Rf-3 QTL, 
vergelijkbaar met de eerder aangetoonde interactie tussen Rf-1 en Rf-4. Opvallend was dat ratten die het 
Rf-3 gebied hadden, een lichte stijging in de kreatinine klaring toonde, wat neerkomt op een verhoogde 
glomerulaire fi ltratie snelheid. Autoregulatie studies toonde aan dat zowel Rf-1A als Rf-1A+3 congene ratten 
een verminderde autoregulatie hadden. Daarentegen had de Rf-3 congene rat een normale autoregulatie, 
vergelijkbaar met de ACI rat. Uit deze studie kan geconcludeerd worden dat zowel het Rf-1 als het Rf-3 
QTL een direct effect hebben op de gevoeligheid voor het ontstaan van nierschade, en dat een interactie 
tussen deze twee QTLs leidt tot een verhoogde nierschade gevoeligheid. Daarnaast bevat het Rf-3 QTL 
geen genen die de autoregulatie beïnvloeden. 
De Rf-1B+4 en Rf-1B+5 dubbel congenen zijn vergeleken met de Rf-1B enkel congeen in 
Hoofdstuk 6. Alle vier de modellen zijn gebruikt om de nierschade gevoeligheid te testen. Ook is er 
gekeken naar de autoregulatie van de nierdoorbloeding. De Rf-1B+4 ontwikkelde nierschade vergelijkbaar 
met de Rf-1A+4 dubbel congene rat. De Rf-1B+5 dubbel congene rat daarentegen, was even gevoelig voor 
nierschade als de Rf-1B enkel congene rat, onafhankelijk welk model er gebruikt werd. In alle ratten bleek 
de autoregulatie van de nierdoorbloeding vermindert. Conclusies van deze studies was dat het Rf-5 gebied 
geen invloed heeft op de nierschade gevoeligheid, alleen of in combinatie met Rf-1. We gaan er daarom van 
uit dat er geen genen in het Rf-5 gebied aanwezig zijn die de gevoeligheid voor het ontstaan van nierschade 
kunnen beïnvloeden. 
In Hoofdstuk 7 is de nierschade gevoeligheid in Rf-1A+2 dubbel congenen vergeleken met de 
FHH en FHL rat. Ook is er een algemene genoom scan uitgevoerd op de FHH en FHL ratten. De nierschade 
gevoeligheid is alleen maar getest met het twee-nierig en UNX model, omdat uit eerdere studies is gebleken 
dat L-NAME in deze ratten tot een hoge sterfte leidt. De Rf-1A+2 dubbel congeen is de enige dubbel 
congeen die een verhoogde bloeddruk heeft. De waarde (~145 mmHg) ligt tussen die van de FHL (lage 
bloeddruk) en de FHH (hoge bloeddruk) in. De FHH ontwikkelt veel nierschade, zeker na het verwijderen 
van een nier (UNX). De FHL ontwikkelt ook enige nierschade, echter een stuk minder dan de FHH rat. De 
Rf-1A+2 dubbel congene rat heeft ook een verhoogde nierschade gevoeligheid, vergelijkbaar met de FHL 
rat. Een genoom scan toonde aan dat de FHH en FHL ratten voor 75% identiek aan elkaar zijn. In de Rf-
gebieden zijn ze zelfs voor 86% identiek. Er zijn verschillen gevonden in de Rf-2, Rf-4 en Rf-5 gebieden, 
maar de Rf-1 en Rf-3 gebieden zijn identiek aan elkaar. We kunnen concluderen dat het Rf-2 gebied een 
gen bevat dat de bloeddruk beinvloedt maar ook de nierschade gevoeligheid verhoogt. Het verschil van 
nierschade gevoeligheid tussen FHH en FHL wordt naast een verschil in bloeddruk ook nog verklaard door 
een verschil in Rf-gebieden. 
In Hoofdstuk 8 is de toepasbaarheid van het “remnant kidney model” (RKM) getest. In het RKM 
wordt een nier verwijderd en bij de overblijvende nier wordt 1/2 tot 2/3 van de nierfunctie weggehaald door 
het samenbinden van een gedeelte van de nierslagaderen. Dit model is in diverse Rf-congenen, ACI, FHH 
en FHL ratten uitgevoerd. Als eerste werd er gekeken of er verschillen aantoonbaar gemaakt konden worden 
tussen de ACI, FHL en FHH rat. De FHH overleefde dit model niet, maar er konden wel duidelijk verschillen 
aangetoond worden tussen de ACI en FHL ratten. De FHL ontwikkelde veel meer nierschade dan de ACI 
rat. Als tweede werd er gekeken of er verschillen waren tussen nierschade gevoeligheid tussen de ACI, Rf-
1B en Rf-5 enkel congene ratten. De Rf-1B enkel congeen ontwikkelde veel nierschade en was signifi cant 
verschillend. Echter, zowel de Rf-5 als de ACI ontwikkelde al een redelijk hoog niveau van nierschade. De 
laatste vergelijking werd gemaakt tussen de Rf-1A, Rf-4, en Rf-1A+4 ten opzichte van de ACI rat. Zowel 
de Rf-1A en Rf-1A+4 ontwikkelde meer nierschade dan de ACI rat, maar het interactieve effect tussen Rf-1 
en Rf-4 was niet meer aan te tonen met RKM. De conclusie van deze studie is dat geschiktheid van RKM 
als een model om snel verschillen in gevoeligheid voor het ontstaan van nierschade aan te tonen in twijfel 
genomen kan worden. Het UNX met of zonder L-NAME geinduceerde hoge bloeddruk is, ondanks een 
langere duur van het experiment, meer geschikt.
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Hoofdstuk 9 bevat de algemene discussie, enkele potentiële studies voor de toekomst en de 
uiteindelijke conclusies van dit proefschrift. Het fysiologisch genoom onderzoek van de rat nierschade QTLs 
Rf-1 tot en met Rf-5 leidt tot de volgende conclusies:
1. Het Rf-1 gebied van de FHH bevat een of meerdere genen die de gevoeligheid voor het ontstaan van 
nierschade direct beïnvloeden en een verminderde autoregulatie van de nierdoorbloeding veroorzaken. 
Of deze genen dezelfde zijn moet nog verder onderzocht worden.
2. Een direct effect van Rf-2 hebben we nog niet kunnen testen. Als het Rf-2 gebied met het Rf-1 gebied 
is gecombineerd zoals in de Rf-1A+2 dubbel congeen, dan is er een signifi cante stijging in nierschade 
te zien ten opzichte van de Rf-1A enkel congeen. Het Rf-2 gebied, waar ook Bpfh-1 in zit, verhoogt de 
bloeddruk.
3. Het Rf-3 gebied van de FHH bevat een of meerdere genen die de gevoeligheid voor het ontstaan van 
nierschade direct beïnvloeden. Als het Rf-3 gebied met Rf-1 gecombineerd wordt is een synergistische 
samenwerking te zien die leidt tot een verhoogde nierschade gevoeligheid. De Rf-3 enkel congene 
ratten hebben een normale autoregulatie. Het exacte mechanisme van Rf-3 in het beïnvloeden van 
nierschade gevoeligheid moet nog ontdekt worden.
4. Het Rf-4 gebied van de FHH bevat geen genen die de gevoeligheid voor het ontstaan van nierschade 
direct beïnvloeden. Daarentegen is er een synergistische interactie aanwezig wanneer Rf-4 met Rf-1 
gecombineerd wordt. De Rf-4 enkel congene ratten hebben een normale autoregulatie. Het exacte 
mechanisme van Rf-4 in het beïnvloeden van nierschade gevoeligheid moet nog ontdekt worden.
5. Het Rf-5 gebied bevat geen genen die direct de gevoeligheid voor het ontstaan van nierschade 
beïnvloeden, niet op zichzelf en niet in combinatie met Rf-1. 
6. De geschiktheid van RKM als een model om snel verschillen in gevoeligheid voor het ontstaan van 
nierschade aan te tonen kan in twijfel genomen worden. De vier modellen die hiervoor gebruikt zijn, 
met name UNX en 2K+L-NAME, zijn ondanks een langere duur van het experiment, meer geschikt 
voor het bepalen van verschillen in nierschade gevoeligheid.
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Dit proefschrift had hier niet gelegen zonder de steun van vele mensen. Hier wil ik ze graag 
bedanken voor alle hulp in de afgelopen vier jaar.
Prof. Hazebroek, al heb ik u de afgelopen vier jaar niet veel gezien, de keren dat ik u zag wist 
u me te overtuigen van mijn kunnen en dat waardeer ik zeer in u. Ik vind het fi jn u als promotor gehad te 
hebben.
Bram, bedankt dat je me de kans hebt gegeven om dit onderzoek te doen. Jouw enthousiasme 
voor de FHH rat werkt aanstekelijk. In de afgelopen vier jaar hebben we veel meegemaakt. Vele congressen 
hebben we bezocht, en het maakte niet uit in welke stad we kwamen, over iedere stad wist je wel wat leuks 
te vertellen. Het mooie was dat zodra we in het buitenland waren er bij jou een knopje omging, op Bram 
reageerde je niet, maar alleen nog op Abraham. Maar iets wat me altijd bij zal blijven is hoe je al je grafi ekjes 
mooi op grafi ekpapier maakte, ik denk dat er nog weinig mensen zijn die dat doen en kunnen.
Patricia, ik ben blij dat ik zo nauw met je heb mogen samenwerken. Zonder jou had de afdeling 
net zo goed kunnen stoppen met bestaan, zo onmisbaar ben je. We hebben aardig wat uurtjes samen onder 
de microscopen zitten turen, gelukkig was een half woord al genoeg om elkaar te begrijpen. Maar buiten 
werken hebben we ook leuke dingen beleefd, zoals een tripje naar New York en Cold Spring Harbor (als de 
lange dames van Bram), winkelen in Rotterdam, en skiën en snowboarden in Snowworld. Vooral dat laatste 
is erg goed voor onze lachspieren geweest. Ik vind het hartstikke fi jn dat je mijn paranimf wilt zijn, een prima 
afsluiting van 4 jaar lang samenwerken. Ik zal onze samenwerking in het lab enorm missen.
Mirjam, zo’n 5 maanden lang ben je bij ons stagiaire geweest en was je het zonnetje van de 
afdeling. Altijd had je vrolijke verhalen, en ook je acties op je werk konden goed op de lachspieren werken. 
Ik heb eindelijk iemand gevonden die net zoals ik in enthousiasme dingen omver gooit, en we noemden 
elkaar niet voor niets Lompie 1 en 2. Ik vind het fi jn dat we na je stageperiode vrienden zijn gebleven en was 
ook blij dat je ja zei toen ik je vroeg om mijn paranimf te zijn. Nou maar hopen dat we er door heen komen 
zonder dingen omver te gooien ;)
Ik zou graag bij deze Jessica, Esther, Ed, Michael, Albert, Roy, Ron, Enno, Piet, Agnes, Edwin, 
Yvonne, Marcel, Henk, Joyce, Dennis en Patricia van het EDC willen bedanken voor alle goeie zorgen 
voor de Provoost ratten. In de tijd dat mijn kantoor (lees bezemkast) nog in het EDC was hadden we altijd 
gezellige lunchpauzes. De ratten zorgden vaak voor leuke taferelen, vooral ontsnappingen zorgden ervoor 
dat we op onze knieën door de stallen heen konden. 
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Pim, jaren heb je voor ons de analyses gedaan op de plasma’s en urines. Als er een keertje haast 
bij was dan zorgde je ervoor dat we snel de resultaten binnenkregen. Met je vrolijke grijze krullen en guitige 
ogen wist je me altijd weer moed in te spreken voor het schrijven van artikelen. Bedankt voor al je inzet.
Ineke, het geduld dat jij toont bij iedereen, daar kan ik alleen maar respect voor hebben en alleen 
maar hopen dat ik dat ooit ook kan tonen. Het was altijd fi jn als Patricia en ik weer eens bij je terechtkonden 
als we de dubbelmicroscoop nodig hadden.
Ik wil graag de hele afdeling pathologie bedanken, Diane en Mark in het bijzonder. Diane, jij was 
zeker in het begin mijn steun en toeverlaat als ik weer iets niet kon vinden op het lab. En Mark, bedankt 
voor je begrip als ik de niertjes weer zo snel mogelijk gekleurd moest hebben omdat ik persé de resultaten 
nodig had voor een of ander artikel.
Pascal, Annelies en Marieke, jullie hebben me zover gekregen om in het bestuur van MAIOR 
te komen. Nadat jullie stopten ben ik nog een tijd doorgegaan en heb ik samengewerkt met Victor, Karin, 
Debby, Laetitia en Mauricio. Inmiddels is MAIOR geen MAIOR meer, maar ProMEras. Ik heb het altijd 
leuk gevonden om samen met jullie me in te zetten voor de belangen van promovendi. Jullie boden altijd 
een luisterend oor en hebben me gesteund in het proces van het schrijven van dit proefschrift. Hartstikke 
bedankt hiervoor en iedereen ook heel veel succes met het schrijven van jullie eigen proefschrift. 
Een tijd lang ben ik editor geweest van CUBIC en daar heb ik met diverse mensen nauw 
samengewerkt om toch ieder kwartaal weer een CUBIC op tafel te krijgen. Iedereen was altijd begripvol 
als je niet zoveel tijd had omdat er weer eens deadlines voor artikelen waren. Julien en Willem, met jullie 
hebben we van een saaie lay-out de supergave CUBIC gecreëerd. Jullie kregen het helaas te druk, en 
vervolgens had ik het plezier om met Ward, Merel, Fanny en Elaine verder te gaan. De CUBIC van Juli 
2005 was mijn laatste, maar ik kan in ieder geval terugkijken op een gezellige tijd van schrijven, mailen en 
editing. Hartstikke bedankt voor de leuke tijd en iedereen ook heel veel succes met het schrijven van jullie 
eigen proefschrift.
Howard, I think I have seen you more at conventions than during my 6-month stay in Milwaukee. 
Most of the time you were impossible to reach, however, when succeeding in reaching you, I always got 
good critics on my work. Your thoughts helped me a lot with fi nishing manuscripts. 
Lorie, thank you for the great talks we had during my stay in Milwaukee. And especially thanks for 
nailing down Howard for all the signatures I needed from him. You were a great help.
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Joe, you’re like a giant friendly bear. You like working hard, but you’re still the sweetest guy in 
the lab, at least to me. You were fortunately less impossible to reach for comments on my research and 
manuscripts. Thanks for all your help.
Kendall, thanks for arranging almost everything during my stay in Milwaukee. You made sure I had 
a place to stay. Whenever I had a problem, I could ask you for help which I really appreciate.
Artur, where shall I start? I could always discuss my research with you, and you really gave 
interesting feedback. I enjoyed our lunches at the Children’s Hospital. A lot of people looked strange at us, 
since you only came up to my shoulders, but I promise you, this will be the last time that I’m teasing you with 
your height. And I will never forget the lab trip to Cold Spring Harbor in 2003. During this meeting I found out 
that not all scientifi c meetings are purely scientifi c. Good luck with fi nishing your thesis.
Pawjai, I have never seen someone performing research in such a precise way. You taught me a 
lot in conducting research in a careful, structured way. Besides your work I also enjoyed your homemade 
Thai food very much.
Mike T, thanks for all your help. When I wanted to buy a car during my stay in Milwaukee, you 
didn’t mind helping me fi nd a good one. I will never forget your comment on one car. You were so honest 
to say it was just a piece of crap. I was surprised it didn’t even broke down when we drove in it for around 
a block. 
Nadia, Jaime, Carol and Michelle, you were a great help during my stay in Milwaukee. Whenever I 
had a question, I could ask it to you girls, and I would always get an answer that would help me continue my 
research. And to the rest of the HMGC whom I haven’t mentioned yet, thanks for the wonderful time.
Nadi, you were the best roommate I could have ever wished for. You taught me to cook hot food, 
and more importantly to eat it too. Besides cooking and eating, we have done so many things. We went 
to Chicago and Madison, although it would have been better if we had had nicer weather. Ice skating was 
defi nitely fun, since it was the fi rst time for you. It was really nice to have such a close friend in a country so 
far away from your own. 
Philipp, we shared the same humor, something a lot of Americans could not understand. I think we 
were the only ones laughing during the Kill Bill movie, and I enjoyed watching Blackadder with you. When 
I needed a ride to the airport, I could always count on you. What was also funny is that you started crying 
whenever Nadi and I were cooking, only because you couldn’t handle the spices we were using.
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Jan en Nelly, al heb ik jullie pas het laatste jaar van mijn AIO-periode ontmoet, jullie zijn toch een 
grote steun voor me geweest. Altijd een enthousiast oor als ik weer eens wat over mijn onderzoek vertelde. 
Straks worden het veel enthousiaste verhalen over mijn geneeskunde opleiding. En Nelly, bedankt dat ik 
jouw artistieke kunsten mag vereeuwigen.
Marja, Rob, Ingmar, Marten, Tineke, Sef, Sanne en Opa, bedankt voor alle interesse die jullie 
hebben getoond in mijn onderzoek. En ik ga er uiteraard vanuit dat jullie een muzikale noot aan het feest 
zullen bijdragen. ;)
Val(erie), anderhalf jaar hebben we een huis gedeeld, en daar heb ik erg van genoten. Allebei 
hebben we een druk leven, maar toch vonden we wel de tijd om samen het eten klaar te maken. Het 
knutselen aan je maquette voor je afstudeeropdracht heb ik erg leuk gevonden, ik moet alleen nog steeds 
een keer het eindresultaat zien. Nu ben jij inmiddels student af en een hardwerkende vrouw, en ik ben weer 
een student, met andere woorden, de rollen zijn omgedraaid. Het leuke was dat we het altijd over onze 
eigen studies hadden, en beiden geen ene mallemoer van de studie van de ander snapte. Bedankt voor al 
je steun en vooral de grappige kaartjes en telefoontjes toen ik in Amerika zat.
Jolanda, het is al weer 5½ jaar geleden dat we elkaar op de trein tijdens onze bijbaantjes 
leerden kennen. Je stond er op dat je aanwezig was tijdens mijn afstuderen. Dit keer hoop ik dat je vrij 
kan krijgen om bij mijn verdediging van mijn proefschrift te zijn. Je bent altijd een positieveling over mijn 
proefschrift geweest. Je dwong me vaak genoeg om ook nog lol te maken en aan iets anders te denken 
dan aan mijn proefschrift, en dat waardeer ik zo in je. Je hebt me geleerd mijn onderzoek uit te leggen aan 
niet-wetenschappers, iets waar veel mensen je dankbaar voor zullen zijn. Ook al snap je weinig van het 
onderzoek, je toonde altijd interesse, hetgeen ik enorm waardeer.
Rogier, je kwam in mijn leven in het laatste jaar van mijn AIO-periode. Je steun en toeverlaat in 
alles wat ik doe zijn onwijs belangrijk voor me. Ik kom woorden te kort om uit te leggen hoeveel je voor me 
betekent.
Pap en mam, jullie hebben me altijd gesteund, welke beslissing ik ook maakte. Altijd wisten jullie 
me moed in te praten als er weer eens een artikel werd afgewezen. Hoe wanhopig ik ook was, jullie wisten 
me op te beuren. Toen ik vertelde dat ik de opleiding geneeskunde wilde gaan doen, waren jullie alleen 
maar positief. Bedankt voor al jullie steun en vertrouwen.
Dankwoord
